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Abstract 
Evidence from animal models and human intervention studies indicates that 
polyphenols can potentially attenuate the postprandial glycaemic response by 
inhibition of α-glucosidases, critical for carbohydrate digestion, and by 
attenuation of monosaccharide transport across small intestinal enterocytes. 
Therefore, this study evaluated the effect of polyphenols, including an 
oleuropein-rich olive leaf extract, on sucrose hydrolysis and transport.  
Controlling the glycaemic response reduces the risk of development and 
progression of type 2 diabetes, much like the anti-diabetic drug acarbose. An in 
vitro inhibition assay for sucrase and maltase activity was optimised using 
Caco-2/TC7 cells as a human enzyme source and compared to a rat enzyme. 
Inhibitors were more effective on human compared to rat sucrase while the 
reverse was true for maltase. Chronic sucrose exposure led to altered N- and 
O-glycosylation and the sucrase Km increased by 15% compared to cells 
cultured in glucose. A chronic 3-day treatment with 1.5 mg/mL olive leaf extract 
reduced the sucrase specific activity by 31% and 26% for cells cultured in 
glucose and sucrose, respectively. Sucrase N-glycosylation increased in cells 
cultured in sucrose and this could have led to the decrease in Km. Oleuropein 
treatment decreased cell surface sucrase by 41% when cultured long-term in 
glucose but not sucrose. Transport studies for glucose-cultured cells showed 
that chronic treatment reduced sucrase hydrolysis and attenuated of fructose 
transport and GLUT2-mediated glucose transport. These results show for the 
first time that chronic treatment with olive polyphenols can reduce the sucrose 
hydrolysis and modulate glucose and fructose transport. Changes in post-
translational modifications of sucrase with different treatments opens up new 
areas of research. Investigations are warranted regarding the use of olive leaf 
extract in humans for glycaemic control after sugar consumption with the 
suggestion that sugar intake might impact the effectiveness of the treatment.  
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1 Introduction 
1.1 Diabetes  
 Pathogenesis 1.1.1
The prevalence of type 2 diabetes has doubled over the last thirty years and 
affects an estimated one in ten people worldwide, and non-communicable 
diseases including cardiovascular disease and type 2 diabetes account for 
more deaths than infectious diseases (WHO, 2012). The incidence of type 2 
diabetes in 2013 was estimated to be 382 million people worldwide and is 
projected to reach approximately 600 million by 2035 (Guariguata et al., 2014). 
The pathogenesis of type 2 diabetes involves the development of insulin 
resistance as well as impaired β-cell function. During its development, patients 
pass through a phase of impaired glucose tolerance. Glucose is required as 
fuel source in the body and the levels of glucose in the blood need to be 
constantly maintained. To meet the requirement, glucose is produced during 
fasting by gluconeogenesis in the liver and kidney and from breakdown of 
glycogen in the liver. Following meal consumption, glucose is formed from the 
breakdown of carbohydrates and passes through the gut leading to a rise in 
blood glucose. This prompts the release of insulin from β-cells in the liver which 
signals for uptake in the insulin-responsive tissues, in turn reducing blood 
glucose levels (Macdonald, 2014). A sign of impaired glucose homeostasis is 
insulin resistance, in which the insulin is less effective at signalling glucose 
uptake and hyperinsulinemia occurs to keep blood glucose normal. This can 
progress to the development of type 2 diabetes in which insulin secretion is 
now impaired and there is not enough insulin released to compensate for the 
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insulin resistance (Merlotti et al., 2014). Individuals at risk of cardiovascular 
disease and type 2 diabetes are referred to as having metabolic syndrome 
which is defined by the International Diabetes Association as including a 
minimum of two of the following: low HDL cholesterol, high serum triglycerides, 
high systolic or diastolic blood pressure and increased fasting glucose (Gu and 
Lambert, 2013).  
Interventions that improve insulin sensitivity or reduce the stress on β-cells by 
reducing hyperglycaemia should aid in preventing the development and 
progression of type 2 diabetes. Postprandial blood glucose levels range from 
3.8 to 7.6 mmol/L in healthy individuals and the function of the β-cells drops by 
60% at levels above 6.6 mmol/L (Augustin et al., 2015). Hyperglycaemia is also 
involved in pathways leading to endothelial function and further diabetic 
complications (Augustin et al., 2015).   
 Glycaemic load/glycaemic index and health 1.1.2
 
The post-prandial glycaemic response (GR) is the change in concentration of 
blood glucose after a food or meal is ingested. The glycaemic index (GI) is a 
system for indexing foods based on their glycaemic response; it is defined as 
the GR for a portion of food containing 50 g of available carbohydrate 
expressed as a percentage of 50 g of the control, usually glucose or white 
bread (Wolever et al., 1991; Augustin et al., 2015). Foods that are digested and 
absorbed quickly with GI ≥70 are called high-GI foods, whilst those with GI ≤ 55 
are called low-GI (Aston, 2006). Glycaemic load (GL) refers to the available 
carbohydrates present in a serving of food. The GI depends on many 
3 
 
 
 
properties of the food, firstly the carbohydrate content. For example, the GI of 
the monosaccharide glucose is greater than fructose (Atkinson et al., 2008). 
Amylose, a straight-chain starch, is more readily digested than amylopectin, a 
branched starch, therefore would exhibit a higher GI (Morris and Zemel, 1999). 
Other food components influence GI, including fat and fibre content, both which 
lower GI (Björck and Elmståhl, 2003). Standardised methods exist for the 
determination of GI (Brouns et al., 2005). 
A meta-analysis of 37 observational studies found that high GI diets increased 
the risk of chronic type 2 diabetes and heart disease (Barclay et al., 2008) 
which supports the notion that postprandial hyperglycaemia contributes to 
chronic disease risk. A more recent meta-analysis of three large cohorts in 
which the primary endpoint was type 2 diabetes also suggests that high GI 
diets are unfavourable (Bhupathiraju et al., 2014). In addition to epidemiological 
studies that demonstrate a diet with low glycaemic response plays a role in the 
prevention of metabolic syndrome, an intervention study meta-analysis 
demonstrated that reducing the glycaemic impact of the diet has a positive 
effect on health markers(Livesey et al., 2008). Fasting blood glucose was 
reduced with consumption of lower GI/GL foods and this effect was greater in 
participants with metabolic disorder or type 2 diabetes. There was no effect on 
fasting insulin levels, however the insulin sensitivity was improved even in non-
diabetics (Livesey et al., 2008).  
There is some debate regarding the use of GI/GL as a dietary 
recommendation. The diets used to evaluate effects from high and low GI differ 
in composition other than just the carbohydrate amount making the results 
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difficult to interpret and distinguish the dietary factors involved. Furthermore, 
inter-individual variations occur so not everyone will benefit from low GI/GL. In 
light of these discussions, an international consensus summit was held in to 
review the current body of evidence related to glycaemic response. The panel 
agreed that reducing postprandial glycaemia has recognised beneficial 
physiological effects and reducing the GI/GL of the diet is a suitable approach, 
although more beneficial to those with metabolic syndrome or obesity (Augustin 
et al., 2015). Overall studies do provide strong evidence to suggest that a low-
GI diet can reduce hyperglycaemia and body weight. These in turn are well 
established at reducing the risk of insulin resistance, β-cell dysfunction, 
inflammation, endothelial dysfunction and blood pressure to improve overall 
health status (Aston, 2006) (Figure  1-1). 
 
Figure  1-1. Relationship between GI and type 2 diabetes 
 
 Current diabetes treatment strategies 1.1.3
Pharmacological treatments for type 2 diabetes are based on the strategy of 
reducing the GI of the diet by slowing down carbohydrate digestion. These 
include the anti-hyperglycaemic drugs acarbose, volibose and miglitol, all of 
which are α-glucosidase inhibitors (Breuer, 2003). Chronic 3-year treatment 
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with acarbose reduced the absolute risk of developing type 2 diabetes by 6% in 
patients with impaired glucose tolerance (Nijpels et al., 2008). In a similar 
double-blind randomised, placebo controlled trial, acarbose reduced the 
progression from impaired glucose tolerance to type 2 diabetes by 25% and 
improved glucose tolerance (Chiasson et al., 2002). Gastro-intestinal side 
effects are common with acarbose, and high study dropout rates have been 
reported in intervention trials (Nijpels et al., 2008).  
In patients with metabolic syndrome, lifestyle modifications, diet and weight 
loss have been as effective as pharmacological treatments (Magkos et al., 
2009).  An intervention trial was performed on participants at high risk for 
diabetes to compare the anti-hyperglycaemic drug metformin to a group with 
intensive lifestyle modification. Participants with the modified lifestyle were 
guided to lose and maintain 7% of their initial body weight with a low calorie 
and low fat diet and perform moderate physical activity for 150 minutes per 
week. Lifestyle modification was able to reduce the incidence of diabetes by 
58% compared to the placebo group while metformin led to a 31% reduction 
(Knowler et al., 2002). The large scale PREDIMED study investigate the 
relationship between the Mediterranean diet and health markers (Martínez-
González et al., 2010). The intervention study group that followed a 
Mediterranean diet supplemented with olive oil was able to reduce relative risk 
of type 2 diabetes by 40% (Martínez-González et al., 2015). These results 
highlight that diet and lifestyle are important modifiable factors in both the 
prevention and treatment of type 2 diabetes. 
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1.2 Carbohydrate metabolism 
 Digestion and uptake 1.2.1
Carbohydrates play a key role in the diet as they yield the principle substrate of 
energy metabolism and influence the blood glucose response. The four main 
classes of readily available dietary carbohydrates are monosaccharides, 
disaccharides, oligosaccharides and polysaccharides. Monosaccharides and 
disaccharides are commonly referred to as sugars. The dietary 
monosaccharides are glucose, fructose and galactose whilst sucrose and 
lactose are disaccharides. A series of 3-7 or 10 monosaccharides linked 
together are defined as oligosaccharides and polysaccharides, respectively 
(Cummings and Stephen, 2007). Starch is a storage polysaccharides from 
plants such as cereals, root vegetables and legumes. It consists of two 
polymers: amylose and amylopectin, both containing only glucose molecules. 
Amylose contains glucose residues linked by α-1,4 glycosidic bonds and 
amylopectin contains both α -1,4 and α -1,6 bonds and is highly branched 
(Morris and Zemel, 1999). 
Carbohydrates must be digested into monosaccharides in order to be absorbed 
in the gut and this requires the action of several enzymes. Starch is digested by 
salivary and pancreatic α-amylase (EC 3.2.1.1) which hydrolyses α-1,4 bonds 
releasing maltose, maltotriose and α-dextrans and some glucose (Cummings 
and Stephen, 2007). Further digestion to yield monosaccharides occurs by α-
glucosidases found at the brush border of the small intestine: sucrase 
isomaltase (EC 3.2.1.48, EC 3.2.1.10) (SI), maltase glucoamlyase (EC 3.2.1.20) 
(MGAM) and trehalase. The β-glucosidase lactase (EC 3.2.1.108) is 
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responsible for the hydrolysis of lactose from milk. The substrates for each of 
the enzymes are presented in Table 1-1. Sucrase isomaltase provides 80% of 
the total maltase activity as well as the majority of isomaltase activity (Van 
Beers et al., 1995) so plays a vital role in starch and sugar digestion and is 
further described in  1.2.4. 
Table 1-1. Substrate specificities of intestinal brush border glucosidases. na= 
not applicable. (Adapted from Van Beers et al., 1995). 
 
Enzyme Subunit Specificity Substrates 
Trehalase na α,α’-trehalose α,α’-trehalose 
Maltase 
glucoamylase 
(MGAM) 
Maltase 
And  
Glucoamylase 
α-1,4 glucosyl 
bonds 
Maltose, 
amylopectin, 
glycogen, 
starch, amylose, 
isomaltose  
Sucrase 
isomaltase (SI) 
Sucrase α-1,4 and α-1,2  
glucosyl bonds 
Sucrose, 
maltose 
Isomaltase α-1,6 glucosyl 
bonds 
Isomaltose, 
maltose 
Lactase na β-1,4 glucosyl 
bonds 
Lactose, 
cellobiose, 
cellulose, 
glucosyl- and 
galactosyl-
lactosylceramide 
 
Glucose is primarily transported into small intestinal enterocytes by the sodium-
dependent glucose co-transporter SGLT1 which is permanently present at the 
luminal (apical) side and has a Km for glucose of 0.5 mM (Kellett et al., 2008; 
Röder et al., 2014). The facilitated transporter GLUT2 is also responsible for 
uptake of glucose at the apical side and it has been proposed that GLUT2 is 
translocated to the apical membrane to assist with glucose transport under 
conditions of high glucose (Kellett et al., 2008; Ait-Omar et al., 2011). Fructose 
is transported by GLUT2 and GLUT5, the latter being specific for fructose 
(Douard and Ferraris, 2008). GLUT2 is primarily responsible for transport of 
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sugars out of the enterocytes at the basolateral side and also for uptake into β-
cells (Kellett et al., 2008). 
 Carbohydrate intake in the UK 1.2.2
The Scientific Advisory Committee on Nutrition (SACN), who advise Public 
Health England, have recently recommended that daily intake of “free sugars” 
should be halved, down to no more than 5% of total daily calories.  The newly 
adopted terminology “free sugars” is defined as “all monosaccharides and 
disaccharides added to foods by the manufacturer, cook or consumer, plus 
sugars naturally present in honey, syrup and unsweetened fruit juices. Under 
this definition lactose when naturally present in milk and milk products is 
excluded”. These were previously referred to as “non-extrinsic milk sugars” 
(SACN, 2015). 
A recent report from SACN summarised data for the consumption of 
carbohydrates from The National Diet and Nutrition Survey with data from 3450 
adults aged 19 years and over and 3378 children aged 1½-18 years collected 
over between 2008-2012 (PHE, 2014). For adults, 45% of total dietary intake 
was carbohydrates, in alignment with national recommendations. The mean 
intake of sugar was 95-103 g/day for adults, approximately 1/5th of total energy 
intake. All age groups on average had 11% of their total energy intake from 
sugar, higher than the original recommendation of 10%. The most commonly 
consumed sugar was sucrose, which accounted for half of the total sugar 
intake (40-50 g/day). Soft drinks and fruit were top contributors to total sugar, 
13% each, followed by table sugar (sucrose) at 9%. The mean starch 
consumption was 110-135 g/day in adults (SACN, 2015). One of the key 
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factors behind the recommendation to decrease free sugars was the strong 
evidence that high sugar intake leads to increased energy intake, and therefore 
obesity, an established type 2 diabetes risk factor (Grundy et al., 2005).  
 Sugar and health 1.2.3
Despite the fact that controlling glycaemic response has a positive effect on 
health markers, the commonly accepted perspective is that sugar is not a 
cause of diabetes, but is a cause of obesity which is a proven risk factor for 
diabetes (Zimmet et al., 2001; Grundy et al., 2005). However, a recent study 
found that sugar intake was an independent risk factor for diabetes and 
cardiovascular disease (Schmidt, 2014). In an analysis of population-level data 
from 174 countries, the relationship between obesity and diabetes was not 
directly associated. A statistical analysis of multi-variate data from numerous 
countries over time was conducted. It determined that sugar availability, based 
on food supply data, was found to be an independent and statistically 
significant determinant of diabetes (Basu et al., 2013). Similarly, the incidence 
of diabetes and obesity has been correlated to high availability of high fructose 
corn syrup, which consists of approximately 55% fructose and 45% glucose 
(Goran et al., 2013). The SACN report on carbohydrates highlights that there 
are a lack of studies to be able to draw conclusions on the health effect of 
individual sugars. Data from four randomised controlled trials with 1 to 6 
months follow up provided evidence that higher consumption of sugars leads to 
increased energy consumption and is therefore detrimental to health (SACN, 
2015). A meta-analysis of four cohort studies investigating sucrose, the most 
commonly consumed sweetener, found borderline association between high 
10 
 
 
 
sucrose and reduced incidence of type 2 diabetes (SACN, 2015). There was an 
association between sugar-sweetened beverages and type 2 diabetes and 
obesity (SACN, 2015). Dietary sugar intake can also indirectly lead to 
dysregulation of lipid and carbohydrate metabolism through increased body 
weight and fat. In agreement with the findings in the SACN report, a systematic 
review and meta-analysis of cohort studies and randomised controlled trials 
found that the intake of free sugars in ad libitum diets was associated to 
increased body weight due to an overall increase in energy intake (Te Morenga 
et al., 2013).  
The metabolic consequences of glucose, sucrose and fructose intake differs. 
The GI of fructose and sucrose are lower than glucose (Atkinson et al., 2008) 
which prompted the food industry, particularly in the USA, to increase the use 
of fructose as a sweetener in the form of high-fructose corn syrup (Augustin et 
al., 2015; Stanhope, 2016). The correlation between fructose and fructose 
containing sugars with obesity and diabetes has prompted investigations into 
the potentially harmful effects of fructose, for which some controversy still 
remains. Glucose and fructose are utilised in glycolysis, gluconeogenesis, TCA 
cycle, lactate formation, pentose phosphate shunt and lipid synthesis however 
they enter these pathways differently (Sun and Empie, 2012). Glucose 
homeostasis requires insulin whereas fructose metabolism is insulin-
independent (Laville and Nazare, 2009; Sun and Empie, 2012). Fructose 
stimulates de novo lipogenesis in the liver, which leads to increased 
triglycerides. This stimulation requires both glucose and insulin to be present; 
hence sucrose intake has lipogenic effects. The change in lipid composition of 
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cell membranes has an effect on the uptake of glucose, resulting in insulin 
sensitivity (Laville and Nazare, 2009; Lim et al., 2010; Douard, 2012). 
Furthermore, the elevated triglycerides from fructose or sucrose intake in turn 
causes obesity and leptin resistance, where satiety signals do not reach the 
brain and this leads to further consumption of food, to exacerbate the obesity 
problem (Lim et al., 2010). One of the harmful effects of fructose that is often 
reported is related to the involvement in the de novo lipogenesis pathway, 
however this pathway is minor in humans and requires excess energy intake, 
which could explain why some studies observed no deleterious effects 
compared to glucose (Laville and Nazare, 2009). Furthermore, a review of 
several studies suggests that fructose exerts harmful effects only with intake > 
100 g/day and many studies reporting harmful effects of fructose use high 
concentrations that are not physiologically relevant and performed in a similar 
manner to toxicology studies (Augustin et al., 2015). The deleterious effects 
from fructose and fructose containing sugars on plasma lipids and de novo 
lipogenesis is still under debate (Sun and Empie, 2012; Stanhope, 2016). 
Further studies to investigate the effects of individual sugars on the 
development of diabetes will help provide valuable dietary recommendations to 
help tackle its rising incidence.  
 Sucrase isomaltase 1.2.4
Sucrase isomaltase (SI) is a highly N- and O-glycosylated brush border type-II 
membrane protein with various α-glucosidase activities, and is trafficked to the 
cell surface through the association with lipid rafts (Naim et al., 2012). SI 
consists of two subunits, sucrase and isomaltase, which are cleaved by luminal 
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proteases but remain associated through non-covalent interactions (Quan and 
Gray, 1993). The sucrase subunit has both maltase (α-1,4) and sucrase (α-1,2) 
activities, while the isomaltase subunit has maltase (α-1,4)  and isomaltase (α-
1,6) activities (Jones et al., 2011) (Figure  1-2). SI is therefore involved in the 
digestion of both sugars and starch. Type 2 diabetic patients have increased 
levels of SI, which potentially increases the rate of sugar digestion and uptake 
and exacerbates the problem, making it an interesting target (Dyer et al., 2002). 
The sucrase subunit is the sole enzyme responsible for hydrolysis of sucrose. 
Maltase glucoamylase is another brush border which hydrolyses (α-1,4) bonds 
from substrates including maltose and isomaltase as well as amylopectin, 
glycogen, starch and amylose, although its isomaltase activity is very minimal 
in comparison to SI (Van Beers et al., 1995). Sucrase isomaltase is more 
abundant in humans than maltase glucoamylase and accounts for 80% of 
maltase activity  (Semenza, 1986). Of these two brush border α-glucosidases, 
SI plays a greater role in starch and sugar digestion. 
In the endoplasmic reticulum (ER), N-glycans are attached to SI which are 
essential for folding and movement out of the ER (Danielsen, 1992) and the 
size of 210 kDa represents this immature form of the enzyme, referred to as 
Pro-SI. At the Golgi complex, SI is further N- and O-glycosylated to yield 
mature SI, of size 240 kDa (Naim et al., 2012). In human intestinal biopsies, 
two subunits are detected due to the cleavage by luminal proteases, 120-140 
kDa size is isomaltase and 140-150 size is sucrase (Conklin et al., 1975). The 
time required for processing of the Pro-SI to functional SI at the cell surface is 
between 1-3 hours (Danielsen, 1992). The first published sequence of the 
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human SI gene (Chantret et al., 1992) was used to predict that there are 18 N-
glycosylation sites although the actual sites of glycosylation have not been 
confirmed. The active site of each subunit and the proteolytic cleavage site 
have been identified (Van Beers et al., 1995).  
 
Figure  1-2. The sucrase isomaltase at the ER is N-glycosylated and this 
immature form is 210 kDa. Further N- and O-glycoyslation occurs at the 
Golgi leading to the mature 240 kDa form which is then trafficked to the 
apical brush border via lipid rafts. The type-2 transmembrane protein is 
cleaved by luminal proteases into two active subunits which remain 
associated. The isomaltase subunit has maltase and isomaltase activity and 
sucrase subunit has maltase and sucrase activity. 
 
The study of Congenital Sucrase Isomaltase Deficiency (CSID), in which 
digestion of sucrose is absent or reduced, has aided in uncovering information 
about SI trafficking and cell polarisation. The disorder is an autosomal 
recessive disorder that occurs in 0.2% of people of European descent and 
leads to abdominal pain and severe discomfort upon the ingestion of sucrose. 
The disorder has several phenotypes that have been identified and typically 
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only affects the sucrase subunit, with isomaltase activity remaining normal or 
sometimes absent. Point mutations in the isomaltase lead to phenotype I which 
has partial or absent sucrase and isomaltase activity due to alteration of 
trafficking. Only the immature 210 kDa form is present (Naim et al., 2012).  
 Regulation of sucrase isomaltase 1.2.5
Regulation of SI has generally been reported as transcriptionally controlled 
(Van Beers et al., 1995). In Caco-2 cells, a common model of the small 
intestine, SI expression was related to glucose consumption; a low glucose 
consuming Caco-2 clonal cell line expressed higher levels of SI. In this clone, 
the amount of SI increased during differentiation and this corresponded to the 
mRNA expression levels (Chantret et al., 1994). The expression level of SI 
mRNA did not appear to change between cells cultured in 1 or 25 mM glucose 
(Mahraoui et al., 1994). Most previous reports on SI detected transcriptional 
regulation, for example forskolin and monensin both decreased SI activity in 
Caco-2 cells through reduced transcription (Chantret et al., 1993). 
There have been some reports that SI can be regulated by its substrate and 
products. Studies in cells and rats have shown that monosaccharides have 
regulatory effects on sucrase at the mRNA level, but these compare the 
expression to that of a starved or low-carbohydrate state (Ferraris et al., 1992; 
Quan and Gray, 1993; Kishi et al., 1999) . In rats, a carbohydrate-free diet for 
7-days decreased sucrase activity by 50%, there was no change in Km but a 
decrease in Vmax, indicating less available or active enzyme. The reduced 
activity was hypothesised to be due to changes in post-translational 
modifications, identified by altered migration on western blots (Quan and Gray, 
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1993). There have been several studies that investigated SI activity in response 
to dietary sucrose in rats and mice. Rats were fed a control sugar-free diet or 
either glucose, fructose or sucrose diets with three meals given in a 12 hour 
period. SI and SGLT1 mRNA levels were enhanced by sucrose in comparison 
to the no sugar diet (Kishi et al., 1999). Fructose and sucrose both increased 
mRNA to a greater extent than glucose. In another study in rats there was an 
increase in SI mRNA levels in as little as 3 hours after they were force-fed 
sucrose. Prior to sucrose loading, the rats had been fed a carbohydrate-free 
cellulose diet. The activity of sucrase also increased but an hour after the 
mRNA increase, suggesting approximately 1 hour for processing of SI to the 
functional form (Broyart et al., 1990). An increase in SI specific activity has also 
been observed in rats and mice fed a high sucrose diet in comparison to a low 
carbohydrate diet (Ferraris et al., 1992). A sucrose diet given to rats following a 
low starch diet induced sucrase and maltase activities within 6 hours and rats 
on high starch diet had increase level of SI activities compared to low-starch 
diet (Samulitis-dos Santos et al., 1992). These studies suggest that there is an 
increase in SI activity in response to sucrose after starvation or a low starch or 
no carbohydrate diet. The studies thus far do not provide evidence regarding 
whether sucrose, in comparison to glucose, can induce SI. 
There is some evidence that the small intestine may be able to sense and 
respond to sugars (Le Gall et al., 2007). Human intestinal enterocytes in the 
duodenum express T1R2 and T1R3 taste receptors which are activated by 
sugar, upon which α-gustucin within the cell activates adenyl cyclase and 
cAMP increases (Alpers, 2010).  The mRNA expression of the taste receptors 
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is negatively correlated to blood glucose levels in type 2 diabetic patients 
(Young et al., 2009). SGLT1 mRNA and protein are both upregulated by 
glucose, and in rats this was linked to the taste receptor cascade since mice 
without T1R3 or α-gustducin no longer showed SGLT1 regulation by glucose 
(Margolskee et al., 2007) T1R2 and T1R3 have been identified on the 
basolateral membranes in Caco-2/TC7 cells (Le Gall et al., 2007). Glucose, 
fructose, sucrose and a mixture of glucose and fructose all simulated the SI 
promotor activity in Caco-2/TC7 cells however the control was under starvation; 
it is expected that the addition of sugars will stimulate the promotor in 
comparison to the control which has no energy substrate provided (Le Gall et 
al., 2007). 
Type 2 diabetic patients have increased levels of SI, GLUT2, SGLT1 and 
SLUT5 which potentially increases the rate of sugar digestion and uptake and 
exacerbates the problem (Dyer et al., 2002). The increase in SI was also 
observed in a diabetic rat model and was found to be due to a decrease in its 
degradation rate (Olsen and Korsmo, 1977). In obese patients with insulin 
resistance, an increase in GLUT2 was observed at the apical membrane of the 
gut, as compared to healthy lean individuals (Ait-Omar et al., 2011). An 
increase in intestinal digestion of carbohydrates was also observed in a 
diabetic mouse model (Adachi et al., 2003). Since the level of carbohydrate-
digesting enzymes and transporters are altered during disease, a greater 
understanding of if and how their substrates are involved in their regulation is of 
interest. 
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1.3 Polyphenols and health 
 Overview 1.3.1
Historically, plant extracts have been used for therapeutic purposes, for 
example in Chinese traditional medicine and the observed health benefits are 
hypothesised to be in part due to their high phenolic content. It has been 
reported that up to 30% of patients with type 2 diabetes turn to alternative 
therapies such as plant supplements (Dragan et al., 2015), therefore an 
understanding of their mechanism of action is important. Polyphenols are plant 
secondary metabolites that are found in high abundance in plant based foods 
such as berries, fruits, soya, coffee, chocolate and beverages such as tea and 
coffee. Their basic structure includes an aromatic ring with one or more 
hydroxyl groups and they are classified into groups based on the number of 
phenol rings and how they are linked together. The estimated dietary intake of 
polyphenols is 1 g/day (de Bock et al., 2012). The effects of polyphenols on 
glucose homeostasis and their potential to aid in reducing the risk of diabetes 
has been extensively reviewed (Bahadoran et al., 2013; de Bock et al., 2012; 
Williamson, 2013; Hanhineva et al., 2010; Kim et al., 2016; Babu et al., 2013). 
Polyphenols have been associated with decreased incidence of disease 
including diabetes, cardiovascular disease and osteoporosis (Laville and 
Nazare, 2009; Hanhineva et al., 2010; Scalbert et al., 2005). For example, an 
epidemiological study suggests that polyphenol-rich tea and coffee can reduce 
the risk of type 2 diabetes (Huxley et al., 2009). Clinical intervention trials have 
been able to provide evidence for specific polyphenols; for example 
consumption of a dark chocolate rich in catechins and procyanidins for 15 days 
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was able to improve insulin sensitivity and reduce blood pressure in healthy 
patients and in those with hypertension (Grassi et al., 2005). A strong 
adherence to the Mediterranean diet was associated with a significant reduced 
risk of mortality from all causes, including a 9% reduction in mortality from 
cardiovascular disease (Sofi et al., 2008) and part of the protective effect is 
attributed to high consumption of polyphenol-rich foods (Martínez-González et 
al., 2015).  
There are several mechanisms through which polyphenols could influence 
glucose homeostasis in the body and aid in prevention and development of 
type 2 diabetes and further complications (Thomas and Pfeiffer, 2012; 
Williamson, 2013; Hanhineva et al., 2010). Firstly, the small intestine is an 
important target for polyphenols to aid in glucose homeostasis by their ability to 
inhibit α-glucosidases and subsequent transport of monosaccharides through 
the enterocytes (Hanhineva et al., 2010; Williamson, 2013). Postprandial 
polyphenol concentration is the highest in the gut lumen and can reach 
millimolar concentrations, making this a key site at which they may exert 
beneficial effects (Williamson, 2013). A common strategy for reducing the risk 
of metabolic syndrome is by inhibition of carbohydrate digestion to lead to 
reduced blood glucose response, much like the anti-hyperglycaemic drug 
acarbose (Van de Laar et al., 2005). Polyphenols have also exerted action at 
the liver with effects on β-cell function; ferulic acid and cinnamic acid 
derivatives promoted insulin secretion in a rat model (Adisakwattana et al., 
2008). The uptake of glucose by tissues can also be influenced; for example, 
polyphenol polymers found in cinnamon exhibited insulin-like action (Anderson 
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et al., 2004).  Finally, hepatic function can be affected; epigallocatechin gallate 
(EGCG) decreased endogenous glucose production in the liver (Wolfram et al., 
2006) and the citrus polyphenols hesperetin and naringenin were able to 
reduce blood glucose through changed in hepatic glucose regulating enzymes 
(Jung et al., 2004). The observed health benefits of polyphenols in 
observational studies are a combination of these mechanisms exerted by 
complex mixtures of polyphenols in the whole diet. Further mechanistic studies 
and randomised controlled trials are required to identify particular polyphenols 
or combinations of polyphenols to make more detailed dietary 
recommendations and health claims.  
 Acute inhibition of α-glucosidases by polyphenols  1.3.2
Polyphenols have the potential to act as α-glucosidase inhibitors and therefore 
have the potential to lower the glycaemic response, much like the 
pharmacological treatments such as acarbose, described in Section 1.1.3. The 
in vitro inhibitory effect of polyphenols on α-glucosidase activity has been 
previously reviewed and summarised (Hanhineva et al., 2010). Inhibition of α-
glucosidase and α-amylase has been reported by flavonoids (anthocyanins, 
catechins, flavanones, flavanols, isoflavones), phenolic acids, and tannins. 
However, the published reports to date that evaluate the inhibition of α-
glucosidase and α-amylase enzymes have substantial limitations. For example, 
it was recently reported that polyphenols can interfere with detection of assay 
products using the 3,5-dinitrosalicylic acid (DNS) assay which quantifies 
reducing sugars and is commonly used for α-amylase assays (Nyambe-
Silavwe et al., 2015). The aromatic DNS reagent reacts with reducing sugars 
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and the formation of 3-amino-5-nitrosalicylic acid is monitored by its 
absorbance at 540 nm. Inhibition assays for α-glucosidase often use similar 
spectrophotometric techniques to quantify glucose, such as those based on 
glucose oxidase or hexokinase glucose assays. These assays are readily 
available and are commonly used because glucose does not have a 
chromophore so cannot be readily quantified directly without specialised 
analytical systems such as ion chromatography. It is hypothesised that 
polyphenols may also interfere with these enzymatic techniques and this is 
rarely accounted for in the literature. 
Although human enzymes are always the intended target for therapeutic 
interventions, many studies use the more readily available rat intestinal 
preparations in vitro. However, there is only 74% homology between the rat 
and human sucrase isomaltase (Van Beers et al., 1995), which raises the 
question as to whether using the rat assay is physiologically relevant to 
humans. Some studies use yeast enzyme sources, but flavonoids exert 
different inhibitory effects towards yeast or rat α-glucosidase; anthocyanidins, 
isoflavones and flavonols were strong inhibitors of yeast α-glucosidase with 
IC50 values less than 15 µM, whereas they only weakly inhibited rat α-
glucosidases with IC50 values at low mM concentrations (Tadera et al., 2006). 
There are limited studies investigating inhibition of sucrase from a human 
source. One report investigated inhibition of α-glucosidases by an extract from 
mulberry leaves using the human Caco-2 cell model with cells cultured on 
porous filters, however this method involves the subsequent transport and 
metabolism of the enzymatic assay products (Hansawasdi and Kawabata, 
21 
 
 
 
2006). Further experiments to investigate the effects on transport 
independently from the digestion would be required to identify the effect on the 
digestive enzymes alone. Other inhibition assays have been developed using 
human Caco-2 cell lysates, however one failed to address the potential 
interference of the inhibitors on the detection method and limited assay kinetics 
were provided (Krog-Mikkelsen et al., 2011). Another assay provided details to 
satisfy assay kinetics, but samples required further processing including 
derivatisation before GC/MS analysis, which may not be as practical for large 
scale screening, and additionally the cells were not fully differentiated (Jockovic 
et al., 2013). 
Additionally, some literature reports use p-nitrophenyl α-D-glucoside as the 
substrate however this substrate is non-specific so the effects on specific 
enzyme activities are indistinguishable. The concentration of the inhibitors is 
another important consideration. Some polyphenols have poor solubility. For 
example, quercetin has been reported to be an inhibitor, with an IC50 value of 
1450 µM towards sucrase and 710 µM towards maltase (Ishikawa et al., 2007). 
However, quercetin requires ethanol or DMSO for solubility (Srinivas et al., 
2010) and would therefore have limited solubility in aqueous solutions so would 
not be soluble at these high concentrations in assay buffer. It is probable that 
quercetin had precipitated from the solution and interfered with the detection by 
spectrophotometry. Furthermore, flavonoids can absorb in UV/Vis so their 
presence in the sample will affect the glucose quantification. 
In setting up an inhibition assay, the time course and enzyme activity need to 
fall within the linear range. Outside of the linear range, the reaction reaches the 
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steady-state does not apply so Michaelis-Menten kinetics are not valid 
(Bisswanger, 2014). Furthermore, if the substrate concentration is too high, the 
ability of competitive inhibitors to bind and inhibit an enzyme is reduced (Acker 
and Auld, 2014). The amount of enzyme units present in the assay can also 
affect the inhibition outcome (Nyambe-Silavwe et al., 2015). It is therefore 
essential that the assay is optimised prior to use; some literature reports fail to 
describe the assay conditions in full, making comparison between different 
reports difficult.  
Although there are an abundance of reports on polyphenols and α- glucosidase 
inhibition, experiments that take into account these issues are required to 
confirm and strengthen the evidence. There are very few results in the literature 
with strong evidence of sucrase inhibition by polyphenols using the human 
enzyme. 
 Acute inhibition of glucose transport 1.3.3
Selected polyphenols can inhibit glucose transport and the first reported effect 
was by the flavonoid glucoside phloridzin and was evaluated in a hamster 
model using radiolabelled glucose (Alvarado, 1967). Phloridzin is now a well-
established inhibitor of glucose transport that is specific to active transport via 
SGLT1. The first use of the human intestinal cell model Caco-2 to evaluate 
acute inhibition of glucose transport by polyphenols screened several classes 
of compounds (Johnston et al., 2005). Radiolabelled glucose (D-[6-3H]-glucose) 
was used as the substrate on the apical side and the radioactivity was 
determined after transport on apical and basolateral sides. Inhibition of glucose 
transport via SGLT1 occurred with 100 µM neohesperidin dihydrochalcone by a 
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similar extent to the phloridzin control. The aglycones quercetin, phloretin, 
apigenin, and myricetin inhibited glucose transport via GLUT2. The catechins  
(-)-epigallocatechin gallate, (-)-epicatechin gallate and (-)-epigallocatechin were 
able to inhibit glucose transport by both facilitated transport by SGLT1 and 
active transport by GLUT2 (Johnston et al., 2005). A review of polyphenols and 
glucose homeostasis summarises other in vitro transport assays (Williamson, 
2013). For example, strawberry and apple polyphenols inhibited transport via 
both GLUT2 and SGLT1, with stronger effects on GLUT2 (Manzano and 
Williamson, 2010).  
 Chronic effects on α-glucosidases and transport 1.3.4
Chronic intake of acarbose in patients with impaired glucose tolerance led to a 
6% reduction in the risk of the progression to type 2 diabetes (Nijpels et al., 
2008). The mechanism of action of acarbose is through its inhibition of starch 
and sugar digestion so it is possible that polyphenols, with their similar 
inhibitory effect, might also reduce the risk of diabetes. Other mechanisms by 
which acarbose could lead to chronic health benefits have not been 
established. There are other chronic mechanisms which could lead to reduction 
in starch or sugar digestion. For example, reduced expression or protein levels 
of an enzyme or decreased trafficking to the cell surface could lead to less 
active enzyme present at the cell surface. This in turn would lower the 
glycaemic response chronically without the requirement for direct inhibition. 
Acute effects require the inhibitor to be consumed with the meal, however a 
chronic change in the level of the enzyme would provide a more constant 
change. This approach would be particularly suited to diabetic patients who 
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have an increase in the level of α-glucosidase enzymes and transporters (Dyer 
et al., 2002).  
The in vitro studies that investigate the effects of polyphenols on α-glucosidase 
enzymes and glucose transport have been predominantly acute studies 
(Section 1.3.3). There are limited reports where chronic treatments have been 
used (Section 1.3.4). One study found that an anthocyanin-rich berry extract 
reduced glucose transport by GLUT2 after a chronic 16 hour treatment in Caco-
2/TC7 cells (Alzaid et al., 2013) but there are very few other studies 
investigating chronic effects of polyphenols in the small intestine. Polyphenol 
rich diets such as the Mediterranean diet are linked to reduction in chronic 
diseases, however, there is a gap in knowledge regarding mechanisms by 
which these chronic health benefits occur. More studies using chronic 
treatments are required to help understand the health benefits of regular 
consumption of polyphenol-rich foods. 
1.4 Caco2/TC7 cell model 
The Caco-2 cell line is a primary cell line that was derived from a colon 
carcinoma and is commonly used as a model for the small intestine. Upon 
differentiation, these cells form a polarised monolayer with an apical brush 
border, representing the gut lumen, and basolateral side, representing the 
interstitial fluid, and they express small intestinal hydrolases and transport 
proteins (Sambuy et al., 2005). Caco-2 cells have been used for the 
investigation of polyphenol transport (Teng et al., 2012; Kosińska and 
Andlauer, 2012) and to investigate the influence of polyphenols on glucose 
transport (Johnston et al., 2005). The model is also reported to be suitable for 
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screening compounds for their effect on glycaemic response. First, inhibition of 
sucrase was observed by the naturally occurring pentose L-arabinose using the 
Caco-2 cell model. Next, a cross-over design human intervention study 
determined the effect in vivo using sucrose beverages with and without L-
arabinose. Attenuation of both the blood glucose and insulin responses 
occurred which validated the use of the in vitro assay in identifying inhibitors 
that will have in vivo effects (Krog-Mikkelsen et al., 2011).  
Clones of the Caco-2 cell model were created for the purpose of investigating 
the transcriptional control of SI as it had been observed that glucose could play 
a role. The clones from a late passages had increased growth rate and cell 
density, were more homogeneous and had a 7-10 fold increase in sucrase 
activity whereas the clones from a lower passage demonstrated increased 
glucose consumption and lower SI activity (Chantret et al., 1994). The TC7 
clone was described as a low glucose consuming clone and it is commonly 
used due to the fact that the cells are more stable and have more homogenous 
expression of proteins as compared to the parental line (Sambuy et al., 2005; 
Caro et al., 1995). Upon review of their characteristics, they have been 
recommended as a more suitable model for the small intestine as compared to 
the parental line (Sambuy et al., 2005). Further, they have also been 
characterised for the purpose of drug transport and transformation studies and 
are favourable to the parental line due to greater taurocholic acid transport, 
higher activity of UDP-glucuronosyltransferases and highly inducible 
cytochrome P450IA1 genes, all of which are important characteristics for drug 
metabolism studies (Caro et al., 1995). The experiments in this thesis involved 
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SI and the monosaccharide transporters SGLT1, GLUT2 and GLUT5, all of 
which are present in the small intestinal enterocytes and are concomitantly 
expressed in the Caco-2/TC7 cell line (Mahraoui et al., 1994). The glucose 
transporters GLUT1 and GLUT3 are also expressed in Caco-2/TC7 cells 
however they will not play a role in glucose transport in this model because 
their expression is high during the initial phase of growth and then very low 
after Day 20 (Mahraoui et al., 1994) and this is similar to the in vivo situation 
where glucose transport occurs through GLUT2 and SGLT1 (Kellett et al., 
2008). The homogeneity of the Caco-2/TC7 cell line, expression of SI, GLUT2, 
and GLUT5 and the fact that SI mRNA and protein remain stable up until at 
least passage 40 (Chantret et al., 1994) make it a suitable model for studying 
sucrose hydrolysis and subsequent transport of the monosaccharides. 
1.5 Project Aims and hypothesis 
This thesis investigates the hypothesis that in addition to acute inhibition of 
sucrase activity, polyphenols might exhibit chronic reduction in sucrase activity. 
The α-glucosidase enzyme sucrase isomaltase is the main focus in this thesis 
since sucrose is the most commonly consumed sweetener in Europe and this 
enzyme is involved in both starch and sugar digestion. Furthermore, sucrose is 
specifically hydrolysed by sucrase whereas activities towards other starch and 
sugar substrates arise from several enzymes. The mechanisms that are 
evaluated include transcription, translation, processing and trafficking, 
hydrolysis and transport (Figure 1-3).  
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Figure  1-3. Potential mechanisms by which polyphenols could affect sucrase 
isomaltase and the subsequent glycaemic response. After a chronic 
treatment, the effects on transcription and translation can be determined by 
quantifying changes in mRNA and protein. The effects on post-translational 
modifications and trafficking can be evaluated by determining cell surface 
protein and analysis of the enzyme size. The activity of sucrase enzyme can 
be determined with in vitro enzyme assays and sugar transport studies can 
be performed. 
 
Diabetic patients have increased levels of sucrase isomaltase therefore 
lowering its expression through chronic polyphenol intake would be beneficial in 
controlling the glycaemic impact in response to sucrose leading to health 
benefits. This hypothesis is investigated and addressed using the Caco-2/TC7 
cell model with the following aims: 
1)  To optimise a method for the acute inhibition of sucrase and maltase by 
polyphenols which will address some of the limitations that were 
presented in Section 1.3.2. (Chapter 3). 
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2) To characterise the Caco-2/TC7 cell model and evaluate the effects of 
glucose and sucrose exposure on sucrase isomaltase (Chapter 4). 
3) To evaluate if a polyphenol-rich extract from olive leaves that is known to 
be an acute sucrase and maltase inhibitor exhibits any chronic changes 
to sucrase isomaltase with the goal of reducing sucrase activity (Chapter 
5).  
4) To perform transport studies with glucose or sucrose as the substrate 
using Caco-2/TC7 cells that are cultured in situ on porous supports to 
further investigate the chronic and acute effects of the polyphenol-rich 
olive leaf extract (Chapter 6).  
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2 General methodology 
2.1 Caco-2/TC7 cell culture 
 Materials and equipment 2.1.1
Caco-2/TC7 cells were a kind gift from Dr M. Rousset, U178 INSERM, Villejuif, 
France. Dulbeccos’s modified Eagle’s Medium, fetal bovine serum, glucose, 
non-essential amino acids, penicillin/streptomycin solution, sucrose, trypsin 
were from Sigma Aldrich, Dorset, UK.  Dulbeccos’s modified Eagle’s Medium 
without glucose, Glutamax™ and SYBR® Safe stain were from Thermo Fisher, 
Loughborough, UK. Cell culture flasks and plates (75 cm2 flasks, 6-well plates, 
12-well plates, 6-well and 12-well transwell® plates with PET membrane at 0.4 
µM) were from Corning, Amsterdam, The Netherlands. LDH cytotoxicity 
detection kit was from Roche, Burgess Hill, UK. Human intestine tissue total 
RNA reference sample was from DV biologics, California, USA. Zymoclean™ 
gel extraction PCR recovery kit was from Zymo Research, California, USA. 
Cloneamp HiFi PCR premix and In-fusion cloning kit were from Takara Bio 
Europe, Saint-Germain-en-Laye, France 
  Medium preparation 2.1.2
The standard Caco-2/TC7 cell culture medium contained high glucose (25 mM) 
Dulbeccos’s modified Eagle’s Medium (DMEM) supplemented with 20% (v/v) 
fetal bovine serum, 2% (v/v) Glutamax™, 2% (v/v) non-essential amino acids, 
100 U/mL and 0.1 mg/mL streptomycin. Apical medium was prepared as above 
but with the absence of fetal bovine serum. For comparison of 25 mM glucose 
and 25 mM sucrose, DMEM medium with no glucose was supplemented with 
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either 25 mM glucose or 25 mM sucrose and with 20% (v/v) fetal bovine serum, 
2% (v/v) non-essential amino acids, 100 U/mL penicillin and 0.1 mg/mL 
streptomycin. 
 Cell line maintenance and seeding 2.1.3
Caco-2/TC7 cells were routinely cultured at a density of 1.2 x 106 cells per 75 
cm2 culture flask in standard medium and maintained in an incubator at 37°C 
with 10% (v/v) CO2. Medium was replaced every two days and at this seeding 
density, 80% confluence was reached in three days at which point the cells 
were sub-cultured by detaching with 0.25% (v/v) trypsin. All cell counting was 
carried out using a haemocytometer. Cell Seeding for experiments was carried 
out according to Table  2-1. A diagram of the transwell® filters is presented in 
Figure  2-1. Cell culture on transwell® filters allows the formation of a polarised 
monolayer and access to the apical side, representing the gut lumen, and the 
basolateral side. From day 1-7, regular medium containing FBS was added to 
both sides. From confluence at day 7, apical medium (no FBS) was added on 
the apical side for the remaining days of culture.  
 
Figure  2-1. Transwell® filter plates for polarised cell culture 
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Table  2-1. Seeding Density for Caco-2/TC7 Cells 
Plate 
Description 
Seeding 
Density 
(cells/cm2) 
Growth 
Area (cm2) 
Medium 
Volume 
(mL) 
Corning 
Product 
Number 
Experiment 
Types 
6-well solid 
support 
64000 
 
9.5 2 mL 3506 mRNA, 
protein 
12-well solid 
support 
64000 
 
3.8 1 mL 3512 mRNA, 
protein, LDH 
Assay  
6-well 
transwell® 
64000 
 
4.67 2 mL 
basolateral, 
1 mL apical 
3450 Cell surface 
biotinylation  
12-well 
Transwell® 
64000 
 
1.12 1 mL 
basolateral, 
0.5 mL 
apical 
3460 Transport  
 
 Chronic treatments 2.1.4
Intestinal enterocytes differentiate in vivo as they move from the crypt towards 
the villus tip where they are shed every 4-5 days as a self-renewal process 
(Umar, 2010). During cellular differentiation, the cells will be exposed to the 
nutrients within the intestinal lumen. In an attempt to mimic the in vivo exposure 
in vitro, Caco-2/TC7 cells were treated with polyphenol-rich extracts over the 
final three days of differentiation; days 18, 19, 20 with experiment on day 21. 
After chronic treatment, the effect on sucrase isomaltase mRNA, sucrase 
activity and sucrase isomaltase total and cell surface protein and the effect on 
glucose and sucrose transport across Caco-2/TC7 cells was evaluated. For 
treatment on solid supports, the treatment extract was dissolved directly into 
medium and then sterile filtered with 0.2 µM filter prior to adding to the cells. 
For treatment on transwell® filters, the treatment extract was dissolved into 
apical medium, sterile filtered and then added to the apical side only.  
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  Cell viability by LDH 2.1.5
Caco-2/TC7 cell viability was determined for experiments with chronic 
treatments. Cells were seeded on 12-well solid supports and maintained and 
treated as previously described (Section 2.1.3 and 2.1.4) and viability was 
determined using the LDH cytotoxicity detection kit according to the 
manufacturer’s protocol.  Lactate dehydrogenase (LDH) is released into cell 
culture medium in cells that are damaged and no longer viable, so the activity 
of LDH released into the medium can be used to determine the viability of the 
cells. 
2.2 Gene expression 
 Materials and equipment 2.2.1
The QX200 Droplet Digital PCR system which includes the Biorad C1000 
Touch™ Thermal Cycle with Deep Well Reaction Module, QX200™ droplet 
Reader, QX200™ Droplet generator and PX1™ PCR plate sealer, all 
consumables for the system and the ddPCR™ Supermix (1863024) were from 
Biorad Laboratories UK, Hemel, Hertfordshire, UK. The GoScript™ Reverse 
Transcription System was from Promega, Madison, WI, USA. The 
RNAqueous® kit was from Ambion, Life Technologies, Thermo Fisher 
Scientific, Loughborough, UK. The TaqMan® probes listed in Table  2-2  were 
from Life Technologies, Paisley, UK.  The StepOne Real time PCR System was 
from Applied Biosystems, Life Technologies Ltd, Cheshire, UK.  
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Table  2-2. Taqman® Primers and probes used for digital PCR 
Gene ID Target Life Technologies 
Primer/Probe ID 
CDX2 CDX2 Hs01078080_m1 
SLC2A2 GLUT2 Hs01096905_m1    
SLC2A5 GLUT5 Hs01086390_m1 
SLC SGLT1 Hs01573790_m1  
SI sucrase isomaltase Hs00356112_m1 
TAF1 TBP Hs00936234_m1  
 
 Digital PCR 2.2.2
2.2.2.1 Background 
Droplet digital PCR (ddPCR) was used to quantitate changes in gene 
expression. The method of ddPCR involves partitioning a gene amplification 
PCR reaction into more than 15,000 nano-litre sized droplets prior to 
performing the PCR cycle, and then reading each individual droplet as either 
positive or negative for the gene of interest. The template for the reaction is 
spread over the droplets with the requirement that some of the droplets will be 
negative meaning they contain no template of the gene of interest and others 
will be positive for the template of the gene of interest. Quantitation is based on 
the proportion of positive droplets relative to the total number of droplets and 
their known volume, yielding a result in copies/µL of the gene of interest. This 
calculation is based on a Poisson distribution with Poisson correction to correct 
for the fact that some droplets may contain multiple copies of the template 
(Huggett et al., 2013). The PCR detection uses TaqMan® probes in which the 
probe for the gene of interest is fluorescently conjugated to 6-
carboxyfluorescein (FAM) with absorption at 494 nm and emission at 518 nm 
and the probe for the reference gene is conjugated to reference dye VIC with 
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absorption at 538 nm and emission at 554 nm. The different flourophores allow 
for simultaneous determination of the gene of interest with the reference gene. 
The tata-box binding protein (TBP) was used as the house-keeping/reference 
gene to correct for gene expression, allowing quantification and comparison of 
the relative expression of various genes analysed. A method summary is 
presented in Figure  2-1. 
 
Figure  2-2. Droplet digital PCR method flow chart 
 
2.2.2.2 Procedure  
Caco-2/TC7 cells were seeded on 6-well culture plates and grown as described 
in  2.1.3. On day 21, total RNA was extracted using the RNAqueous Total RNA 
Isolation kit according to the manufacturer’s protocol. The concentration of the 
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sample was determined using the Nanodrop®. 250 ng of total RNA was 
converted into cDNA by reverse transcription using the GoScript™ Reverse 
Transcription System, according the manufacturer’s protocol. Each 20 µL 
assay consisted of individual cDNA template (2.5 ng for SI, CDX2 or 5 ng for  
GLUT2, GLUT5, SGLT1), 1 µL of 20x FAM-labelled Taqman primer for gene of 
interest and 0.33 µL of 60x VIC-labelled Taqman primer for TBP (TATA-box 
binding protein) housekeeping control and 10 µL ddPCR Supermix. Droplets 
were prepared with QX100 droplet generator before cycling in C1000 touch 
thermal cycler: 95°C for 10 min followed by 40 cycles of 94°C for 30 sec, 
57.8°C for 60 sec with a final incubation at 98°C for 10 min. The droplets were 
analysed on a QX100 droplet reader and analysed using Quantasoft software 
which determines the concentration of target cDNA in copies/µL based on the 
Poisson distribution from the fraction of positive droplets ( >10000 droplets per 
assay). Each individual cDNA sample was analysed with technical triplicates. 
Results are reported as the ratio between target and housekeeping gene 
copies/µL. 
 Sequencing the SI gene from Caco-2/TC7 cells 2.2.3
2.2.3.1 Background 
The method for the preparation of gene-specific DNA for sequencing analysis is 
presented in Figure  2-3. Briefly, total RNA was extracted from cells and 
converted to single stranded complementary cDNA using a gene-specific 
primer for the reverse transcription reaction. The primer was designed to be 
located outside of the open reading frame (ORF) for the gene of interest. The 
cDNA products were of varying lengths and then PCR was used to amplify the 
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cDNA containing the full length of the gene. For the PCR reaction, gene- 
specific PCR primers were used that anneal to the start and end of the gene of 
interest. The PCR product was run on an agarose gel next to a size ladder to 
identify the band at the size of the gene of interest. This band was extracted 
from the gel using a gel extraction kit and the purified gene-specific DNA was 
sent for Sanger sequencing analysis.  
 
Figure  2-3. Method flow chart for preparation of gene-specific DNA for 
sequencing. Reverse transcription of total TNA is performed using a gene- 
specific primer and the resulting cDNA is amplified with gene-specific 
primers. The amplified product is run on a PCR gel and the band at the size 
of the target gene is extracted and sent for Sanger sequencing analysis. 
 
 
 
37 
 
 
 
 
2.2.3.2 Primer design and reverse transcription to generate cDNA 
The reference sequence for human sucrase isomaltase mRNA was obtained 
from the NCBI database (NM_001041.3) and used to design primers. Sucrase 
isomaltase was reverse transcribed in two parts due to the length (~5.5 kb). 
Two sucrase isomaltase gene-specific primers were designed; the first was 
located beyond the stop codon of the open reading frame for sucrase 
isomaltase and the other was mid-way through the sequence at position 1811 
of the reference sequence: 
RT primer 1 5’ tagagtacaagaaccaagtgaagagggaaaattg    
RT primer 2 5’ cagcaaatgttgagcgggtaaga   
 
Total RNA was extracted from Caco-2/TC7 as described in Section 2.2.2.2. The 
human intestine tissue total RNA sample was analysed as a control. Reverse 
transcription (RT) was performed on both total RNA samples using the 
GoScript™ RT System with the sucrase isomaltase gene-specific primers. One 
control sample was prepared without any RNA template and another control 
sample was prepared without any RT enzyme, to check for DNA contamination.  
2.2.3.3 PCR amplification of sucrase isomaltase 
Two sets of primers were designed for the amplification of the two RT products: 
1- forward 5’ ccatggcgggcattgctgctgaccagttgatttctattg 
1- reverse 5’ cagcaaatgttgagcgggtaaga   
2- forward 5’ gcttcattcttscccgctcaacatttgctg 
2- reverse 5’ cgctaccggtcgccaccatggcaagaaagaaatttag 
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The PCR reaction to amplify sucrase isomaltase from the cDNA sample was 
performed using the Cloneamp™ HiFi PCR Premix. The PCR sample 
contained 4% DMSO to enhance unwinding of the DNA. The PCR cycle started 
at 98°C for 1 min, followed by 40 cycles of 98°C for 30 sec and 72°C for 6 min. 
The samples were then held at 72°C for 12 min and finally kept at 4°C. The 
resulting PCR products were run on a 0.1% agarose gel containing SYBR® 
Safe stain for the visualisation of DNA. The two PCR product bands were 
extracted from the gel using the Zymoclean™ gel extraction PCR recovery kit. 
The two PCR products overlap and cover the entire coding region of SI so were 
cloned together using the In-fusion cloning kit which uses a recombinase 
enzyme to fuse the overlapping homologous sequences together. Lastly, the 
full SI product produced through the cloning kit was amplified by PCR using the 
original PCR primers 1-Forward and 2-Reverse and the product was run on a 
0.1% agarose gel to confirm the size of the product. The band was extracted 
from the gel as described previously and sent for DNA Sanger sequencing by 
Beckman Coulter Genetics. Table  2-3 lists the primers that were used for the 
sequencing analysis. 
Table  2-3. Primers used for Sanger sequencing of SI mRNA 
Primer Name Sequence 
Suc510-F 5’ actcaaaatcagacacccaatcgtttccgg 
Suc1174-F 5’ gtggtaaggagaaaccgggaagctggc 
Suc1811-F 5’ gcttcattcttacccgctcaacatttgctg 
Suc2461-F 5’ caagaaccagatgtaacaacaacagcaagc 
Suc3014-F 5’ cagtcaactcagctcgctattcatccatggg 
Suc3594-F 5’ ccagccaactcctgctctaacttacc 
Suc4161-F 5’ caggacttccacagcagagtggtgggc 
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2.3 Protein analysis 
 Materials and equipment 2.3.1
Bradford reagent, octyl β-D-glucopyranoside, phosphate buffered saline with 
MgCl2 and CaCl2 (PBS+), protease inhibitor cocktail, sodium chloride, and 
trizma base were from Sigma-Aldrich, Dorset, UK. Rapid PNGase F was from 
New England Biolabs, Hitchin, UK. Cell surface protein isolation kit, NuPage 
LDS 4x sample buffer, and Pierce™ Microplate BCA protein assay kit were 
from Thermo Fisher Scientific, Loughborough, UK. The sucrase isomaltase 
antibody HBB2/614/88-s was from the Developmental Studies Hybridoma 
Bank, Iowa, USA. The α-actinin antibody MAB8279 was from R&D Systems, 
Abingdon, UK. The Simple Western WES system and 66-440 kDa mouse 
master kit (PS-MK11 or MK09) were from ProteinSimple®, California. The 
Nanodrop ND-1000 spectrophotometer was from Thermo Scientific, 
Loughborough, UK. The PHERAstar FS plate reader was from BMG labtech, 
Ortenberg, Germany. 
 Determination of total protein 2.3.2
Either the Bradford assay (Bradford, 1976) or the BCA assay (Smith et al., 
1985) were used for total protein determination in cell lysates according to the 
manufacturer’s protocol and protein standard curves were prepared using 
bovine serum albumin.  The BCA assay was used when samples contained 
octyl β-D-glucopyranoside as the kit was reducing reagent compatible. All other 
samples use the Bradford assay. For the Bradford assay, the absorbance was 
measured at 595 and 450 nm and the ratio of 595/450 was used for the 
standard curve as the linearization is improved (Zor and Selinger, 1996). 
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 Determination of target proteins using automated western blot 2.3.3
technology: ProteinSimple® WES  
2.3.3.1 Background 
ProteinSimple™ WES, was used as an alternative to traditional western blot as 
it is an automated system and can provide greater reproducibility. Furthermore, 
the system is highly sensitive and low sample volume is required for the 
analysis. The samples are loaded into capillaries containing a proprietary UV-
activated chemical linked reagent and proteins are separated by size, 
immobilized and target proteins are identified using primary antibodies and 
immuno-probed using a horseradish peroxidase-conjugated secondary 
antibody and chemiluminescent substrate (Figure  2-4). The peak area of 
chemillumenscence is reported for each protein of interest, and results can be 
viewed in traditional western blot lane view or by pherogram peak view. 
 
Figure  2-4. Schematic diagram for ProteinSimple® Simple Western WES 
system for quantification of target proteins.  
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2.3.3.2 Procedure 
Caco-2/TC7 cells were cultured as described in  2.1. Cells were washed with 
ice-cold PBS and scraped into lysis buffer containing 60 mM octyl β-D-
glucopyranoside, 150 mM NaCl, 20 mM Tris pH 7.4 and 0.5% protease inhibitor 
cocktail. Samples were passed through a 21G needle 15 times then kept on ice 
for 10 min with vortexing every few minutes. The lysate was centrifuged at 
14000 g for 10 min at 4°C. The total protein concentration of the supernatant 
was determined by the BCA assay (Section  2.3.2). The samples were then 
prepared for ProteinSimple WES™ analysis according to the manufacturer’s 
recommendations. Samples were denatured at 95°C for 5 min prior to loading 
on the analysis plate. The sample concentration and antibody concentration 
were determined prior to any quantification runs, as detailed in section  2.3.3.3. 
2.3.3.3 Antibody set-up  
For quantification by WES, the antibody for the protein of interest and a loading 
control were set up by determining the appropriate antibody concentration and 
linearity range. The two antibodies are analysed in the same sample capillary 
so the linearity must be checked when they are measured in the same capillary 
(multiplexed), rather than in independent capillaries, to ensure they do not 
interfere with each other. The manufacturer recommends that the antibody 
concentration used should be near saturation for the detection, providing that 
the chosen concentration gives linearity over the range of total protein 
concentrations and there is no interference or unusually high background.  The 
SI antibody was evaluated from 0.48 to 4.8 mg/mL (Figure  2-5A) and saturation 
was achieved with 1.92 mg/mL which was a 1/25 dilution. The antibody 
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concentrations were also evaluated for α-actinin and a 1/100 dilution was 
chosen. A representative pherogram is presented in Figure  2-5B for a Caco-
2/TC7 lysate at 0.2 mg/mL using the chosen antibody concentrations. The 
assay had linear fit from 0.025 to 0.2 mg/mL total protein concentration for SI, 
α-actinin and the ratio of SI/α-actinin (Figure  2-5C and D).  
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Figure  2-5. ProteinSimple™ WES optimisation for the quantification of sucrase 
isomaltase with α-actinin as the loading control. A) The peak area of SI in 
Caco-2/TC7 cell lysate at 0.1mg/mL protein concentration use 4 different SI 
antibody concentrations. B) Representative pherogram of SI/α-actinin in 
Caco-2/TC7 lysates at 0.2 mg/mL total protein. C) Linearity of SI, α-actinin 
and the ratio of SI/α-actinin from 0.025 to 0.2 mg/mL total protein D) Lane 
view of multiplexed run with SI and α-actinin in Caco-2/TC7 lysates from 
0.025 to 0.2 mg/mL total protein. 
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2.3.3.4 Data analysis 
The ProteinSimple® Compass software version 2.6.7 was used for analysis, 
which performs automatic peak integration to give the chemiluminescent peak 
areas for the proteins analysed. The ratio of SI/α-actinin was used to perform 
quantification of sucrase isomaltase protein.  
 Cell surface protein – biotinylation method 2.3.4
2.3.4.1 Background 
The amount of sucrase isomaltase at the cell surface was determined to 
investigate effects on trafficking. A cell surface biotinylation method was used 
to purify apical cell surface proteins (Figure  2-6). The sulfo-NHS-SS- Biotin 
(sulfosuccinimidyl-2-(biotinamido)ethyl-1,3-dithiopropionate) reagent is 
commonly used for the biotinylation of cell surface proteins by reacting with 
primary amino groups on the side chains of lysine and the N-terminus of 
proteins to form a stable amine bond. The negative charge of the sulfonate 
group makes the reagent impermeable to the cell membrane. The biotinylated 
surface proteins are then extracted with NeutrAvidin agarose resin based on 
the strong non-covalent interaction between biotin and avidin. NeutrAvidin is 
used in this kit rather than streptavidin as it reduces non-specific binding 
(Daniels, 1998). Beads are added in excess to ensure the binding capacity is 
not fully saturated. The resin beads are washed to remove the non-biotinylated 
proteins then the surface proteins are eluted from with a reducing buffer. The 
protein released is only modified by a small sulfhydryl group. The method used 
here is based on the Thermo Fisher cell surface protein isolation kit (89881) 
with some modifications. The kit was scaled down for the labelling of 6-well 
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transwell® plates, as opposed to 75 cm2 culture flasks as used in the provided 
protocol. To wash the beads, high and low ionic strength washes were used to 
help clear all non-biotinylated proteins, as recommended in published method 
in Methods in Enzymology (Daniels, 1998). 
 
Figure  2-6. Biotinylation of cell surface proteins utilising the strong nature of the 
biotin- streptavidin non-covalent bond. A) Protein amino groups at the N-
terminus or on amino acid side chains are biotinylated using NHS-S-S-biotin 
reagent to yield the biotinylated protein and sulfo-NHS by-product B) The 
biotinylated proteins are added to streptavidin-agarose beads and incubated 
for 1 h at room temperature. The beads are washed to remove non-
biotinylated proteins and then heated at 95°C in reducing sample buffer 
containing 50 mM DTT to cleave the disulfide bond, releasing the purified 
surface proteins from the biotin label. 
 
46 
 
 
 
2.3.4.2 Preparation of reagents 
Stock solutions of 5 M sodium chloride and 1 M trizma base at pH 7.4, adjusted 
with hydrochloric acid, were prepared and stored at room temperature. A 1 mM 
dithiothreitol (DTT) stock solution was prepared by dissolving the pre-weighed 
tubes from the cell surface biotinylation kit in 50 µL of deionised water. Cell 
lysis buffer was prepared containing 60 mM octyl β-D-glucopyranoside, 150 
mM NaCl, 20 mM trizma base and 0.5% protease inhibitor. Wash solution 1 
was prepared containing 10 mM octyl β-D-glucopyranoside, 500 mM sodium 
chloride and 20 mM trizma base. Wash 2 was prepared containing 20 mM 
trizma base pH 7.4. Tris buffered saline (TBS) was prepared as 150 mM 
sodium chloride and 20 mM trizma base pH 7.4. For the biotinylation reagent, 
0.25 mg/mL of biotin EZ-Link™ Sulfo-NHS-SS-Biotin from the cell surface 
protein isolation kit was prepared in PBS+.  The quenching solution was 
provided in the kit. The elution solution was prepared as 50 µM DTT in 50% 
NuPage LDS sample buffer and 50% deionised water.  
2.3.4.3 Procedure 
Caco-2/TC-7 cells were cultured for 21 days on 6-well transwell® inserts as 
described in Section  2.1 to form a fully differentiated and polarised monolayer. 
The cells were washed three times with PBS+ and 1 mL of biotinylation reagent 
was added to the apical side of the filter and 1.5 mL of PBS+ to the basolateral 
side. The plate was rotated on ice at 4°C for 30 min. The reaction was stopped 
by adding 50 µL of quenching buffer to the apical side and 100 µL to the 
basolateral side then rotating for 5 min at 4°C.  The wells were washed twice 
with TBS to bind any residual biotin and lysed with 0.5 mL of lysis buffer. The 
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cells were mixed vigorously with lysis buffer, transferred into a microcentrifuge 
tube and left on ice for 10 min with occasional vortexing. The lysate was 
centrifuged at 14000 g for 10 min at 4°C and the supernatant was removed and 
transferred to a clean microcentrifuge tube. The total protein concentration in 
the supernatant was measured using a Nanodrop™ and an aliquot of 0.3 mg of 
protein in 150 uL lysis buffer was prepared. 50 µL of streptavidin agarose resin 
slurry was pre-washed with PBS+ and then lysis buffer and sample was added 
and rotated for one hour at room temperature. The resin was washed with 0.5 
mL of each of lysis buffer, wash 1 and wash 2. The purified surface proteins 
were eluted by the addition of 40 µL of elution solution followed by heating for 
15 min at 37°C. The samples were stored at -80°C until analysis by 
ProteinSimple® WES, as described in section  2.3.3.  
2.3.4.4 Data Analysis and Statistics 
Each sample well generates two samples: the total cell lysate containing all 
proteins within the cell, and the purified surface fraction from the streptavidin 
bead extraction. The peak area of SI and loading control α-actinin were 
determined in both the total lysate and the purified surface fraction using WES. 
The absence of α-actinin in the cell surface fraction indicates that the 
biotinylation specifically labels the cell surface and is not internalised, since α-
actinin is only located within the cell. The ratio of the peak area of SI to the 
peak area of α-actinin in the total cell lysate was used to compare the amount 
of total sucrase between the control and treated cells. The absolute amount of 
SI in the cell surface purified fraction was reported. 
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Figure  2-7. Cell surface biotinylation sample flow chart with example of 
bonolive treatment. 
 
 Protein sample digestion with PNGase F 2.3.5
PNGase F enzyme performs the de-glycosylation of all N-linked 
oligosaccharides from a protein so was therefore used to investigate the N-
glycosylation of sucrase isomaltase. Protein lysate samples in lysis buffer were 
digested with rapid PNGase F. Following the manufacturer’s instructions, 5 µg 
of total protein from the cell lysate was digested with PNGase F alongside a 
mock treated sample in which water was added in the place of PNGase F 
enzyme. Samples were incubated for 10 min at 50°C. 5.6 µL of the sample was 
added to 1.2 µL of WES master mix and heated for 5 min at 95°C to deactivate 
the PNGase F enzyme and denatured for the analysis. The samples were then 
analysed using ProteinSimple® WES as detailed in section  2.3.3. 
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2.4 Quantification of glucose 
 Materials and equipment 2.4.1
Glucose, Greiner 96-well flat bottom plates, fructose, hexokinase reagent, 
sodium phosphate mono- and di-basic and sucrose were from Sigma Aldrich, 
Dorset, UK. The PHERAstar FS plate reader was from BMG labtech, 
Ortenberg, Germany. The ICS4000 system for high-performance anion 
exchange with pulsed amperometric detection (HPAE-PAD), Carbopac PA20 
column (0.4 x 150 mm), CarboPac PA20 Guard column (0.4 mm x 35 mm) 13 
mm 0.2 µM PTFE filters, 250 µL polypropylene vials and pre-slit snap caps 
were from Thermo Fisher, Loughborough, UK.  
 Hexokinase assay 2.4.2
2.4.2.1 Background 
The hexokinase assay from Sigma was used for the quantitative determination 
of glucose in enzyme assay samples. The assay is based on the following 
reactions: 
Glucose + ATP Heokinase  Glucose-6-Phosphate + ADP 
Glucose-6-Phosphase + NAD G6PDH  6-Phosphogluconate + NADH 
The absorbance of NADH is determined at 340 nm and is proportional to the 
concentration of glucose. The hexokinase reagent containing 1.5 mM NAD, 1.0 
mM ATP, 1.0 unit/ml of hexokinase and 1.0 unit/ml of glucose-6-phosphate 
dehydrogenase (G6PDH) is used for the reaction.   
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2.4.2.2 Procedure 
Glucose standard solutions were prepared at 0.05, 0.1, 0.3, 0.5, 0.8, 1, 2, 5 and 
10 mM glucose in 10 mM phosphate buffer. According to the manufacturer’s 
protocol, 10 µL of each standard or test sample was added to a 96-well plate in 
triplicate for Atest and triplicate for Asample blank.  250 µL of hexokinase reagent 
was added to Atest wells and 250 µL of deionised water was added to Asample blank 
wells. Reagent blank control and water blank control wells were also included 
in triplicate. The plate was shaken for 30 sec and incubated at 30°C for 15 min, 
followed by measurement of the absorbance at 340 nm. Acorr was determined 
by correction of the blank controls as follows: 
Acorr = Atest – Atotal blank 
Atotal blank = Asample blank + Areagent blank – Awater blank 
The mean Acorr  value for 0 mM glucose samples was subtracted from all 
glucose standards and plotted against glucose concentration in mM and the 
linear fit was determined.  
2.4.2.3 Method accuracy, precision and linearity 
The method was validated by the independent preparation and analysis of four 
standard curves. The linearity was confirmed for glucose concentrations 
between 0.05 to 10 mM, and a representative standard curve is presented in 
Figure  2-8. At each concentration level, the variation between technical 
triplicates was less than 2% with the exception of the lowest concentration of 
0.05 mM, for which the variation was less than 5%. To determine the accuracy, 
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the concentration at each standard level was calculated using the equation of 
the standard curve and the percent difference from the expected value was 
determined. For all concentration levels the percent difference was ≤2% and for 
the lowest concentration of 0.05 mM the percent difference was ≤5%. The 
slope from four independent standard curves had a variation of 0.4% indicating 
low inter-assay variation. 
 
Figure  2-8. Calibration curve for the quantification of glucose standards by 
hexokinase assay. The values are presented as mean ± SEM (linear fit Y= 
0.168x; R2= 0.99; average relative standard deviation 4.1%, n=4). Error bars 
are smaller than the data points.   
 
 Method optimisation and validation for the quantification of 2.4.3
glucose, sucrose and fructose by HPAE-PAD 
2.4.3.1 Background 
The analysis of monosaccharides and disaccharides by conventional HPLC/UV 
method is challenging due to the highly polar nature of carbohydrates and their 
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lack of a suitable chromophore. Methods in the past have utilised derivatisation 
methods which introduce time and variability into the analysis. High 
performance anion exchange chromatrography (HPAE) with pulsed 
amperometric detection (PAD) offers a solution to these challenges. 
Carbohydrates are weakly acidic and therefore ionised at high pH 
concentrations, and based on this HPAE separation utilises a basic NaOH 
eluent with a hydrophobic anion exchange resin to achieve separation. PAD 
detection utilises a gold working electrode upon which the analytes are undergo 
an oxidation reaction and the resulting current is measured in coulombs. A 
method was set up using Thermo Dionex ICS-4000 HPAE-PAD system for the 
analysis of sugars in enzyme assay samples, cell transport assays and cell 
sugar uptake. The method was validated for the quantitation of glucose, 
sucrose and fructose. 
2.4.3.2 Standard and sample preparation 
Glucose, sucrose and fructose standard solutions were prepared in deionised 
water at 50 mM. A mixed standard containing all three components was 
prepared at 1000 µM and subsequently diluted to working standard 
concentration range from 0.5 µM to 50 µM. HPAE-PAD was used for the 
analysis of transport samples (Chapter 6) and inhibition assay samples 
(Chapter 3). Inhibition samples were diluted with deionised water to fall within 
the calibration range. Since assay samples contained biological material, the 
protein in the samples was precipitated prior to analysis by the addition of 
acetonitrile (1:1 v/v), vortexed and centrifuged at 17000 g for 10 min. The 
resulting supernatant was diluted with deionised water to fall within the 
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calibration range and the total sample dilution was 25-fold. All standards and 
samples were filtered with 13 mm 0.2 µM PTFE filters into polypropylene vials 
and maintained at 4°C in the auto-sampler. Inhibition assay samples were in 
phosphate buffer and transport samples were in transport buffer, so standards 
were prepared in these buffers to confirm that they do not affect quantification. 
The assay samples contained 2% acetonitrile and this was also confirmed to 
have no impact on quantification. 
2.4.3.3 Instrument and method parameters 
The HPAE-PAD system had an electrochemical detector, palladium reference 
electrode, gold working electrode and was operated with Chromeleon® 
software version 7.2 SR4. Capillary separation of carbohydrates was done 
using the capillary Carbopac PA20 column, 0.4 x 150 mm with CarboPac PA20 
Guard, 0.4 x 35 mm with the column at 30°C and compartment at 15°C. The 
detection was performed using a gold working electrode and palladium 
reference electrode with a collection rate of 2.00 Hz using the “Gold, Carbo, 
Quad” waveform. Different concentrations of sodium hydroxide eluent were 
evaluated to achieve isocratic baseline separation of glucose, fructose and 
sucrose and 25 mM NaOH was chosen. The analysis method starts at 25 mM 
NaOH eluent for 10 min followed by a wash at 100 mM for 15 min to remove 
any salts or impurities and then re-equilibration at 25 mM for 13 min. The flow 
rate was 0.008 mL/min with 0.04 µL injection volume and 20x capillary overfill. 
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2.4.3.4 Specificity 
Individual glucose, fructose and sucrose solutions were prepared at 10 µM and 
analysed alongside a mixed standard to identify the elution order (Figure  2-9). 
Glucose eluted first with a retention time of 7.8 min ± 0.13% followed by 
fructose at 9.3 min ± 0.17% and then sucrose at 10.9 min ± 0.20%. 
 
Figure  2-9. Identification of glucose, fructose and sucrose peaks from HPAE-
PAD chromatograms by analysis of individual standards. 
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2.4.3.5 Precision 
For the determination of method precision, 10 injections were performed from 
one vial containing 5 µM standard mixture of glucose, fructose and sucrose. 
The actual concentration was determined for each injection and the mean was 
4.9 ± 0.08 (SD) µM with 1.7% CV for glucose, 4.7 ± 0.13 (SD) µM with 2.9% 
CV for fructose and 5.0 ± 0.17 (SD) µM with 3.3% CV for sucrose. The 
accuracy compared to the standard curve was -1.3%, -7.0% and -0.5% for 
glucose, fructose and sucrose respectively.  
2.4.3.6 Linearity and Accuracy of Calibration Range 
 
 
Figure  2-10. HPAE-PAD calibration standard curves for glucose (A) fructose 
(B) and sucrose (C) from 0.5 µM to 50 µM. 
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The standard curve calibration samples at 0.5, 1.0, 2.5, 5.0, 10, 25 and 50 were 
injected 4 times. The linear equations were used to calculate the actual 
concentration of each injection and the accuracy was determined by comparing 
the calculated concentration to the expected concentration. For glucose and 
sucrose, accuracy at 0.5 µM was 76% and 67% respectively and therefore 
quantitation at this level was not accurate as the values should be at least ± 
10% of the expected value. For all other levels, accuracy was within ± 5% of 
the expected value. For sucrose, accuracy within ± 5% of the expected value 
occurred from 2.5 to 50 µM. The accurate quantitation range for glucose and 
fructose was between 1.0 to 50 µM and for sucrose was between 2.5 to 50 µM. 
Samples below the lower limit for accuracy were reported as less than limit of 
quantitation (<LOQ). Samples for which no peak was observed are reported as 
not detected (ND).  
2.5 Preparation of polyphenols and extracts and controls 
 Materials  2.5.1
Polyphenols: 5-caffeoyl-quinic acid, (+)-catechin, (-)-epicatechin, (-)-
epigallocatechin gallate, galangin, hesperitin, kaempferol, luteolin, naringenin 
and quercetin were from Sigma Aldrich, Dorset, UK. Apigenin was from 
Phytolab, Vestenbergsgreuth, Germany. 
Extracts: Bonolive was kindly supplied by BioActor BV, The Netherlands as a 
powder containing 40% (w/w) of the bioactive oleuropein (OLE).  Green tea 
water-soluble extract was from Nestlé, Choladi, India. The green tea extract 
was analysed by HPLC (Nyambe-Silavwe and Williamson, 2016) and 1 mg/mL 
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contained 199.8 mg/g (-)-epigallocatechin gallate, 124.4 mg/g (-)-
epigallocatechin, 34.4 mg/g (-)-epicatechin gallate and 23.3 mg/g (-)-
epicatechin. The German chamomile was from Phytolab, Vestenbergsgreuth, 
Germany and a maltodextrin-free sample was kindly prepared by Jose A. Villa-
Rodriguez. Note that maltodextrin was removed as it can act as a substrate to 
sucrase isomaltase to produce glucose during the enzyme assays. 
Positive Controls: acarbose and forskolin were from Sigma Aldrich, Dorset, UK. 
 Procedure 2.5.2
Individual polyphenols were dissolved in DMSO and diluted for subsequent use 
into sample buffer. Control samples were spiked with an equivalent amount of 
DMSO and DMSO did not exceed 2% of the sample volume. Positive controls 
and extracts were water-soluble so were prepared in deionised water. 
2.6 Statistics and sample replicate notation 
All values shown are the mean of n independent experiments ± standard error 
of the mean, unless otherwise stated. Each experiment had between 3-6 
technical replicates. N is the total number of technical replicates. For cell 
experiments, 3 different passages of cells were used. For analysis of statistical 
significance between multiple groups, ANOVA was used. If the ANOVA 
indicated a difference between the groups (p<0.05), Tukey post-hoc analysis 
was performed to determine the p-values. For the comparison of the means of 
two groups, unpaired Students t-test was performed, with confidence level at 
95%. Levene’s test was performed to confirm the equality of variances. 
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3 Inhibition of human and rat sucrase and maltase activities: 
optimisation of the assay using acarbose and polyphenols 
3.1 Abstract 
The anti-diabetic drug acarbose reduces the post prandial blood glycaemic 
response by inhibiting -glucosidases (maltase and sucrase), required for the 
digestion of carbohydrates, and -amylase, required for the digestion of starch. 
Chronic intake of acarbose led to a 6% reduction of type 2 diabetes risk (Nijpels 
et al., 2008). Other compounds such as polyphenols have been reported to 
exhibit a comparable activity. However, for assessing this activity, many assays 
use a rat intestinal extract as the α-glucosidase source, and then extrapolate to 
human tissues. Results in this chapter demonstrate that cell-free extracts from 
fully differentiated intestinal Caco-2/TC7 monolayers are a suitable source of 
the human enzymes sucrase and maltase, and the in vitro assay was optimised 
by comparing enzymatic and chromatographic methods to detect the products. 
Human sucrase was more susceptible than the rat enzyme to inhibition by 
acarbose, a polyphenol-rich green tea extract, and pure (-)-epigallocatechin 
gallate, whereas the reverse was observed when assessing rat maltase 
activity. 5-Caffeoyl-quinic acid up to 500 µM did not inhibit any of the measured 
activities. We demonstrate that spurious results can be obtained if the amount 
of enzyme and assay conditions are not optimised, and if the tested compound 
inhibits or interferes with the product detection methodology. The data show 
that for sucrase and maltase activities, the inhibition of rat and human enzymes 
can be several-fold different. 
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3.2 Introduction 
The prevalence of type 2 diabetes has doubled over the last thirty years and 
affects an estimated one in ten worldwide, and non-communicable diseases 
including cardiovascular disease and diabetes mellitus account for more deaths 
than infectious diseases (WHO, 2012). A meta-analysis of intervention studies 
suggests that reducing the glycaemic impact of the diet can favourably affect 
health markers for type 2 diabetes (Livesey et al., 2008). One current 
pharmaceutical therapy for diabetes is based on the strategy of reducing the 
glycaemic impact though inhibition of α-glucosidase enzymes in the gut and 
these include the anti-hyperglycaemic drugs  acarbose, voglibose and miglitol 
(Breuer, 2003). Type 2 diabetic patients have increased levels of SI which 
exacerbates the problem, making it an interesting target for inhibition (Dyer et 
al., 2002). Natural products have been sought as alternatives or adjuncts to 
these treatments, since the drugs exhibit gastro-intestinal side effects.   
Consumption of polyphenols has been associated with decreased incidence of 
disease including type 2 diabetes, cardiovascular disease and osteoporosis 
(Scalbert et al., 2005; Laville and Nazare, 2009; Hanhineva et al., 2010). Part 
of this effect is the potential for polyphenols to influence sugar digestion and 
absorption (Williamson, 2013). The small intestine is an important target for 
polyphenols to aid in glucose homeostasis by the inhibition of α-glucosidases 
and subsequent transport of monosaccharides through the enterocytes 
(Hanhineva et al., 2010). In an intervention study where acarbose was taken for 
three years, the risk for diabetes was reduced by 6% compared to the control 
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(Nijpels et al., 2008) so there is potential that chronic intake of a diet rich in 
polyphenols could improve diabetes risk through the same mechanism, i.e. the 
inhibition of α-glucosidases. 
Although polyphenols have the potential to act as α-glucosidase inhibitors 
(Hanhineva et al., 2010) , there are substantial limitations to some of the 
methods used to date (Section 1.3.2). Although human enzymes are always 
the intended target for therapeutic interventions, many studies use the more 
readily available rat intestinal preparations in vitro with a variety of detection 
methods for the products, typically enzyme-linked spectrophotometric assays 
based on glucose oxidase or hexokinase (Jo et al., 2009; Gupta et al., 2010; 
Kim et al., 2011; Priscilla et al., 2014). However there has been no proper 
comparison between the inhibition of human and rat enzymes, and very few 
studies have used human enzyme. Furthermore, there is only 74% homology 
between the rat and human enzyme (Van Beers et al., 1995). Polyphenols 
inhibition assays are further complicated by their effects on the glucose 
detection methods, and this is not always taken into account and was 
addressed here.  
The aim is to first optimise the assay for sucrase and maltase inhibition using a 
human enzyme source from Caco-2/TC7 cells. This includes evaluating 
methods for the preparation of the enzyme source and detection methods. Next, 
the optimised assay is used to determine inhibition of selected polyphenols and 
extracts; acarbose, green tea, (-)-epigallocatechin gallate since inhibition of rat 
sucrase and maltase has been observed in the Williamson lab (Nyambe Thesis, 
2016). The results from the assay using the rat enzyme source are compared 
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here to use of a human enzyme source. Other polyphenols and extracts 
available in our laboratory are screened for sucrase inhibition for comparison 
with literature values. 
3.3 Method optimisation 
 Background on human enzyme assay  3.3.1
The human enzyme assay was set up using Caco-2/TC7 cell lysates as the 
enzyme source, based on same principle as the enzyme assay using rat 
intestinal powder (Nyambe-Silavwe and Williamson, 2016). Assay samples of 
250 µL contained sucrose or maltose substrate, Caco-2/TC7 cell lysate 
preparation in 0.1 M phosphate buffer (pH 7.0). Samples were incubated for the 
optimised time (determined in 3.3.7.1) at 37°C and the reaction was stopped by 
boiling for 10 min at 95°C which denatures the enzyme. Samples were 
centrifuged at 17000 g for 10 min. Finally, the concentration of glucose 
produced was quantified. For all assays, the enzyme was pre-warmed at 37°C 
and the substrate and inhibitor were pre-warmed in a separate tube. In the 
upcoming sections, the apparent Km and Vmax kinetic parameters were 
determined and the linear ranges for time and enzyme concentration were 
optimised. Two methods for the preparation of the cell lysate were evaluated. In 
addition, enzymatic and chromatographic detection of glucose, the effect of 
substrate concentration and the effect of enzyme amount on apparent inhibition 
were evaluated. The potential interference from inhibitors on the detection 
methods was addressed.   
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The assay flow chart for the final IC50 determination is presented in Figure  3-1. 
First, the cell lysate was prepared from Caco-2/TC7. Next, using the optimised 
parameters, the specific activity of the cell lysate was determined. One enzyme 
unit (U) is equal the amount of enzyme that catalyses the hydrolysis of 1 µmol 
of substrate per min. Finally, the assay was used to determine the inhibition of 
sucrase and maltase by selected polyphenols with the same amount of activity 
(based on number of units added per assay).   
 
Figure  3-1. Method flow chart for the sucrase isomaltase enzyme assay. A) The 
cell lysate was prepared from Caco-2/TC7 cells. B) An enzyme activity assay 
was performed with varying enzyme concentrations to determine the 
Units/mg of total protein in the lysate. C) Enzyme inhibition assay with 
specified number of units. The inhibition assay includes the optional SPE 
step to remove the inhibitors form the assay if they were shown to interfere 
with the detection method. Two alternative detection methods were 
evaluated. 
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 Materials and equipment 3.3.2
Sodium potassium monobasic, sodium potassium dibasic, glucose, sucrose, 
maltose, intestinal acetone powder from rat, protease inhibitors, L-cysteine, 
papain from papaya latex were from Sigma Aldrich, Dorset, UK. Oasis MAX 
cartridges were purchased from Waters Corporation Ltd., Milford, MA, USA. 
Polyphenols and inhibitors are described in Section 2.5.  Other methods are 
found in general methodology (Chapter 2). 
 Preparation of enzyme source 3.3.3
Caco-2/TC7 cells were cultured in 75 cm2 flasks as described in Section 2.1 to 
full differentiation of 21 days. The cells were washed three times with cold 
phosphate buffered saline and cells were scraped with 1 mL of assay buffer (10 
mM phosphate buffer, pH 7.0) containing protease inhibitors. The cell lysates 
were snap frozen in a dry ice and ethanol bath and stored at -80°C until 
required. On the day of assay, cell lysates were thawed, vortexed and then 
passed 10-15 times though a 21G needle syringe, and referred to as a cell-free 
extract since it contains no intact cells. Papain-digested lysates were also 
prepared to evaluate different lysate preparation methods.  Fully differentiated 
cells were washed with warm PBS and then incubated at 37°C for 15 min with 
2 mL papain solution containing 1 mg/mL papain and 0.5 mg/mL L-cysteine 
(Auricchio et al., 1963). After the incubation, cells were scraped and transferred 
into microcentrifuge tubes and centrifuged at 210 g for 10 min at 4°C. The 
supernatant was used for the assay. The protein content of the lysate, either 
crude or papain-digested, was determined by Bradford Assay (Section 2.3.2) 
and the lysate was diluted in assay buffer as required. 
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 Assay controls 3.3.4
A control was included where the enzyme was deactivated by 10 min boiling 
prior to the assay to confirm that the deactivation step was sufficient. A control 
sample with no substrate and no enzyme was also analysed with each 
experiment. 
 Glucose detection methods – hexokinase and HPAE-PAD  3.3.5
The glucose produced in the enzyme reaction was quantitated enzymatically 
using hexokinase (Section 2.5), or chromatographically with high performance 
anion exchange chromatography with pulsed amperometric detection (HPAE-
PAD) (Section 2.7). Before HPAE-PAD analysis, protein in the samples was 
precipitated by the addition of acetonitrile (1:1 v/v) and samples were vortexed 
and centrifuged at 17000 g for 10 min. The resulting supernatant was diluted 
with deionised water to fall within the calibration range, filtered through a 0.2 
µM PTFE filter and maintained at 4°C in the autosampler.  
 Effect of polyphenols on hexokinase assay and removal by SPE 3.3.6
To evaluate if polyphenols or polyphenol-rich extracts interfere with the 
hexokinase assay, 250 µL samples containing 5 mM glucose were prepared in 
assay buffer with and without polyphenols or extracts at the highest tested 
concentration. The hexokinase assay was performed to measure the amount of 
glucose and the samples were compared to the control. Independent sample T-
test was performed to determine if the inhibitors had significant effect on the 
assay. Any inhibitors which interfered significantly were removed by SPE prior 
to analysis. Oasis MAX 3 cc cartridges were preconditioned with 1 mL of 
65 
 
 
 
deionised water and 1 mL of methanol then dried under vacuum for 5 min. The 
sample collection tube was placed under the cartridge and 200 µL of sample 
was passed through and collected while polyphenols were retained. 
 Determination of assay conditions 3.3.7
3.3.7.1 Determination of reaction time and enzyme concentration and 
kinetic parameters Km and Vmax 
A time course was determined for sucrase and maltase using 10 mM substrate 
for each. Sucrase exhibited a linear production of glucose up to 40 min and 
maltase was linear up to 15 min (Figure  3-2). An assay time of 10 min was 
selected for both as this falls well within the linear range and is convenient for 
handling assays with both sucrase and maltase simultaneously. 
 
Figure  3-2.Time course for sucrase (A) and maltase (B) assay. Results are 
presented as mean ± SEM (n=3). Error bars not visible are smaller than the 
data point.  
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A specific activity assay was performed for maltase and sucrase with different 
amounts of enzyme added based on the total protein concentration, up to 0.3 
mg total protein with 10 mM substrate concentration and 10 min incubation. 
The specific activity of sucrase was 130 ± 4 mU/mg and for maltase was 725 ± 
36 mU/mg (Figure  3-3). Sucrase specific activity was proportional to total 
protein up to 1.28 mg/mL whereas maltase was proportional up to 0.64 mg/mL. 
The amount of protein used for assays was selected to be within the linear 
range to satisfy the conditions of initial rate: 0.05 U per assay for maltase and 
0.02 U per assay for sucrase. 
 
Figure  3-3. Specific activity in the Caco-2/TC7 cell lysate for sucrase (A) and 
maltase (B). The enzyme assay was performed with 10 mM substrate, 10 
min incubation time and different amounts of enzyme up to 0.3 mg total 
protein. Results are presented as mean ± SEM (n=3). 
 
Using the conditions established, the apparent Km and Vmax for sucrase and 
maltase were determined using Lineweaver-Burk plots (Figure  3-4). For 
sucrose, apparent Km = 9.5 mM and Vmax = 0.053 µmol/min; for maltose, 
apparent Km = 7.5 mM and Vmax = 0.379 µmol/min. 
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Figure  3-4. Lineweaver-Burk plot for the determination of apparent Km and Vmax 
for sucrase (A) and maltase (B). Results are presented as mean ± SEM 
(n=3). Error bars not visible are smaller than the data point. 
 
3.3.7.2 Effect of substrate concentration on measured inhibition 
The inhibition of maltase and sucrase by acarbose at 2.5 µM was determined 
with different substrate concentrations. There was no significant difference on 
the sucrase inhibition using 1, 10 (≈Km) or 100 mM substrate (Figure3-5A). 
Maltase was evaluated with 1, 7 (≈Km), 10 and 100 mM substrate. At 100 mM, 
which is ≥ 10-fold the apparent Km, the inhibition of maltase by acarbose was 
less than that determined with 1, 7 or 10 mM substrate (p<0.001) (Figure 3-5B). 
For convenience in handling multiple assay sample types, 10 mM was used for 
both sucrose and maltose. 
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Figure  3-5. Effect of substrate concentration on apparent inhibition. Substrate 
concentrations of 1, 10 (~Km) and 100 mM were evaluated for sucrose (A) 
and 1, 7 (~Km), 10 and 100 mM for maltose (B) were used in the assay for 
inhibition by acarbose at 2.5 µM. Results are presented as mean ± SEM 
(n=3). 
 
3.3.7.3 Effect on number of units on enzyme inhibition 
The impact of the amount of enzyme in the assay was evaluated by 
determining the IC50 value for the inhibition of maltase by acarbose with two 
different enzyme concentrations: the optimised amount (0.05 units per assay) 
which falls within the linear range, and 0.2 units per assay which is above the 
linear range. As shown in Figure  3-6, the IC50 value was over-estimated when 
the number of units is above the linear range of the assay (p<0.001). 
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Figure  3-6. The effect of amount of enzyme in the assay for the inhibition of 
maltase by acarbose. Results are presented as mean ± SEM (n=3).  
 
3.3.7.4 Effect of lysate preparation on activity and inhibition 
Two different methods for the preparation of the cell lysate were evaluated to 
determine if release of sucrase from the brush border changes the inhibition 
observed. The papain-treatment gives an increase in enzyme specific activity 
when assessed using both sucrase and maltase activities (Figure 3-7). Next, 
the inhibition of sucrase and maltase by acarbose was evaluated with both 
preparations using equal amounts of activity per assay. As shown in Figure  3-8, 
the inhibition observed was the same regardless of the papain treatment. 
Therefore, both the crude lysate and papain-digested preparation are both 
suitable for inhibition assays.  
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Figure  3-7. Effect of papain treatment on inhibition on the activity of sucrase (A) 
and maltase (B). Either a crude lysate of Caco-2/TC7 cells or the 
supernatant from papain-digested Caco-2/TC7 cells was used as the 
enzyme source for sucrase or maltase assay with 10mM substrate, 10 min 
incubation time and increasing amounts of total protein. Results are 
presented as mean ± SEM (n=3).  
 
 
Figure  3-8. Effect of papain treatment on acarbose inhibition of sucrase (A) and 
maltase (B). Either a crude lysate of Caco-2/TC7 cells or the supernatant 
from papain-digested Caco-2/TC7 cells was used as the enzyme source with 
10 mM substrate, 10 min incubation time and increasing concentrations of 
acarbose. Results are presented as mean ± SEM (n=3). 
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3.3.7.5 Determination of possible interference in the hexokinase-linked 
estimation of glucose and removal by solid phase extraction 
All inhibitors were evaluated at their highest used concentration for interference 
with the hexokinase assay for the quantification of glucose according. Apigenin, 
(+)-catechin, (-)-epicatechin, galangin, hesperetin, kaempferol, luteolin, 
naringenin and quercetin were evaluated at their screening concentration (see 
Section  3.4.1) and there was no difference in glucose compared to the control 
(all p>0.05). EGCG at 1000 µM led to an apparent 23% increase in glucose 
concentration (p<0.001, n=3), green tea at 5.0 mg/mL caused an apparent 13% 
decrease in glucose concentration (p=0.002, n=3) and 5-caffeoyl-quinic acid at 
500 µM caused an apparent decrease of 10% (p<0.001, n=3). Bonolive at 5 
mg/mL led to an 11% decrease in glucose concentration (p<0.001, n=3). The 
positive control acarbose at 100 µM had no significant effect on the assay 
compared to the control (p=1.0, n=3). Based on these results, EGCG, green 
tea, 5-caffeoyl-quinic acid and bonolive assay samples all required solid phase 
extraction to remove polyphenols prior to glucose quantification by the 
hexokinase assay.  
3.3.7.6 Comparison of detection methods for glucose 
Since several of the test compounds were shown to interfere with the 
hexokinase assay, chromatographic quantitation of sugars using HPAE-PAD 
was evaluated as a potential alternative for estimation of product compared to 
the enzymatic detection. The chromatographic method should allow elimination 
of the solid phase extraction (SPE) step, which could introduce errors and 
additional cost.  
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Figure  3-9. Evaluation of inhibitor interference in chromatographic analysis of 
sugars. Inhibitors were directly added at their highest evaluated 
concentration to assay samples containing no substrate. The “control” was 
spiked with 2.5 µM glucose (G) fructose (F) and sucrose (S).   
 
The selected inhibitors were first checked for interference with HPAE-PAD.  
Blank samples (no sugars) containing the inhibitors at their highest testing 
concentration were prepared and diluted for analysis by HPAE-PAD. Of the 
inhibitors tested, EGCG and acarbose did not interfere with glucose 
quantification, however bonolive and green tea did. After solid phase extraction, 
the bonolive interference was absent. For green tea, SPE did not completely 
remove the glucose interference; hence the extract contains some glucose 
(See  3.3.7.7). EGCG assay samples were selected to compare the HPAE-PAD 
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method with the hexokinase assay because they would normally require SPE 
prior to hexokinase analysis and EGCG does not interfere with HPAE-PAD.  
Table  3-1. Comparison of glucose detection methods for the inhibition of 
maltase by EGCG. Glucose was quantified using HPAE-PAD or underwent 
SPE followed by the hexokinase assay. Results are presented as mean of 
three technical triplicates. SD= standard deviation, %CV= coefficient of 
variation. 
 
 SPE/Hexokinase No SPE/HPAE-PAD 
EGCG (µM) Glucose 
(mM) 
SD % CV Glucose 
(mM) 
SD % CV 
0 1.7 0.2 8.6 2.7 0.1 2.6 
100 1.1 0.0 2.4 2.1 0.1 3.6 
250 1.1 0.1 7.0 1.8 0.0 2.6 
500 0.7 0.1 17.4 1.3 0.1 9.7 
750 0.8 0.1 13.7 1.4 0.1 5.2 
1000 0.7 0.1 8.1 1.3 0.0 3.3 
Mean   9.5   4.5 
 
Glucose in the samples from the inhibition of maltase by EGCG was 
quantitated using both methods (Table 3-1). SPE-removal of EGCG was 
performed before analysis using hexokinase but not before analysis by HPAE-
PAD. The variation between technical triplicates was from hexokinase method 
ranged from 2.4 to 17.4% (mean 9.5%) whilst variation was lower using HPAE-
PAD, from 2.6 to 9.7% (mean 4.5%). Therefore, the enzyme-linked method 
showed ~2-fold greater variation than the chromatographic method. This 
variation is due to the SPE step; glucose standards analysed by hexokinase 
with and without SPE show greater variation after SPE. The concentrations of 
glucose determined enzymatically were 43 ± 4.3% lower, but the loss was 
consistent and standards are also passed through SPE (Table 3-1). 
Importantly, the IC50 values were not different when determined enzymatically 
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and chromatographically (677 ± 241 and 633 ± 35 µM respectively; p=0.77, 
n=3) (Figure 3-10).  
 
Figure  3-10. Comparison of glucose detection methods for the inhibition of 
maltase by EGCG. The amount of glucose produced was determined using 
HPAE-PAD or samples were passed through SPE and then glucose 
determined by the hexokinase assay. The percent inhibition was determined 
from n=3 experiments and presented as mean ± SEM.  
 
Overall, the standard deviation was greater for the hexokinase detection due to 
the fact that the samples underwent SPE therefore the HPAE-PAD analysis 
offers a more accurate result. However, green tea and bonolive interfered with 
the glucose quantitation therefore the samples would still need to undergo SPE 
or blank correction on the HPAE-PAD system. Use of HPAE-PAD offers an 
alternative providing the inhibitors do not interfere with the analysis.  
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3.3.7.7 Green Tea analysis using HPAE-PAD 
As mentioned in Section  3.3.7.5, the green tea extract contained glucose 
(Figure  3-9). Green tea samples were prepared between 1 and 5 mg/mL, the 
inhibition testing concentration range, and diluted as assay samples 25-fold for 
HPAE-PAD analysis. A standard curve is presented in Figure  3-11. Inhibition 
samples with green tea were analysed using HPAE-PAD and the results were 
corrected for the glucose content in the extract by subtraction using the 
standard curve.  
 
Figure  3-11. Green tea extract standard samples analysed using HPAE-PAD. 
Green tea samples from 1 to 5 mg/mL were diluted 25-fold for HPAE-PAD 
analysis to quantify the concentration of glucose present in the extract. 
Glucose results were multiplied by the dilution factor and presented as mean 
± SEM (linear fit, Y=80.0x, R2 = 0.99, n=3). 
 
 Human enzyme final inhibition assay 3.3.8
The final inhibition assay used 0.05 units per sample for maltase and 0.02 units 
per sample for sucrase, 10 mM substrate concentration for sucrose and 
maltose and 10 min incubation time. The hexokinase assay was primarily used 
as the detection method and inhibitors were evaluated for interference with the 
hexokinase and removed by SPE if necessary. Green tea inhibition samples 
76 
 
 
 
were analysed by HPAE-PAD and results were corrected with green tea 
standards because the green tea extract contained glucose, fructose and 
sucrose. The inhibitor was added to the reaction mixture at the reported 
concentrations. For inhibitors dissolved in DMSO, control samples were 
included to ensure no interference and a maximum of 2% of the total reaction 
volume was DMSO.  
 Rat enzyme assay method 3.3.9
The rat enzyme assay procedure is the same as the human assay but with rat 
intestinal powder used as the enzyme source. The method was set-up in the 
same manner as the human assay here; time course, kinetics and specific 
activity were determined and the assay parameters were chosen so that 
glucose production is within the linear range and substrate concentration is 
near the Km (Nyambe-Silavwe and Williamson, 2016). For maltase, 4 mg 
solid/mL was used with 3 mM maltose and 20 min incubation time. For sucrase, 
20 mg solid/mL was used with 16 mM sucrose and 20 min incubation time. All 
samples from the rat assay were analysed by hexokinase and SPE was 
performed as required. 
 Data analysis and statistics 3.3.10
The enzyme assay utilises cells as the enzyme source, which exhibit biological 
variation. Therefore, IC50 determinations and dose response experiments were 
performed in triplicate with three different passage of cells (n=3) and the results 
are presented as mean ± SEM. For screening experiments, one assay was 
done with three replicates and the results are presented as mean ± SD.  
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The percent inhibition was calculated using the following formula: 
% Inhibition = 100-([glucose]inhibitor/[glucose]control x100) 
The IC50 is defined as the concentration of inhibitor at which the amount of 
product produced in the assay is half of that in the control.  The IC50 values 
were determined graphically by plotting percent inhibition versus inhibitor 
concentration for each of the n=3 experiments and the mean value ± SD was 
reported. All statistics were performed using SPSS version 22.  
3.4 Inhibition results 
 Human assay inhibition results – screening 3.4.1
Selected polyphenol and polyphenol-rich extracts were screened for their 
inhibitory action towards sucrase (Table  3-2) and maltase (Table 3-3). The 
compounds chosen were based on inhibition reported in the literature as 
discussed in the literature review, or based on results from other lab members 
who used the rat inhibition assay. The screening concentration for some pure 
polyphenols was limited by their solubility, therefore, inhibition may occur at 
higher concentrations, although the concentrations tested are in the region of 
what is achievable in the gut lumen (Williamson, 2013).  
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Table  3-2. Screening pure polyphenols and polyphenol-rich extracts as 
inhibitors of sucrase. The results are presented as mean ± SD (n=3). 
Significance was determined by independent sample T-test; *** p<0.001, ** 
p<0.01, * p<0.05, ns= not significant. 
 
Polyphenols/ 
Polyphenol-rich 
extracts 
Screening 
Concentration 
% Inhibition 
 
Apigenin 30 µM NS 
Bonolive 1 mg/mL 30 ± 3.0 *** 
(+)-Catechin 100 µM NS 
5-Caffeoyl quinic acid 500 µM 24 ± 6.1 ** 
(-)-Epicatechin 100 µM NS 
(-)-Epigallocatechin 
Gallate 
500 µM 48 ± 5.6 *** 
Galangin 30 µM NS 
German Chamomile 
(maltodextrin free) 
2 mg/mL NS 
Green Tea  1 mg/mL 32 ± 5.9 ** 
Hesperetin 30 µM NS 
Kaempferol 30 µM NS 
Luteolin 30 µM NS 
Naringenin 30 µM NS 
Quercetin 30 µM 11 ± 0.7 * 
 
 
Table  3-3. Screening pure polyphenols as inhibitors of maltase. The results are 
presented as mean ± SD (n=3). Significance was determined by independent 
sample T-test; *** p<0.001, ns= not significant. 
 
Polyphenols/ 
Polyphenol-rich 
extracts 
Screening 
Concentration 
% Inhibition 
 
Bonolive 2.0 mg/mL 78 ± 6.6 *** 
5-Caffeoyl quinic acid 500 µM NS  
(-)-Epigallocatechin 
Gallate 
500 µM 48 ± 5.6 *** 
Green Tea  1.5 mg/mL 75 ± 1.5 *** 
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 Human assay inhibition results – IC50 determinations 3.4.2
The IC50 values were determined for positive control acarbose as well as for 
green tea, EGCG and bonolive, all which exhibited statistically significant 
inhibition from the screening assays of both sucrase and maltase.   
3.4.2.1 Inhibition of sucrase and maltase by Acarbose 
 
Figure  3-12. IC50 determination for sucrase (A) and maltase (B) inhibition by 
acarbose. Results are presented as mean ± SEM (n=3). 
 
The IC50 value for acarbose was 2.5 ± 0.5 µM for sucrase and 5.7 ± 1.4 µM for 
maltase.  
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3.4.2.2 Green tea inhibition of sucrase and maltase 
 
Figure  3-13. Green Tea IC50 determination for sucrase (A) and maltase (B) 
inhibition. Results are presented as mean ± SEM (n=3). 
 
The IC50 value for green tea was 1.0 ± 0.3 mg/mL for sucrase and 0.5 ± 0.003 
mg/mL for maltase.  
3.4.2.3 EGCG inhibition of sucrase and maltase 
 
Figure  3-14. EGCG IC50 determination for sucrase (A) and maltase (B) 
inhibition. Results are presented as mean ± SEM (n=3). 
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The IC50 value for EGCG was 657 ± 150 µM for sucrase and 677 ± 241 µM for 
maltase.  
3.4.2.4 Bonolive Inhibition of Sucrase and Maltase 
 
Figure  3-15. Bonolive IC50 determination for sucrase (A) and maltase (B) 
inhibition. Results are presented as mean ± SEM (n=3). 
 
The IC50 value for bonolive was 3.2 ± 1.0 mg/mL for sucrase and 1.3 ± 0.2 
mg/mL for maltase.  
 Rat enzyme assay results  3.4.3
The rat enzyme assay was used to determine the IC50 of EGCG on sucrase 
inhibition; 950 ± 86 µM (n=3). Bonolive inhibition of sucrase was evaluated up 
to 8 mg/mL and reached a maximum of 39.8 ± 2.9% by 5 mg/mL. Bonolive 
inhibition of maltase was evaluated up to 1.5 mg/mL and the IC50 was 0.6 ± 0.2 
mg/mL (n=3).  All other rat assay results were completed by Hilda Nyambe 
(Nyambe-Silavwe, 2016). Rat enzyme assay results are presented in 
Table  3-4.   
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 Summary of inhibition data from human and rat assays 3.4.4
Results from the human and rat inhibition assays are summarised in Table  3-4. 
Statistical significance for the difference between rat and human assays was 
determined by independent sample t-test.  Of the polyphenols tested in the 
human assay, the strongest inhibitor of maltase was green tea, with IC50 of 0.5 
mg/mL, which contains 218 µM EGCG (Section 2.5.1). 677 µM of pure EGCG 
was required to achieve 50% inhibition. Green tea was also the strongest 
polyphenol inhibitor of sucrase, with IC50 of 1.0 mg/mL, equivalent to 435 µM 
EGCG.  The bonolive was 40% w/w oleuropein so 1.0 mg/mL was equivalent to 
750 µM oleuropein. Maltase inhibition was always stronger against rat enzyme 
as compared to human enzyme whereas sucrase inhibition was always 
stronger against human enzyme, with the exception of bonolive. 
Table  3-4. Inhibition of human or rat sucrase and maltase activities by selected 
compounds. Results are mean ± SD (n=3). Independent sample T-test was 
performed to compare results from rat with human; *** p<0.001, **p<0.01, * 
p<0.05, NA = not applicable. IC50 was not reached for bonolive inhibition of 
sucrase when tested up to 8 mg/mL. # results are from Nyambe-Silavwe, 2016. 
 
Inhibitor Human Rat 
Sucrase IC50 Maltase IC50 Sucrase IC50 Maltase IC50 
Acarbose 
(µM) 
2.5± 0.5  5.7± 1.4  12.3 ± 0.6  ***# 0.42 ± 0.02 **# 
Green Tea 
(mg/mL) 
1.0 ± 0.3  0.5 ± 0.003  1.8 ± 0.3 *# 0.035 ± 0.005 
***# 
EGCG  
(µM) 
657 ± 150  677 ± 241  950 ± 86 * 14 ± 2.0 ***# 
Bonolive 
(mg/mL) 
3.2 ± 1.0  1.3 ± 0.2  > 5 mg/mL 0.6 ± 0.2 ** 
 
3.5 Discussion 
In recent years, polyphenols have been investigated as potential α-glucosidase 
inhibitors for the treatment and prevention of type 2 diabetes, as an alternative 
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to pharmaceutical treatments such as acarbose. The methods used in the 
literature predominantly use enzyme preparations from rat intestine, rather than 
a human source (Matsui et al., 2007; Kamiyama et al., 2010; Honda and Hara, 
1993). The homology between human and rat sucrase-isomaltase is only 74%, 
raising the question as to whether using non-human sources for enzyme assay 
is physiologically relevant to humans. The active site sequence is conserved, 
however there are differences in the N-glycosylation, which can affect inhibition 
due to steric hindrance. The human sequence has 18 predicted N-glycosylation 
sites while the rat has 16, only 9 of which are in homologous position to the 
human (Van Beers et al., 1995). Furthermore, some reports use a yeast α-
glucosidase with a non-specific substrate (p-nitrophenyl α-D-glucoside), which 
provides even less relevant inhibition information. Another limitation of reports 
currently found in the literature is that the assay parameters and details are not 
always given in full, which makes comparison of inhibition values amongst 
different reports impossible. Here, an inhibition assay was optimised for 
sucrase and maltase using a human enzyme source and different assay 
parameters were evaluated to demonstrate their impact on inhibition values. 
The assay was used to evaluate inhibition by some selected polyphenols and 
polyphenol-rich extracts and the inhibition results from the human assay were 
compared to those determined using rat enzyme source.  
During the assay optimisation, two different lysate preparations were 
compared. A crude cell lysate was compared to cells which had been digested 
with papain which proteolytically cleaves the isomaltase stalk from the 
membrane (Brunner et al., 1979). The papain digested enzyme had higher 
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specific activity for both sucrase and maltase and this is expected to be due to 
the fact that the cell debris was removed leading to a solution with higher purity 
of SI. Inhibition of maltase by acarbose was the same whether the enzyme was 
free, after proteolytic cleavage by papain or membrane-bound. The 
unprocessed crude lysate was used for the inhibition assays performed, 
however the papain method offers a suitable alternative with the benefit that 
more units are produced for a given amount of cells.  
The quantitation of glucose by HPAE-PAD was evaluated in an attempt to 
eliminate the SPE step of the protocol, which provides cost savings and also 
reduced the variation between technical triplicates. Assay samples from EGCG 
inhibition were analysed using both glucose detection methods and both yield 
similar IC50 values, however the results from the HPAE-PAD analysis had a 
lower coefficient of variation, therefore providing a more precise result.  
However, green tea interfered with the glucose quantitation therefore the 
samples would still need to undergo SPE or blank correction on the HPAE-PAD 
system. Use of HPAE-PAD offers a suitable alternative providing the inhibitors 
do not interfere with the analysis.  
In setting up the inhibition assays for sucrase and maltase, the time course and 
number of units were chosen to fall within the linear range. Outside of the linear 
range, steady-state reaction so Michaelis-Menten kinetics are not valid 
(Bisswanger, 2014). The importance of working within initial rates was shown 
by acarbose inhibition of maltase: when maltase activity in the assay was high 
and outside the linear range, the apparent IC50 value for acarbose was over-
estimated. Further, an increased concentration of substrate decreases the 
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ability of competitive inhibitors to bind and inhibit an enzyme (Acker and Auld, 
2014). This was demonstrated in the maltase assay, where maltose substrate 
at ~100x the Km led to a decrease in observed inhibition. A substrate 
concentration 10 mM was selected for both sucrase and maltase for 
consistency as it is near their determined Km values, important for identifying all 
types of inhibitors (Acker and Auld, 2014). The sucrase apparent Km measured 
here was 9.5 mM, within the reported range for human sucrase of 9 -11 mM 
(Krog-Mikkelsen et al., 2011; Jockovic et al., 2013; Trugnan et al., 1986) and 
maltase was 7.5 mM, also in agreement with values in the literature (Jockovic 
et al., 2013). 
Results from the rat and human assay were performed under suitably 
determined assay conditions and both used SPE to remove polyphenols before 
analysis of glucose so the differences observed are due solely to the enzyme 
source. EGCG, green tea and acarbose exhibited 1.4 to 4.8-fold stronger 
inhibition of human, compared to rat, sucrase; for maltase, the reverse was true 
(13.5 to 48-fold weaker). Sucrase activity arises solely from the sucrase subunit 
of sucrase isomaltase whereas maltase is derived from both the isomaltase 
and sucrase subunits, as well as other α-glucosidases such as maltase 
glucoamylase (MGAM) (Jones et al., 2012). The difference for the weaker 
inhibition of maltase could be due to the lack of MGAM in Caco-2/TC7 cells 
because there is a combined effect from each maltase catalytic sites. When 
evaluating literature inhibition reports, if a rat enzyme assay was used, the 
reported inhibition is much stronger than would be observed using a human 
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source for maltase. For sucrase, the opposite is true, and greater inhibition 
would be observed in the human assay.   
The IC50 of EGCG for rat sucrase has been reported as 218 µM (Honda and 
Hara, 1993) and 169 µM (Matsui et al., 2007), both stronger than we observed 
here using rat; however both used detection methods for which EGCG 
interferes (Nyambe-Silavwe et al., 2015). The IC50 of EGCG for rat maltase has 
been reported as 40 µM, somewhat weaker than we observed (14 µM). 
Reported results using the enzyme from rat source for acarbose, which does 
not interfere with detection methods, were more similar to ours (IC50 of 0.43 µM 
for maltase and 1.2 µM for sucrase) (Matsui et al., 2007). A Ki of 1.8 µM has 
been reported for 5-caffeoyl-quinic acid for maltase activity using Drosophila 
expression system as the source of sucrase (Simsek et al., 2015), however, 
here it was not found to be a strong inhibitor of human sucrase or maltase at 
500 µM. Detection method interference or the use of sucrase mouse sequence 
for the expression could all explain the dramatic difference. Furthermore, 
glycosylation in the Drosophila expression system differs from mammalian: it 
lacks the ability to produce complex N-glycans due to absence of β-N-
acetylglucosaminidase enzyme (Léonard et al., 2006).  
The values from inhibition screening here differ from some literature reports. 
For example, quercetin, kaempferol, luteolin, naringenin and hesperetin IC50 
values have been reported as 7, 12, 21, 75 and 150 µM, respectively in an 
assay using yeast enzyme activity (Tadera et al., 2006). Here, these were 
screened at 30 µM with human sucrase and only quercetin exhibited mild 
inhibition of 11%. The concentrations tested here were limited by solubility. For 
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example, limited solubility was observed for quercetin above 100 µM when 
spiked into assay buffer. Quercetin was reported to inhibit rat sucrase with an 
IC50 of 363 µM (Kim et al., 2011) which is weaker than we observed in the 
assay with human enzyme, as expected but to a greater extent possibly due to 
solubility issues. The IC50 for quercetin has even been reported as >1 mM (Jo 
et al., 2009), where solubility is an issue and this concentration is not 
physiologically relevant.  Another study reported an IC50 for naringenin as 384 
µM towards yeast α-glucosidase using a generic substrate (Priscilla et al., 
2014).  Here, naringenin was only able to be screened up to 30 µM since poor 
solubility was observed at greater concentrations, so it is unlikely that it would 
remain soluble up to the reported 384 µM. Even more recent publications have 
limitations; the inhibition of α-glucosidases by polyphenols from the plant 
polygonum cuspidatum, which is used in traditional Chinese medicine, was 
recently reported (Zhao et al., 2017). Although the assay does account for 
inference from the polyphenols by trapping them in an in-line SPE, the assay 
used a yeast enzyme with a p-nitrophenyl α-d-glucopyranoside generic 
substrate which does not provide inhibition relevant to mammalian enzymes 
(Tadera et al., 2006). 
The current pharmacological inhibitor acarbose often leads to gastrointestinal 
side-effects (Balfour and McTavish, 1993) due to undigested starch and sugar 
reaching the colon because of inhibition by acarbose towards maltase, sucrase, 
α-amylase and isomaltase. Understanding the specific inhibition of α-
glucosidases by polyphenols or other inhibitors in humans can help to design 
therapeutic treatments with fewer side effects. For example, the naturally 
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occurring pentose L-arabinose, which is solely a sucrase inhibitor, did not 
cause gastrointestinal side-effects in humans (Krog-Mikkelsen et al., 2011). 
Digestion of sucrose by sucrase can be rate-limiting in the glycaemic response 
in rats; in an oral sucrose tolerance test with a formulation containing L-
arabinose, the incremental area under the curve for blood glucose was 
significantly reduced while no change was observed in glucose or starch tests 
(Preuss et al., 2007b; Preuss et al., 2007a). The effect was also confirmed in  
humans; pure L-arabinose led to a delay in glucose absorption in response to 
sucrose intake along with a suppression of insulin (Krog-Mikkelsen et al., 
2011). These studies demonstrate that the strategy of sucrase inhibition does 
translate in an in vivo effect. 
3.6 Conclusion 
When performing assays or considering published inhibition results, the 
interference with any glucose detection method must be considered. Interfering 
compounds can be removed through solid phase extraction, although this 
introduces greater variation to the results, so HPAE-PAD offers an alternative 
detection method which can improve accuracy. The use of human or rat as the 
source of α-glucosidase enzyme impacts the resulting inhibition and the 
optimised human assay used here is more physiologically relevant.  
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4 Chronic effects of sucrose exposure on sucrase isomaltase 
in the Caco-2/TC7 cell model 
4.1 Abstract 
Dietary guidelines in the UK now state that daily intake of sugar should be 
halved, down to no more than 5% of total energy intake. Consumption data 
from the National Diet and Nutrition Survey (NDNS) from 2008-2012 indicated 
that sucrose was the most commonly consumed sweetener and in adults its 
mean consumption was 1/5th of total energy intake (SACN, 2015). To date, 
there is no established mechanistic link between sugar and health and there is 
insufficient to evidence to determine any direct effects of specific sugars on 
health. At the cellular level, there is evidence that small intestinal enterocytes 
can sense sugars (Le Gall et al., 2007) and Caco-2/TC7 cells have been 
reported to respond to maltose (Cheng et al., 2014). The aim here was to 
mimic nutritional sugar stress by evaluating the effects of long-term sucrose 
exposure on sucrase, the enzyme solely responsible for its hydrolysis. 
Compared to the glucose control, exposure to 25 mM sucrose did not change 
the SI mRNA levels, but increased SI protein levels while maintaining the same 
amount at the apical cell surface. In addition, both N- and O-glycosylation of SI, 
required for trafficking to the apical surface (Naim et al., 2012), were altered. 
This could explain the accumulation in the total lysate and could also be 
responsible for the apparent decrease in affinity for sucrose after sucrose 
exposure. Evidence here suggests that sugar exposure can influence post-
translational modifications which could decrease starch or sugar digestion. 
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4.2 Introduction  
Sucrose is hydrolysed solely by the sucrase subunit of SI at the small intestine 
brush border into fructose and glucose (Van Beers et al., 1995). Since SI plays 
a key role in digestion of sugar and starch, its activity will influence the 
postprandial blood glucose response. The focus of this chapter is specifically 
on SI because sucrase is the sole enzyme capable of sucrose hydrolysis and 
the also the main enzyme responsible for maltase and isomaltase activities, so 
has a key role in overall carbohydrate digestion. Furthermore, sucrose is the 
most commonly consumed sweetener in the UK (SACN, 2015). There is some 
evidence in the literature on the effect of dietary exposure to sucrose and its 
effect on sucrase. Studies in cells and rats have shown that monosaccharides 
have regulatory effects on sucrase at the mRNA level, but these compare the 
expression to that of a starved or low-carbohydrate state in which many genes 
can be activated (Ferraris et al., 1992; Quan and Gray, 1993; Kishi et al., 1999) 
(See Section 1.2.5).  There is limited information in the literature as to whether 
sucrose is involved in the regulation of sucrase, in comparison to glucose, 
under normal rather than starved or low-carbohydrate conditions. Most reports 
of SI regulation are transcriptional, for example forskolin and monensin both 
decreased SI activity in Caco-2 cells through reduced transcription (Chantret et 
al., 1993); however in some phenotypes of congenital sucrase isomaltase 
deficiency (CSID) disorder, which affects 0.2% of people of European descent, 
lack of sucrase activity can result from mutations at the site of N- or  O-
glycosylation (Jones et al., 2012).  
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The cDNA sequence of SI in Caco-2 cells is identical in comparison to the 
human small intestine (Chantret et al., 1992) however the sequence in the 
Caco-2/TC7 clone has not been investigated. The first aim of this chapter is to 
characterise SI in the Caco-2/TC7 cell model, firstly by confirming if the 
sequence of SI in the Caco-2/TC7 clone is free from mutations since point 
mutations can lead to lack of function (Naim et al., 2012). The second aim is to 
evaluate sucrase in response to chronic exposure to sucrose with the 
hypothesis that sucrose will increase SI activity. The enterocyte life-span in vivo 
is between 3-5 days and they are exposed to the contents of the gut lumen 
throughout differentiation while they migrate from the crypt to villus tip, where 
they are shed (Ferraris, 2001).  The Caco-2/TC7 cell model is exposed to 
sucrose throughout differentiation and the effects on SI mRNA, protein, activity 
and enzyme kinetics were evaluated in comparison to normal growth conditions 
in glucose. 
4.3 Results 
 Sequencing results  4.3.1
The sucrase isomaltase sequence from human cDNA in the NCBI database 
was used as the reference sequence (NM_001041.3).  Sequencing results 
(Appendix 1) show that the cDNA prepared from the Caco-2/TC7 cell line has 
one base different at position 4632 of the reference sequence. Position 4632 is 
an adenine rather than guanine, resulting in the codon ATA which codes for 
isoleucine, rather than ATG, which codes for methionine (Figure  4-1). The RNA 
from a human intestinal biopsy sample from DV Biologics was also sequenced 
for SI and the same single base difference from the reference was observed. 
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Furthermore, Chantret et al. reported the original sequence for SI from Caco-2 
cells and is in agreement with the sequence found here in both the Caco-2/TC7 
sample and the human biopsy sample (Chantret et al., 1992).  Additionally, the 
National Institutes of Health Mammalian Gene Collection Program, whose aim 
was to identify and sequence a cDNA clone containing a complete ORF for 
each human and mouse gene, uploaded sequence BC132860.1 to the NCBI 
database and also report the same single base difference as compared to the 
reference (Mammalian Gene Collection Program, 2002). The agreement 
between the two samples tested here, the mammalian gene collection program 
and the sequence from Caco-2 cells suggests that there is no mutation present 
in the Caco-2 or Caco-2/TC7 cell line.   
 
Figure  4-1. Sequence comparison of SI from Caco-2/TC7 cells and from human 
intestinal RNA to NCBI reference sequence. 
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 Comparison of Caco-2 with Caco-2/TC7 clone 4.3.2
The amount of SI relative to TBP (Tata-box binding protein) housekeeping 
gene was determined in Caco-2 cells and Caco-2/TC7 cells to confirm that the 
Caco-2/TC7 cell line has increased expression of SI and is therefore a more 
suitable model for this study. Results are presented in Figure  4-2. The Caco-
2/TC7 cell line has 5-fold more SI mRNA as compared to the parental Caco-2 
cell line (p<0.001) (Figure  4-2). 
 
Figure  4-2. Comparison of the mRNA level of SI in Caco-2/TC7 clone in 
comparison to the parental Caco-2 cell line. Cells were cultured in 6-well 
plates for 21 days to reach full differentiation. Total RNA was extracted, 
reverse transcribed to cDNA and the mRNA copies/µL of SI and 
housekeeping gene relative to TBP were determined by digital PCR. Results 
are presented as mean ± SD (n=3) *** p<0.001 
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 Results for the effects of high sucrose exposure in Caco-2/TC7 4.3.3
cells on sucrase isomaltase 
4.3.3.1 Sucrase isomaltase protein: total and cell surface 
ProteinSimple WES was used to determine the amount of SI protein in the total 
cell lysate and in the cell surface fraction after the purification of cell surface 
proteins by biotinylation. Cells were cultured on 6-well transwell® filters in 25 
mM glucose or 25 mM sucrose for 21 days, with four independent experiments 
with 3 wells per condition (n/N=4/12). Each sample was analysed in duplicate. 
There was a 71% increase in the absolute amount of total SI protein when cells 
were cultured in sucrose (p<0.001) (Figure  4-3A). The α-actinin control had no 
significant change with the treatment (Figure  4-3B). The final result was 
corrected for the α-actinin loading control; there was a 79% increase in total SI 
protein  for cells that were cultured in sucrose (p<0.001) (Figure  4-3C). 
 
Figure  4-3. The effect of sucrose on SI protein in Caco-2/TC7 total cell lysate. 
Caco-2/TC7 cells were cultured in 25 mM glucose or 25 mM sucrose on 
transwell® plates for 21 days. ProteinSimple WES analysis was used to 
quantify sucrase (A) and the loading control α-actinin (B) and the ratio of SI/ 
α-actinin was determined (C). Results were normalised to the glucose 
control and are presented as mean ± SEM (n=4) *** p<0.001   
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 In the surface fraction, there was no change in SI (p=0.1) (Figure  4-4A). As a 
proportion of the total protein, there was a decrease at the surface by 30% 
(p=0.009) (Figure  4-4B). 
 
Figure  4-4. The effect of sucrose on surface SI protein in Caco-2/TC7 cells. 
Caco-2/TC7 cells were cultured in 25 mM glucose or 25 mM sucrose on 
transwell® plates for 21 days. After purification of biotinylated cell surface 
proteins, samples were analysed by ProteinSimple WES analysis to quantify 
SI in the surface fraction (A). The ratio of SI at the cell surface to total SI (B), 
where the total SI is corrected for the α-actinin loading control. Results were 
normalised to the glucose control and are presented as mean + SEM (n=4), 
** p<0.01 
4.3.3.2 Protein size analysis  
The ProteinSimple Compass® software assigns a size to the band based on 
the migration in the capillary by aligning the position of reference standards 
within each capillary to those in the ladder standard sample capillary. During 
the protein analysis on WES it was observed that the reported size of SI was 
higher for cells cultured in sucrose as compared to standard culture conditions 
in glucose. Three sample types were analysed; total cell lysate from cells 
cultured on Transwells®, purified cell surface protein for cells cultured on 
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Transwells® and total cell lysate from cells cultured on solid supports. In the 
cells cultured on transwells® the mean size of SI in the cell surface fraction and 
total lysate was determined from the 48 individual capillaries with samples from 
n=4 experiments. Note that at the cell surface there is no α-actinin present. In 
the cells cultured on solid supports the mean size of SI was determined from 
n=3 independent experiments with results from 12 capillaries. In all three 
sample types, the size of SI for cells cultured in sucrose was greater than those 
cultured in glucose (p<0.001). The size of the loading control α-actinin in the 
total lysate did not change (p>0.05) (Table  4-1). 
Table  4-1. Protein size analysis of SI and the α-actinin loading control on 
ProteinSimple WES. Caco-2/TC7 cells were cultured in 25 mM glucose (G; 
control) or 25 mM sucrose (S) for 21 days on solid supports or transwell® filters. 
The mean size of sucrase isomaltase was determined at the cell surface 
fraction after biotinylation (n=48). The mean size of SI and α-actinin was 
determined in the total lysate from cells grown on transwell® filters (n=48) or 
solid supports (n=12). Results are presented as a percentage of the control 
(glucose), mean ± SD, and statistical significance was determined with 
Student’s T-test.  
 
Sample Condition Sucrase Size  
(% of Control) 
P-value α-actinin  
(% of control) 
P-value 
Cell 
Surface 
G 307.6 ± 1.5 <0.001 NA NA 
S 310.3 ± 1.4 NA 
Total 
Lysate 
(transwell) 
G 306.5 ± 4.0 <0.001 100.8 ± 0.8 0.1 
S 310.3 ± 4.1 101.2 ± 0.8 
Total 
Lysate 
(solid 
support) 
G 294.9 ± 1.8 <0.001 100.0 ± 0.3 0.7 
S 297.1 ± 1.5 100.1 ± 0.6 
 
 
To further investigate the nature of this size increase for sucrose grown 
samples, the endoglycosidase PNGase F was used to remove N-glycosylation; 
resulting products of the same size would indicate that the size difference 
observed in untreated samples is due to N-glycosylation while products of a 
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different size would suggest that both N- and O-glycosylation were altered. 
Representative pherograms from mock treated (no PNGase F added) and 
PNGase F treated samples on ProteinSimple WES are presented in Figure  4-5. 
The PNGase F digestion product of sucrase isomaltase was significantly 
different between glucose and sucrose grown cells. No change in the α-actinin 
loading control was observed (Table  4-2). These results suggest that the size 
difference observed in the untreated samples was not due to N-glycosylation 
alone, circumstantially suggesting a change in both N and O-glycosylation. 
Table  4-2. Protein size analysis by WES of SI and α-actinin after PNGase F 
deglycosylation. Caco-2/TC7 cells were cultured in 25 mM glucose or 25 mM 
sucrose on transwell® filters and the total lysate was subjected to PNGase F 
treatment or mock treatment (no PNGase F enzyme). Results for sucrase 
isomaltase and control α -actinin are presented as mean ± SD (n=7). 
 
Sample Sucrase 
Isomaltase 
Size (kDa) 
p-value α-actinin Size 
(kDa) 
p-value 
Glucose Mock 302.3 ± 0.9 <0.001 103.0 ± 0 0.57 
Sucrose Mock 309.3 ± 0.4 103.5 ± 0.2 
Glucose 
PNGase F 
278.3 ± 1.7 <0.001 103.4 ± 0.3 0.55 
Sucrose 
PNGase F 
286.9 ± 2.6 103.7 ± 0.4 
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Figure  4-5. Representative pherograms from ProteinSimple WES of α-actinin 
(first peak) and SI (second peak). Caco-2/TC7 total cell lysates from cells 
cultured in 25 mM glucose or 25 mM sucrose treated with and without 
PNGase F enzyme with the mean size from n=7 samples. 
 
4.3.3.3 Gene expression 
The expression of SI mRNA was evaluated over differentiation in control cells 
and expression was at a maximal level at 14 days and decreased by 31% at 
day 21 when the cells were fully differentiated (Figure  4-6). The expression at 
each time point was significantly different than all the other points, as 
determined by ANOVA followed by Tukey’s post-hoc test (p<0.001 for all). The 
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TBP housekeeping gene also changed with differentiation therefore the 
absolute copies/µL of SI mRNA was reported. 
 
Figure  4-6. The expression of SI mRNA over differentiation in Caco-2/TC7 
control cells cultured in 25 mM glucose. Presented as mean ± SEM (n=3).  
 
No change was observed in the mRNA levels of SI and GLUT2 when Caco-
2/TC7 cells were cultured in 25 mM glucose or 25 mM sucrose. There was a 
significant 47% decrease in SGLT1 mRNA (p<0.001) and a 27% decrease in 
GLUT5 mRNA (p<0.001) when cultured in sucrose (Figure  4-7A). SI mRNA 
was the most abundant, followed by GLUT5, GLUT2 and SGLT1 (Figure  4-7B). 
There was 7.8-fold less SGLT1 as compared to GLUT2 (p<0.001). The TBP 
housekeeping gene was not significantly different between the two conditions, 
indicating it was a suitable control.  
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Figure  4-7. Effect of sucrose on the gene expression of SI, GLUT2, SGLT1 and 
GLUT5 in Caco-2/TC7 cells. Cells were cultured for 21 day in 25 mM 
glucose or 25 mM sucrose. Target gene in copies/µL was divided by the 
TBP housekeeping gene and then normalised to the glucose control. Results 
are presented as mean + SEM, *** p<0.001 from Student’s T-test (n=3). B) 
Relative gene expression of SI, GLUT2, SGLT1 and GLUT5 in Caco-2/TC7 
control samples grown in 25 mM glucose. Results are presented as mean + 
SEM (n=3), *** p<0.001 from ANOVA followed by Tukey’s post-hoc test. 
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Since the protein and mRNA results did not correlate, The expression of SI 
mRNA was also determined from Caco-2/TC7 cells cultured on transwell® 
filters so that they are comparable to the cells used for protein analysis. Cells 
cultured on porous filters are polarised as they are exposed to FBS containing 
medium on the basolateral side only, from confluence day 7 until fully 
differentiated. As seen in Figure  4-8, there was no significant difference 
between SI mRNA from glucose or sucrose grown cells, however there was a 
difference in the absolute amount of SI mRNA between the two different cell 
supports; cells cultured on transwell® filters had a lower ratio of SI/TBP than 
those cultured on solid supports. Growth in 25 mM sucrose appears to have no 
impact on the mRNA of SI regardless of if they are cultured on solid or 
transwell® supports, however there was an increase in the total amount of 
protein when cultured in sucrose on transwell® supports.  
 
Figure  4-8. Comparison of the SI mRNA from Caco-2/TC7 cells cultured in 25 
mM glucose or 25 mM sucrose on either solid or transwell® supports. The 
amount of sucrase isomaltase in copies/µL relative to the TBP housekeeping 
gene is presented as mean + SEM (n=3). ns= not significant. 
102 
 
 
 
4.3.3.4 Sucrase specific activity  
The specific activity of sucrase was determined for cells cultured in glucose and 
sucrose using the sucrase assay developed in Chapter 3. The amount of 
glucose produced in µmol/min was plotted against total milligrams of protein in 
the assay therefore the slope of the line is the specific activity in U/mg where 1 
unit is defined as the amount glucose produced per min (µmol/min). 
Significance was determined by independent sample t-test between the slope 
of the line from each replicate assay. After two weeks growth, at which the cells 
are not yet fully differentiated, the sucrase specific activity was 70.9 mU/mg for 
cells cultured in glucose and 55.3 mU/mg for cells cultured in sucrose and the 
25% difference was significant (p<0.001) (Figure  4-9A). When the cells are fully 
differentiated at three weeks the specific activity was increased and there was 
no difference between cells cultured in glucose or sucrose (p=0.6) 
(Figure  4-9B). 
The specific activity was then evaluated for cells cultured in 25 mM glucose and 
25 mM fructose to see if the change in specific activity observed at two weeks 
was due to intact sucrose or to its hydrolysis products glucose and fructose. 
There was no significant difference between the specific activity of cells 
cultured in 25 mM sucrose or 25 mM glucose + 25 mM fructose (Figure  4-10A). 
The specific activity at two weeks was determined after treatment with forskolin 
as a negative control. Forskolin is reported to reduce SI mRNA through 
transcriptional regulation rather than changed in mRNA stability (Chantret et al., 
1993). Caco-2/TC7 cells were cultured for two weeks and treated with 10 µM 
forskolin for the last 5-days of growth and the SI specific activity was reduced 
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almost 2-fold from 95 mU/mg to 51 mU/mg (p<0.001) (Figure  4-10B). Finally, 
the specific activity of sucrase was also determined for cells cultured on 
transwell® filters for two weeks in comparison to solid supports. The same 
trend was observed on transwell® filters where the sucrase specific activity was 
decreased for cells cultured in sucrose, from 70 mU/mg in glucose to 41 
mU/mg in sucrose (p<0.001) (Figure  4-10C). 
 
Figure  4-9. Sucrase specific activity for cells cultured in 25 mM glucose or 25 
mM sucrose for two weeks (A) or three weeks (B). Presented as mean ± 
SEM (n=3). 
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Figure  4-10. Sucrase specific activity determination in Caco-2/TC7 cells. A) 25 
mM glucose, 25 mM sucrose or 25 mM glucose + fructose for 2 weeks B) 25 
mM sucrose or 25 mM sucrose with 5-day treatment of forskolin at 10 µM as 
a negative control  C) 25 mM glucose and 25 mM sucrose for 2 weeks on 
transwell® plates. Results are mean ± SD (n/N=1/3). 
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4.3.3.5 Sucrase Km/Vmax 
The apparent Km and Vmax of sucrase were determined for cells cultured in 
glucose and sucrose using the sucrase enzyme assay developed in Chapter 3. 
Data from three independent experiments for each of 2 or 3 weeks growth were 
normalised to the glucose control and the average was used to plot the 
Lineweaver-Burk graphs presented in Figure  4-11A&B. The apparent Km and 
Vmax were calculated where the slope = Km / Vmax and the y-intercept = 1/ Vmax. 
Students’ t-test was performed to determine the p-value for 95% significance. 
At two weeks, the Km was 29% higher for cells cultured in sucrose, 17.2 mM 
compared to 12.3 mM for glucose (p<0.001) and the Vmax was not significantly 
different, 0.036 µmol/min in glucose to 0.032 µmol/min in sucrose (p=0.08). 
The results from 3 weeks, at which cells are fully differentiated, are presented 
in Table  4-3. There was no change in the Vmax but the Km increased from 10.7 
mM in glucose to 12.3 mM in sucrose (p=0.01).  
Table  4-3. Kinetic parameters Km and Vmax determined from Caco-2/TC7 cells 
cultured in 25 mM glucose or 25 mM sucrose for 3 weeks. 
 
Carbohydrate 
Source 
Linear Fit R2 Km  
(mM) 
P-
value 
Vmax 
(µmol/min) 
P-
value 
25 mM Glucose y= 201.0x +17.9 0.99 10.7 ± 1.9 0.01 0.06 0.3 
25 mM Sucrose y= 225.5x +19.5 0.99 12.3 ± 3.5 0.05 
 
The Km and Vmax of sucrase were also determined for cells cultured in 25 mM 
glucose + 25 mM fructose (Figure  4-12) after 2 weeks. As with the specific 
activity results, there was no difference between 25 mM glucose + 25 mM 
fructose and 25 mM sucrose (p<0.001), while both were different from 25 mM 
glucose (p<0.001). 
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Figure  4-11. Sucrase Lineweaver-Burk plot for the determination of apparent 
Km and Vmax for cells cultured in 25 mM glucose or 25 mM sucrose for two 
weeks (A) or three weeks (B). Caco-2/TC7 cells were lysed and sucrase 
assay was performed with a range of substrate concentrations, fixed time 
and enzyme amount. Results from three independent experiments were 
normalised and plotted mean ± SEM where [S] is the sucrose substrate 
concentration and v is µmol/min of glucose produced (n=3). 
 
Figure  4-12. Sucrase Lineweaver-Burk plot for the determination of Km and 
Vmax for cells cultured in 25 mM glucose, 25 mM sucrose or 25 mM glucose + 
25 mM fructose for two weeks. Caco-2/TC7 cells were lysed and sucrase 
assay was performed with a range of substrate concentrations, fixed time 
and enzyme amount. Results are presented as mean ± SD where [S] is the 
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sucrose substrate concentration and v is µmol/min of glucose produced (n/N 
= 1/3). 
 Results summary 4.3.4
Table  4-4. Summary of the results for the effect of culturing Caco-2/TC7 cells 
for 21 days in 25 mM sucrose as compared to control cells grown in 25 mM 
glucose. 
 Change in sucrose-grown 
compared to control 
Km ↑ 14%  
(p=0.01) 
Vmax NS 
Total Specific 
Activity 
No change 
mRNA NS 
Total Sucrase 
Protein 
↑ 78% 
(p<0.001) 
Surface Sucrase 
Protein 
NS 
Sucrase Protein 
Size 
↑ 0.8% 
(p<0.001) 
Source of Size 
Change 
N- and O- glycosylation 
 
4.4 Discussion 
In congenital sucrase isomaltase deficiency (CSID) disorder, which occurs in 
0.2% of people of European descent, genetic differences as small as a point 
mutation can lead to lack of function (Naim et al., 2012). Therefore, it was 
important to confirm that the sequence of SI in the Caco-2/TC7 cell line used 
here is identical to the wild-type human SI. The Caco-2/TC7 clone was 
originally developed in order to investigate the transcriptional regulation of the 
expression of SI. It was created from a high Caco-2 passage number (198) 
which has increased growth rate, higher cell density and a 7-10 fold increase in 
sucrase activity (Chantret et al., 1994). To confirm that the provided Caco-
2/TC7 cell line has increased SI expression, making it suitable for its study, the 
SI mRNA level in the cells was compared with the parental line and a 7-fold 
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increase in mRNA was observed. The sucrase specific activity from the 
standard culture conditions in 25 mM glucose was 140 mU/mg, comparable to 
that reported when the clone was prepared and the Km was 10.7 which was 
again in agreement with the literature values reported in the region of 9-11 mM 
(Trugnan et al., 1986; Krog-Mikkelsen et al., 2011; Jockovic et al., 2013). 
It could be hypothesized, that in the presence of high sucrose concentration, 
that sucrase could be up-regulated in order to allow sucrose hydrolysis for the 
subsequent uptake of glucose and fructose for energy and some studies 
support this hypothesis. For example, dietary sucrose upregulated SI at the 
mRNA level in an animal model. Rats were fed either no sugar, glucose, 
fructose or sucrose 3 times over 12 hours and mRNA levels of SI and SGLT1 
were enhanced by sucrose and fructose but not glucose (Kishi et al., 1999). 
The mRNA amounts were determined from the band density on a Northern 
blot; however, technology has greatly advanced and digital PCR allows more 
accurate determination. Furthermore, the β-actinin housekeeping gene 
changed on the representative blot, suggesting it was not a suitable control. 
Other studies have reported that sucrose induces sucrase, however this was 
after a period of starvation and feeding after starvation is known to induce 
many genes  (Section 1.2.5). Here, using ddPCR, there was no difference in 
the level of SI mRNA between Caco-2/TC7 cells cultured in sucrose or glucose. 
There was also no change in specific activity or amount of SI at the cell surface. 
There was however an increase in SI protein in the total cell lysate. It has been 
suggested that SI is primarily regulated through transcription whereby a change 
in SI mRNA will lead to a change in protein (Chantret et al., 1994), however  
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the level of protein depends on several factors including transcription rate, 
nuclear export, transcript stability, translational control and protein degradation 
therefore mRNA is sometimes a poor predictor of protein abundance (Pradet-
Balade et al., 2001).   
The results here suggest that sugar exposure affects post-translational 
modifications; sucrose led to an increase in the size of SI which was 
determined to be due to altered N- and O-glycosylation. Glycosylation refers to 
the carbohydrate oligosaccharide chains that are found attached to lipids and 
proteins at the brush border. There are two types of attachments;  N-glycans 
have N-acetylglucosame (GlcNAc) linked to the amide group of asparagine 
residues in the ASN-X-SER/THR sequence while O-glycans are attached to 
hydroxyl of certain amino acids, primarily serine and threonine. Nine 
monosaccharides are used in the glycosylation process in mammals: fucose, 
galactose, N-acetylgalactosamine, glucose, N-acetylglucosamine, mannose, 
sialic acid and xylose (Ohtsubo and Marth, 2006).  
SI is highly glycosylated with threonine and serine rich regions that are O-
glycosylated and there are 18 predicted N- glycosylation sites (Van Beers et al., 
1995). These sites are only theoretical and the structure and branching of the 
modifications are unknown as well as how many are actually glycosylated in 
vivo. The fully functional size of SI is 240 kDa whereas the inactive precursor is 
210 kDa so 12.5% of the total mass is due to post-translational modifications.  
Altered glycosylation could lead to improper protein folding and the 
conformational change could affect activity. The glycosylation of other brush 
border proteins is related to their activity, for example the activity of dipeptidyl 
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IV (DPP4) is related to its glycosylation state. DPP4 is another highly N-
glycosylated brush border enzyme which exerts exoglycosidase activity and is 
involved in signal transduction and in type 2 diabetic patients, DPP4 inhibitors 
lower blood glucose levels. Inhibition of N-glycosylation by tunicamycin reduced 
the biological stability of DPP4 and decreased the activity (Aertgeerts et al., 
2004). In the non-transformed intestinal cell model IEC-18, Nω-Nitro-L-arginine 
methyl ester (L-NAME) treatment resulted in decreased N-glycosylation on 
SGLT-1 corresponding to a decrease in Km (Arthur et al., 2014). The increase 
in glycosylation observed here could be addition of further sugar residues or 
new additional glycosylation sites. The steric hindrance from the additional 
glycosylation could explain the change in Km since the active site identified in 
the SI sequence is in close proximity to 4 of the 18 predicted glycosylation sites 
(Van Beers et al., 1995). The human SI crystal structure is not available so it is 
unknown how close the glycosylation sites are to the active site once in the 
active folded state. N- and O-glycosylation have wide ranging functions 
including protein quality control, trafficking and activity. Interestingly, the 
diabetes model rats Biobreed have altered glycosylation. This rat model for 
insulin-dependent diabetes displays hyperglycaemia, insulitis, polydipsia, 
polyuria and requires insulin for survival. The size of the mature SI in the 
Biobreed rats is larger than in control rats (240 vs 230 kDa) but the size of the 
pro-SI precursor is identical, implying that the difference in the mature form 
arises from alterations in the complex glycosylation which was further 
confirmed to be changes in both N- and O-glycosylation. The SI was still 
appropriately trafficked to the cell surface but unfortunately the activity was not 
determined (Najjar et al., 2001). Human tissue biopsies show increased activity 
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of SI and increased levels of sugar transporters (Dyer et al., 2002), and since 
trafficking and sorting to the apical membrane is dependent on glycosylation, 
there is the potential that altered glycosylation in diabetes could play a role. 
The impact of altered glycosylation of brush border proteins can extend beyond 
their own activity; for example N-glycans at the brush border can bind to 
pancreatic α-amylase  therefore affecting starch digestion (Asanuma-Date et 
al., 2012). The intestinal brush border is rich in highly glycosylated proteins and 
the ability of luminal exposure to sugars to alter it could have widespread 
implications on overall starch and sugar digestion and overall enterocyte 
absorption.  
The SI protein in the total lysate was increased by 78%, but there was no 
change in sucrase specific activity. The small increase in Km is likely not the 
sole reason to explain the lack of change in activity. The antibody used here is 
specific for the sucrase subunit and would also detect inactive protein (Hauri et 
al., 1985). The amount of SI at the cell surface did not change with sucrose 
exposure so the post-translational changes observed could prevent trafficking 
of SI to the cell surface, leading to the accumulation within the cell. Both N- and 
O-glycosylation were modified here and both are involved in trafficking of SI to 
the cell surface (Naim et al., 2012). Alternatively, the trafficking process may be 
saturated, and therefore not capable of handling the increased internal SI. 
There are some phenotypes observed in the disaccharide malabsorption 
disease CSID in which mutations in SI lead to accumulation in the Golgi as 210 
kDa form, or in the ER, as 240 kDa form (Naim et al., 2012). For example, 
COS-7 cells  transfected with a mutation in SI that occurs in some chronic 
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lymphoma leukaemia cancer patients led to a lower sucrase activity and an 
increase in the immature 210 kD form of SI (Rodríguez et al., 2013). A 
heterozygous mutation of SI that occurs in a different CSID phenotype leads to 
accumulation of the complex glycosylated 240 kDa form in the ER in COS-7 
transfected cells (Keiser et al., 2006; Alfalah et al., 2009). In the latter example, 
less SI was observed at the cell surface by confocal microscopy. Here, cell 
surface biotinylation results suggested no change at the cell surface, and this 
could be due to different protein half-life at the cell surface between the two cell 
lines, or the change observed here may still allow some trafficking to the 
surface. Since the protein change here is a post-translational modification, 
some of the SI produced could be processed as normal.  
Preliminary work was done to purify SI from Caco-2/TC7 cells to send for N-
glycan analysis at the University of York to determine the exact nature of the 
change in glycosylation. The PNGase F digestion used here was only able to 
identify the type of glycosylation difference, but not whether it is altered or 
additional sites. After immunoprecipitation with the SI antibody, the samples 
were run on a gel, stained with Coomassie and a strong band at the size of SI 
was observed (data not shown). Unfortunately, the University of York were 
unable to detect SI in the sample. The sample preparation they performed to 
enable MALDI-TOF analysis (Mariño et al., 2010) involved long incubations and 
glycoproteins are often prone to instability and aggregation. It is also possible 
that the amount of material provided was not enough for detection; however the 
intensity of the Coomassie stained protein band did meet their general 
detection limit requirements. This is an area worth future investigation; however 
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it is beyond the scope of the grant and the capability to undertake the analysis 
which requires outside expertise and equipment.  
The expression of genes related to the transport of glucose and fructose were 
also evaluated. There was no change in GLUT2 expression, but SGLT1 and 
GLUT5 both decreased. A review of several animal studies found that GLUT5 
expression was induced by the presence of fructose, whereas SGLT1 and 
GLUT2 expression is similar between presence of fructose, glucose and non-
metabolizable glucose; however the induction of these genes was compared to 
starved state (Douard and Ferraris, 2008). Here, GLUT2 did not differ between 
cells cultured in glucose and sucrose, whereas SGLT1 and GLUT5 both 
decreased. A review of the literature on SGLT1 suggests that it may be 
primarily regulated by translational or post-translational mechanisms (Ferraris, 
2001), similar to what we observed here for SI. There was approximately 8-fold 
less SGLT1 mRNA than GLUT2 mRNA, in agreement with the original 
characterisation of the Caco-2/TC7 clone (Mahraoui et al., 1994).  
The chronic exposure to sucrose appeared to slow down the maturation of 
sucrase which occurs with differentiation. At two weeks when cells are not yet 
fully differentiated but have reached the peak SI mRNA level, the specific 
activity was decreased and the Km was increased. Once the cells were fully 
differentiated, there was no difference in the activity between cells cultured in 
glucose or sucrose, but there was still a small but significant increase in Km. 
Results indicated that it is the fructose part of sucrose which exerts the effect; 
there was no difference in sucrase activity or enzyme kinetics between cells 
cultured in sucrose or a mixture of glucose and fructose. Fructose, rather than 
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sucrose or glucose, has also been implicated in insulin resistance; glucose 
tolerance tests were performed in rats fed a starch diet for two weeks and then 
either starch (control), sucrose, glucose and fructose (G/F) or fructose and 
starch diets (F/starch). F/starch, sucrose and G/F diets all had the same 
changes and it was therefore proposed that fructose is mediating the effect, 
rather than glucose (Thresher et al., 2000). 
Altered post-translational modifications in response to sugar has been 
previously reported; Caco-2/TC7 cells were reported to sense dietary maltose 
however the methods and results are questionable (Cheng et al., 2014). Caco-
2/TC7 cells were grown to 10-days post confluence and then exposed to 
sucrose, glucose, maltose, isomaltose or fructose on the apical side for up to 
48 hours, with no sugar on the basolateral side. A Western blot of SI was 
presented which suggested a potential size increase of SI for those exposed to 
maltose at 12 hours, but no difference at 3, 6, or 24 hours. Only one blot was 
shown, so it is possible that this altered band was just a case of poor loading 
on that particular lane. Despite this, strong conclusions were made stating that 
Caco-2/TC7 cells can detect and respond to dietary maltose. Furthermore, 
there was questionable cell viability, unclear methods and the cells were used 
at 10 days post confluence and reported to be fully differentiated. Typical 
culture conditions for the Caco-2/TC7 clone require 21 days to reach full 
differentiation, with confluence at 7 days (Chantret et al., 1994), so although 
they report that cells are fully differentiated, this may not be the case as the 
time to reach confluence was also not reported. 
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A limitation to this study is the use of a malignant cell lines and as with any cell 
study, it is possible the effects observed could be related to the malignant state 
in which cells are more glycolytic. Furthermore, regulation in cell models is 
sometimes different to that observed in vivo; for example, in Caco-2/TC7 
glucose increases GLUT5 mRNA dose-dependently but this was not observed 
using an in vivo rat model (Ferraris, 2001), although this difference could be 
due to species rather than the experimental model. Another limitation to the 
experiment is that the cells were exposed to sucrose on the basolateral side, 
which would not be experienced in vivo. The cells were treated in this to ensure 
they utilised sucrose at the apical side rather than uptake glucose from the 
basolateral side. Furthermore, Caco-2 cells express the sweet taste receptors 
T1R1 and T1R2 only on the basolateral side, whereas in vivo they are found in 
the luminal gut mucosa, and it is possible they might play a role in the response 
to sugars, although it is not known if they respond to sucrose (Le Gall et al., 
2007). These taste receptors are potentially involved in the regulation of 
glucose metabolism in cells have been implicated in the insertion of GLUT2 into 
the apical membrane in response to glucose (Alpers, 2010).   
In summary, SI in the Caco-2/TC7 model was altered in response to chronic 
sucrose exposure in comparison to the control cells grown in glucose. Based 
on literature reports, it was expected that SI activity would increase, however 
no change was observed. Evidence here suggests that sugar exposure plays a 
role in post-translational modifications.  
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5 Chronic effects of olive leaf extract on sucrase expression 
and activity in Caco-2/TC7 cells  
5.1 Abstract 
There are many studies investigating the acute inhibition of SI, but limited 
studies investigating chronic effects. Bonolive, an olive leaf extract that is rich in 
oleuropein was used as a model compound to investigate its chronic impact on 
SI. Small intestinal enterocytes are exposed to the gut lumen as they 
differentiate and migrate up the villi and have a total life-span of 3-5 days. In 
order to mimic chronic nutritional exposure, the Caco-2/TC7 cell model was 
treated with 1.5 mg/mL of bonolive, a concentration achievable after 
consumption of bonolive supplement, for the last 3 days of differentiation. In 
Chapter 4, it was observed that sucrase from cells cultured in sucrose had 
altered glycosylation and Km, and so the treatment here was evaluated on cells 
cultured in both glucose and sucrose. Chronic bonolive treatment reduced the 
sucrase specific activity by 31% and 26% for cells cultured in glucose and 
sucrose, respectively. SI mRNA expression decreased by 78% for cells 
cultured in glucose and by 74% for cells cultured in sucrose. An increase in N-
glycosylation with bonolive treatment occurred for cells cultured in sucrose and 
this could be related to the decrease in Km that was observed. Bonolive was 
reduced the amount of sucrase at the cell surface by 41% but only for cells 
cultured in glucose. These results warrant future investigation into the use of 
olive leaf extract in humans for glycaemic control after sugar consumption and 
the effect of the treatment may depend on sugar exposure.  
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5.2 Introduction 
There have been many investigations into the health benefits of olive oil and 
other olive products in recent years due to the reported health benefits of the 
Mediterranean diet. The Mediterranean diet was first described in 1980 the 
Seven Countries study investigating cardiovascular health (Keys, 1980). It was 
further defined as a cultural model of healthy eating based on the observed 
long life expectancy and low rates of chronic diseases for people from Italy and 
Greece in the 1960s. The diet is tied closely to areas strongly involved in olive 
cultivation and generally is defined as consisting of fresh and local produce, 
rich in plant foods, low in processed foods, olive oil as the main fat source, low 
amounts of dairy consumed daily, fruit as desert daily with concentrated sugar 
or honey only consumed 1-2 times per week in low amounts, wine in moderate 
amounts consumed with food, low red meat intake and low to moderate fish 
and poultry intake (Willett et al., 1995). A meta-analysis of 12 prospective 
cohort studies totalling 1.5 million healthy individuals found that increased 
adherence to the Mediterranean diet was associated with a significant reduced 
risk of mortality from all causes, including a 9% reduction in mortality from 
cardiovascular disease (Sofi et al., 2008). Since the diet’s main source of fat is 
olive oil and up to 25-35% of total intake, many studies have investigated the 
health benefit of olive oil and olive products. The large scale intervention study, 
PREDIMED, ran from 2003-2011 to monitor the long-term effects of the 
Mediterranean diet on cardiovascular health and follow-up is ongoing. A 
significant disease risk of cardiovascular disease and type 2 diabetes were 
reduced for Mediterranean diets supplemented with extra-virgin olive oil. The 
relative risk reduction for T2DM was 40% and the number of expected 
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prevented cases of T2DM was 26 for every 1000 hypothetical participants 
(Martínez-González et al., 2015; Martínez-González et al., 2010). These 
studies investigated the diet as a whole and took into account interactions 
between the components of a whole diet, however it is clear that olive oil poses 
a great health benefit, so the mechanisms are of interest.  
The original health benefits of olive oil were originally attributed to its oleic acid 
content however more recently the effects of the polyphenolic components 
have been recognized (Martín‐Peláez et al., 2013). The European Food Safety 
Authority (EFSA) accepted the first olive-based health claim 1924/2006 article 
12 on 19th January 2007 stating that olive oil “contributes to the protection of 
blood lipids to oxidative damage”. This claim and other claims have been 
reviewed by the EFSA (EFSA, 2011) and they commented that the effect was 
due to its fatty acid composition rather than phenolic content. A claim has also 
been accepted to state that “Olive oil polyphenols contribute to the protection of 
blood lipids from oxidative stress” and review by EFSA states that 5 mg of 
hydroxytyrosol and its derivatives, formed from oleuropein, must be consumed 
daily to meet the claim for the protection of LDL particles from oxidative 
damage and this is believed to be achievable in the diet (EFSA, 2011). Other 
claims are yet to be substantiated therefore there are still many ongoing studies 
to investigate other health benefits. A large amount of evidence from a range of 
in vivo and in vitro studies is required to support the claim and there must be a 
cause-and-effect relationship established along with mechanistic information. 
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Figure  5-1. Structures of the key phenolic components found in olives. 
 
The key phenolic compounds found in olives oolea europaea) include the 
parent compound oleuropein, in the class of secoiridoids, and its derivatives 
hydroxytyrosol and tyrosol (Figure  5-1). The concentration of polyphenols found 
in olives varies by cultivar and region (Garcia-Villalba et al., 2011) and further 
depends on the age and processing (Preedy and Watson, 2010). Olive leaves 
have a higher concentration of oleuropein as compared to the olive itself and 
the levels of oleuropein in olive leaf can reach up to 264 mg per g of dried leaf, 
expressed as tyrosol equivalents (Ryan et al., 2003). Oleuropein content is 
used a marker for olive quality (Preedy and Watson, 2010). During the 
processing of olives to produce olive oil, much of the oleuropein is converted to 
hydroxytyrosol and tyrosol (Vissers et al., 2002). 
B) Hydroxytyrosol 
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The bioavailabilty of olive leaf polyphenols has been studied in humans. 
Urinary excretion was evaluated in healthy subjects after consumption of a 
supplement containing oleuropein and found that 15% of the amount consumed 
was excreted as tyrosol and hydroxytyrosol metabolites. During the formation 
of the metabolites, the attached glucose is removed but this study was unable 
to determine if the glycoside is removed before or after intestinal absorption, 
however it was found to be stable in vitro in gastric and duodenal fluids (Vissers 
et al., 2002). After consumption of an olive leaf extract in capsule form, 
oleuropein concentration in the plasma peaked at 38 minutes and conjugated 
metabolites (glucuronidated and sulphated) of hydroxytyrosol peaked at 93 
minutes. In both the plasma and urine, the phase II metabolites were the most 
predominant, however oleuropein was also present with the glucose group still 
attached. Males were more efficient at conjugation of oleuropein than females 
and overall inter-individual variation was observed (Bock et al., 2013). Caco-2 
cells were unable to produce glucuronidated metabolites as these cells lack the 
enzymes required. The sulphated metabolites were formed and found in 
predominantly on the basolateral side (Rubió et al., 2014). In contrast, another 
study found that no uptake of oleuropein occurred in the Caco-2 cell model or 
across rat intestinal segments (Corona et al., 2006) however this was based on 
the fact that no oleuropein was detected. Their in vivo data demonstrate 
presence of conjugates so oleuropein is more likely taken up and the majority 
converted.  
Recent investigations into the health benefits of olive polyphenols suggest that 
they may affect carbohydrate digestion and glucose transport. Inhibition studies 
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with a Sacchariomyces cervisae source of α-glycosidases indicated that 
hydroxytyrosol was a strong inhibitor with IC50 of 150 µM and oleuropein with 
IC50 of 400 µM, while acarbose IC50 was 200 µM (Hadrich et al., 2014). 
However, the limitations are the use of yeast enzyme source with a non-
specific substrate p-nitrophenyl-α-D-glucopyranoside (pNPG) and the fact that 
the the interference of the polyphenols on the detection method was not taken 
into account (Nyambe-Silavwe et al., 2015). The potential for olive leaf 
polyphenols to act as acute α-glucosidase inhibitors was confirmed using the 
optimised human sucrase assay in Chapter 3. The olive leaf extract bonolive 
exhibited inhibition towards sucrase and maltase with IC50 values of 3.2 and 
1.3 mg/mL, respectively.  
Chronic effects of an olive leaf extract containing 35% (w/w) oleuropein were 
observed in a type 2 diabetic mouse model. Mice that were fed 0.2% (w/w) 
olive leaf extract from 4-weeks of age showed a decrease in non-fasting blood 
glucose from 9-weeks onwards. Impaired glucose tolerance occurred at 8-
weeks in this model and it was attenuated by the olive leaf extract at 11-weeks 
and 24-weeks, while no change in insulin levels or weight were observed. The 
results suggest that chronic intake of an oleuropein rich olive leaf extract can 
inhibit the progression of type 2 diabetes in mice (Murotomi et al., 2015). In 
humans, a double-blind crossover study was performed to evaluate the chronic 
consumption of an olive leaf extract on insulin sensitivity. Overweight middle-
aged male participants, who were expected to be insulin resistant, consumed 
either placebo or olive leaf extract containing predominately oleuropein (51 mg 
per day) and hydroxytyrosol (9.7 mg per day) for 6-weeks, followed by a 6-
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week washout and then the alternative treatment.  A 75 g oral glucose 
tolerance test was performed at the end of each treatment period and a 15% 
improvement on insulin sensitivity occurred along with a 6% reduction in blood 
glucose (AUC) and insulin was decreased by 14% (de Bock et al., 2013). 
These studies suggest that oleuropein can influence glucose homeostasis. 
A decrease in glucose transport is a potential mechanism by which the blood 
glucose and insulin levels were reduced in the aforementioned study. It is 
currently not known whether chronic intake had an effect on glucose transport 
or the expression level of transporters. The anti-diabetic drug acarbose, an α-
glucosidase and α-amylase inhibitor, reduces type 2 diabetes risk by 6%  
suggesting that acute inhibitors can exert chronic effects. Since it is reported 
that olive leaf polyphenols can inhibit α-amylase and α-glucosidase, a greater 
effect compared to glucose alone could be observed following consumption of 
starch or sucrose.  
Bonolive extract was originally evaluated and is currently on the market as a 
treatment for osteoporosis. It has been standardised for its oleuropein content, 
which is >40% (w/w). A double-blind, randomised parallel group study was 
performed on 64 female subjects with osteoporosis in which the participants 
consumed 250 mg of extract and 1000 mg of calcium or 1000 mg of calcium 
(placebo) for one year. Pro-osteoblastic marker osteocalcin was found to 
increase with the treatment and bone mineral density remained stable in the 
treatment group but decreased in the control.  
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The aim here is to evaluate the chronic effects of the olive leaf extract bonolive 
on surcrase. Intestinal cells differentiate over 3-5 days and are constantly being 
regenerated and while they differentiate as they migrate from the base of the 
villi to the tip where they are exfoliated, continually being exposed to the 
contents of the gut lumen (Ferraris, 2001). The Caco-2/TC7 cell model was 
treated with bonolive for the final 3-days of differentiation and chronic effects 
are evaluated by determining mRNA and protein levels, activity, and kinetics of 
SI following treatment (Figure  5-2). 
 
Figure  5-2. Determination of the effects from chronic 3-day bonolive treatment 
on sucrase isomatase in the Caco-2/TC7 cell model. The medium was 
refreshed each day and the medium for the treatment wells contained 
bonolive. 
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5.3 Results 
 Chronic effect of bonolive on Caco-2/TC7 viability  5.3.1
Caco-2/TC7 cells were cultured on 12-well solid supports. The viability was 
determinated after 3-day chronic bonolive treatment at 1.5 mg/mL using the 
LDH Assay (Section 2.1.5).  There was no loss in viability as determined from 
n/N=3/9 replicates. 
 Chronic effect of bonolive on gene expression 5.3.2
5.3.2.1 Chronic treatment: 3 days at 1.5 mg/mL 
The impact of chronic bonolive treatment on SI mRNA levels was investigated 
in the intestinal Caco-2/TC7 cell model. For all gene expression experiments, 
there was no significant change in the TBP housekeeping gene between the 
treatments. The ratio of the gene of interest to TBP was determined for each of 
n=3 biological replicates. There was variation in the SI/TBP ratio between the 
biological replicates so the results of each experiment were normalised to the 
control. 
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Figure  5-3. The effect of chronic bonolive treatment on gene expression for SI 
(A), GLUT2 (B), SGLT1 (C) and GLUT5 (D). Caco-2/TC7 cells were cultured 
in 25 mM glucose or 25 mM sucrose for 21 days and treated with 1.5 mg/mL 
bonolive for the final 3 days. Total mRNA was extracted, converted to cDNA 
and the copies/µL of target relative to TBP housekeeping gene were 
determined using ddPCR. Results were normalised to the glucose control 
and are presented as mean + SEM, *** p<0.001, ** p<0.01, n/N = 3/3, 
analysed in triplicate. 
 
A concentration of 1.5 mg/mL bonolive, equivalent to 1100 µM oleuropein, was 
found to decrease sucrase-isomaltase mRNA by 78% (p<0.001) for cells 
cultured in glucose and 74% (p<0.001) for cells cultured in sucrose (Figure 5-
3A). The effect of chronic bonolive treatment on the expression levels of the 
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related genes for GLUT2, SGLT1 and GLUT5 were also determined. GLUT2 
was reduced by 55% (p<0.001) when cultured in glucose and by 30% in 
sucrose (p<0.01) (Figure 5-3B). There was a 27% (p<0.001) reduction in 
SGLT1 when cultured in glucose (Figure 5-3C). There was no statistically 
significant change in SGLT1 for cells cultured in sucrose. However, SI mRNA 
levels were already reduced by 54% from growth in sucrose, as discussed in 
Chapter 4. The GLUT5 gene expression showed the greatest variation, 
suggesting inconsistent expression, particularly when cultured in sucrose. 
Nevertheless, there was a statistically significant 360% (p<0.01) increase in 
GLUT5 with bonolive treatment for cells cultured in sucrose. When cultured in 
glucose, GLUT5 appeared to increase (62%), although the result was not 
statistically significant due to the high variation between samples (p=0.6) 
(Figure 5-3D). The analysis for GLUT5 was performed after storage of the 
cDNA samples for longer than 1 year so it is possible that the high variation is 
due to instability of the sample. The SI transcription factor CDX2 increased by 
16% (p<0.05) with bonolive treatment when cultured in glucose but there was 
no change when cultured in sucrose (Figure 5-4) so the reduction of SI is not 
due to reduction in its transcription factor. 
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Figure  5-4. The effect of chronic bonolive treatment on the gene expression of 
transcription factor CDX2. Caco-2/TC7 cells were cultured in 25 mM glucose 
or 25 mM sucrose for 21 days and treated with 1.5 mg/mL bonolive for the 
final three days. Total mRNA was extracted, converted to cDNA and the 
copies/µL of CDX2 relative to TBP housekeeping gene was determined 
using ddPCR. Results were normalised to the glucose control and are 
presented as mean + SEM, * p<0.05, n/N = 3/9, analysed in triplicate.  
 
5.3.2.2 Dose response and time Course for sucrase gene 
expression 
SI mRNA expression was determined after 12, 24, 48 and 72 hour treatment 
with 1.5 mg/mL bonolive. By 12 hours there was a significant (p<0.001) 
decrease in SI mRNA and the maximum reduction of ~80% occurred by 24 
hours. There was no significant difference between 24 and 48 hours, however 
there was a slight increase between 48 to 72 hours, back up to 70% of the 
control (p<0.01)(Figure  5-5A). The same pattern occurred at all four bonolive 
concentrations (Figure  5-5B). 
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Bonolive treatment at 0.5, 1.0, 1.5 and 2 mg/mL was applied for 72 hour and a  
linear concentration dependent reduction of SI mRNA expression was occurred 
(R2 = 0.98) (Figure  5-5C). The linear reduction also occurred for different 
treatment times (Figure  5-5D). 
 
Figure  5-5. The time and concentration dependence for the effect of bonolive 
treatment on SI expression. Time course (A) with 1.5 mg/mL bonolive for 12, 
24, 48 or 72 h and concentration response (C) with 72 h treatment, both with 
n/N= 3/9, analysed in triplicate. Results presented as normalised mean + 
SEM, p-values determined from ANOVA followed by Tukey’s post-hoc test, 
labels compare to previous point, ***<0.001, **<0.01, ns= not significant. The 
time course was evaluated at four bonolive concentrations (B) and the 
concentration response (D) was evaluated at four time points for n/N=1/3 
replicates, presented as mean ± SD.  
 
129 
 
 
 
5.3.2.3 Comparison of transwell®  filters and solid support cell 
culture plates 
Caco-2/TC7 cells are commonly cultured on transwell® filters which are porous 
supports and allow the polarised growth and access to basolateral and apical 
sides, with the apical side representing the gut lumen. The cells for mRNA 
experiments so far have been performed on solid supports due to high cost of 
the transwell® filters, therefore, a comparison was performed to evaluate if the 
decrease in mRNA with bonolive treatment still occurs when the cells are 
cultured on filters.  
 
Figure  5-6. Comparison of mRNA from Caco-2/TC7 cells grown on solid or 
porous supports. Caco-2/TC7 cells were cultured in 25 mM glucose or 25 
mM sucrose on either solid support or transwell® plates for 21 days and 
treated with 1.5 mg/mL with bonolive for the final 3 days of differentiation. 
Results are presented as mean + SD of the amount of SI in copies/µL 
relative to the TBP housekeeping gene. n/N = 1/3, analysed in triplicate. *** 
p<0.001 
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As seen in Figure 5-6, the decrease in SI mRNA still occurred when cultured on 
transwell® filters, for both sucrose and glucose grown cells, however the ratio 
of the absolute amount of SI relative to TBP is much lower from cells cultured 
on transwell® filters. The absolute concentrations of SI and TBP housekeeping 
gene, as determined by ddPCR are presented as copies/µL in Table  5-1. Cells 
cultured on solid supports had more SI mRNA than those cultured on 
transwell® filters, however they had a decrease in TBP. Nevertheless, a similar 
fold- decrease in SI relative to TBP was observed with chronic bonolive 
treatment on both solid supports and transwell® plates, with p-value of <0.001 
(Table 5-1).  
Table  5-1. Comparison of sucrase mRNA with chronic bonolive treatment for 
Caco2/TC7 cells cultured on transwell® or solid support plates. Caco-2/TC7 
cells were cultured in 25 mM glucose (G) or 25 mM sucrose (S) for 21 days and 
treated with 1.5 mg/mL with bonolive for the final 3 days of differentiation. 
Results are presented as mean ± SD, n/N=1/3.  
 
Plate 
Type 
C
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 SI 
(Copies/µL) 
TBP 
(Copies/uL) 
Ratio 
SI/TBP 
Fold  P-value 
Transwell
® 
G - 532.6 ± 64.4 23.4 ± 2.3 22.8 ± 2.1 
3.2 <0.001 
G + 166.2 ± 25.6 23.5 ± 5.6 7.2 ± 0.7 
S - 591.4 ± 70.2 22.5 ±3.2 26.4 ± 2.2 
2.6 <0.001 
S + 271.2 ± 96.9 25.0± 6.9 10.7 ± 1.1 
Solid 
Support 
G - 1215.6 ± 179.8 11.0 ± 1.1 110.3 ± 11.4 
3.5 <0.001 
G + 477.8 ± 36.5 15.6 ±1.7 31.0 ± 3.3 
S - 991.4 ± 239.1 10.7 ± 2.1 91.7 ± 7.5 
3.6 <0.001 
S + 480.7 ± 99.1 18.1 ± 0.6 25.1 ± 9.3 
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5.3.2.4 Effect of green tea treatment on SI  mRNA expression and 
cell viability  
Green tea was determined to be an acute sucrase and maltase inhibitor in 
Chapter 3. The effect of chronic green tea treatment was evaluated here to see 
if other acute sucrase inhibitors in addition to bonolive would also lead to 
changes in mRNA expression. Caco-2/TC7 cells were treated with 1.0 mg/mL 
green tea from day 3 to 21 and mRNA was extracted and analysed by ddPCR 
(n/N=1/6). Viability was confirmed for the treatment using the LDH assay. 
There was no significant change in SI mRNA expression with the 18 day green 
tea treatment.  
 Chronic effect of bonolive on sucrase isomaltase protein 5.3.3
5.3.3.1 Total and surface SI protein 
Caco-2/TC7 cells were cultured on 6-well transwell® filters and the total and 
surface SI protein were determined by ProteinSimple WES analysis. All protein 
results were normalised to the glucose control for each experiment due to 
variation in the amount of SI between the biological replicates. There was no 
change in SI protein in the total lysate after chronic bonolive treatment for cells 
cultured in glucose or sucrose grown cells when looking at total absolute 
amount of SI (i.e. not corrected for loading control) (Figure  5-7A).  There was a 
difference between glucose and sucrose grown, as discussed in Chapter 4.  
The α-actinin results were presented independently to demonstrate its 
suitability as a loading control (Figure  5-7B). Loading controls normalise the 
results for loading of sample into the capillaries. The same amount of total 
protein of each sample was loaded into each lane, however the loading control 
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can account for pipette error in sample loading and the actual separation into 
the capillary and the ideal loading control will remain consistent throughout 
different sample types. There was no significant difference between the 
absolute amount of α-actinin between the bonolive treated samples and their 
respective controls, or between glucose and sucrose controls, indicating that it 
is a suitable loading control; only the difference between glucose + bonolive 
and sucrose + bonolive was significantly different. For the final result, the 
normalised amount of SI was divided by the normalised amount of α-actinin 
(Figure  5-7C). There was no change in SI in the total lysate with bonolive 
treatment for cells cultured in glucose, however there was a 22% decrease 
(p=0.004) for cells cultured in sucrose.  
The amount of SI at the apical cell surface is presented (Figure  5-8A) and 
results were also determined as a fraction of the total lysate, to represent the 
proportion of SI at the cell surface (Figure  5-8B). The amount of SI at the cell 
surface decreased by 47% (p=0.01) for cells cultured in glucose and there was 
no significant change for cells cultured in sucrose (p=0.4) (Figure 5-8A). When 
the surface sucrase was evaluated relative to total sucrase corrected by the 
loading control α-actinin, the proportion of SI at the surface decreased by 41% 
(p=0.004) for glucose-grown and increased by 25% for sucrose-grown cells (p= 
0.018) (Figure  5-8B).  
Since there was no change in total SI protein for cells cultured in glucose with 
the 3-day bonolive treatment, a longer treatment time was also evaluated. 
Caco-2/TC7 cells grown on solid supports were treated with 1.5 mg/mL 
bonolive for the final 7 days of differentiation and the SI in the total lysate was 
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determined as previously described. There was no change in SI in the total 
lysate after 7-day bonolive treatment (p=0.1, n/N=1/3) (data not shown).  
 
 
Figure  5-7. The effect of chronic bonolive treatment on sucrase-isomaltase 
protein in Caco-2/TC7 total cell lysate. Caco-2/TC7 cells were cultured in 25 
mM glucose or 25 mM sucrose on transwell® plates for 21 days and treated 
with 1.5 mg/mL with bonolive for the final 3 days of differentiation. 
ProteinSimple WES analysis was used to quantify SI (A) and the loading 
control α-actinin (B) and the ratio of SI/α-actinin was determined (C). Results 
were normalised to the glucose control and are presented as mean + SEM, 
n/N = 3/12, analysed in duplicate. 
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Figure  5-8. The effect of chronic bonolive treatment on surface sucrase-
isomaltase protein in Caco-2/TC7 cells. Caco-2/TC7 cells were cultured in 
25 mM glucose or 25 mM sucrose on transwell® plates for 21 days and 
treated with 1.5 mg/mL with bonolive for the final 3 days of differentiation. 
After purification of biotinylated cell surface proteins, samples were analysed 
by ProteinSimple WES analysis to quantify SI (A). The ratio of SI at the cell 
surface to total SI corrected to the α-actinin loading control was determined 
(B). Results were normalised to the glucose control and are presented as 
mean + SEM, n/N = 3/12, analysed in duplicate. 
 
5.3.3.2 Protein size analysis 
In Chapter 4 Section 4.3.3.2, the size of SI and α-actinin were analysed for 
differences between cells cultured in glucose or sucrose. Cells cultured in 
sucrose had an increase in the size of SI which was determined to be due to N- 
and O-glycosylation. In a similar fashion, protein lysate samples were 
evaluated for the effect of bonolive on the size of SI and α-actinin loading 
control. For SI at the cell surface and in the total lysate from cells cultured on 
transwells® or solid supports, the size increased with chronic bonolive 
treatment when the cells were cultured in sucrose (Table  5-2). The increase 
was by 1.0% (p=0.001, n/N=4/12), 0.9% (p<0.001, n/N=4/12) and 1.0% (p=0.04, 
n/N=2/12), respectively. The increase is equivalent to ~2.3 kDa, a small but 
significant increase. There was no change for cells cultured in glucose and 
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there was no change for the α-actinin loading control. Since the protein 
samples were analysed in duplicate, these results are from the data from 48 
individual capillaries for samples cultured on transwells® and from 24 individual 
capillaries for cells cultured on solid supports. As explained in Section 4.3.3.2, 
the accurate size result reported on WES is determined by comparison with 
standard peaks. 
Table  5-2. Protein size analysis of SI and the α-actinin loading control on 
ProteinSimple WES. Caco-2/TC7 cells were cultured in 25 mM glucose 
(G;control) or 25 mM sucrose (S) for 21 days on solid supports or transwell® 
filters. The mean size of SI was determined at the cell surface fraction after 
biotinylation (n=48). The mean size of SI and α-actinin was determined in the 
total lysate from cells grown on transwell® filters (n=48) or solid supports 
(n=12). Results are presented as a percentage of the control (glucose), mean ± 
SD, and statistical significance was determined with ANOVA following by 
Tukey’s post-hoc test.  
 
Sample 
 
 
 
 
C
o
n
d
itio
n
 
B
o
n
o
liv
e
 
Sucrase 
Size 
(% of 
Control) 
P-value 
α-actinin 
(% of 
control) 
P-
value 
Cell 
Surface 
G - 307.6 ± 1.5 
0.4 
NA 
NA 
G + 307.6 ± 1.5 NA 
S - 310.3 ± 1.4 
<0.001 
NA 
NA 
S + 313.1 ± 2.3 NA 
 Total 
Lysate 
(transwell) 
G - 306.5 ± 4.0 
0.9 
100.8 ± 0.3 
0.7 
G + 306.6 ± 4.4 100.1 ± 0.7 
S - 310.3 ± 4.1 
<0.001 
101.2 ± 0.5 
0.8 
S + 312.1 ± 3.4 101.8 ± 0.5 
 Total 
Lysate 
(solid 
support) 
G - 294.9 ± 1.8 
0.06 
100.0 ± 0.0 
0.6 
G + 296.5 ± 1.1 100.2 ± 0.4 
S - 297.1 ± 1.5 
<0.001 
100.1 ± 0.6 
0.9 
S + 299.4 ± 1.0 100.2 ± 0.6 
 
To further investigate the nature of this size increase, samples cultured in 
sucrose with and without bonolive treatment were treated with PNGase F to 
remove N-glycosylation. Representative WES pherograms from the PNGase F 
digests are presented in Figure  5-9. A total of n=7 samples were treated with 
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PNGase and the size of the resulting products are presented in Table  5-3. The 
resulting SI products were the same size after PNGase F digestion (p=0.6, 
n=7) indicating that the size increase observed from bonolive treatment was 
due to N-glycosylation. There was no change in size for the α-actinin control. 
Table  5-3. Protein size analysis by WES of SI and α-actinin after PNGase F de-
glycosylation. Caco-2/TC7 cells were cultured in 25 mM sucrose +/-chronic 
bonolive treatment.  The total lysate was subjected to PNGase F treatment or 
mock treatment. Results for SI and control α -actinin are presented as mean ± 
SD (n=7). 
 
Sample SI size  (kDa) P-value α-actinin 
size 
(kDa) 
 
P-
value 
Sucrose Mock 308.8 ± 1.1 <0.001 103.2 ± 0.8 0.8 
Sucrose + Bonolive 
Mock 
311.3 ± 0.8 103.3 ± 0.8 
Sucrose PNGase F 286.9 ± 6.6 0.6 103.7 ± 1.0 0.8 
Sucrose + Bonolive 
PNGase F 
289.9 ± 7.9 103.9 ± 0.7 
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Figure  5-9. Representative pherograms from ProteinSimple WES analysis of α-
actinin (first peak) and SI (second peak) in samples digested with PNGase 
F. Caco-2/TC7 cells were cultured in 25 mM sucrose and treated +/- 
bonolive for the final three days of differentiation. Total cell lysate was 
digested with (red) and without (black) PNGase F enzyme with the mean 
size from n=7 samples.  
 
 Chronic effect of bonolive on sucrase-isomaltase enzyme activity  5.3.4
5.3.4.1 Chronic treatment: 3 days at 1.5 mg/mL 
Sucrase specific activity was determined after chronic bonolive treatment at 1.5 
mg/mL for the final 3 days of differentiation (n/N=3/9) (Figure  5-10). Chronic 
bonolive treatment reduced the specific activity of sucrase by 31% for cells 
cultured in glucose(p<0.001), from 140.1 ± 0.6 µmol/min/mg to 96.9 ± 0.05 
µmol/min/mg. The reduction in sucrase specific activity was 26% for cells 
cultured in sucrose (p<0.001), from 141.6 ± 0.01 µmol/min/mg to 104.5 ± 0.003 
µmol/min/mg. Statistical significance was determined by ANOVA followed by 
138 
 
 
 
Tukey’s post-hoc test for the slopes of each replicate. There was no difference 
in the specific activity between growth in glucose or sucrose, or bonolive 
treated cells grown in either glucose or sucrose.  
 
Figure  5-10. Effect of chronic bonolive treatment on sucrase specific activity. 
Caco-2/TC7 cells were cultured in 25 mM glucose or 25 mM sucrose for 21 
days and treated for the final three days with 1.5 mg/mL bonolive. The cells 
were lysed and used for sucrase enzyme assay to determine the µmol/min 
of glucose produced per milligram of total protein. The slope of the line 
represents the enzyme activity in µmol/min/mg or mU/mg where 1 unit is 
equal to 1 mol/min. Mean ± SEM, *** p>0.001, n/N = 3/9. 
 
5.3.4.2 Time course and concentration response 
Sucrase specific activity was determined after bonolive treatment for 0, 0.5, 3 
and 7 days. After 0.5 days there was no significant change compared to the 
control. There was a 12% reduction between 12 and 24 hours (p=0.04) to 26% 
of the control. The decrease plateaued after 24 hours and no significant 
difference was observed between 1, 3 and 7 day treatment time (Figure  5-11A). 
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A range of bonolive concentrations up to 2.5 mg/mL were evaluated with 3 day 
treatment and the specific activity decreased with all doses compared to control 
(p<0.001). There was no significant difference between 0.5 and 1.0 and 
between 1.5 and 2.5 mg/mL, but there was a decrease of 27% between 1.0 to 
1.5 mg/mL. The maximal reduction of 39% of the control occurred at 1.5 mg/mL 
(Figure  5-11B). 
A       B 
 
Figure  5-11.  Effect of treatment time and bonolive concentration on sucrase 
specific activity. Caco-2/TC7 cells were cultured on solid support 75 cm2 
flasks in 25 mM glucose for 21 days and treated for the final 0.5, 1, 3 or 7 
days with 1.5 mg/mL bonolive for the time course (A) or treated for 3 days 
with 0.5, 1, 1.5, 2.5 mg/mL bonolive for 3 days. The specific activity was 
determined for each treatment based on the µmol/min/mg of protein. Results 
were normalised to the control of each experiment and are presented as 
mean ± SEM, ### p<0.001 compared to control, * p<0.05, ns = not 
significant, n/N=3/6. 
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5.3.4.3 Effect on Km and Vmax 
The chronic bonolive treatment was evaluated for its effect on the kinetic 
parameters Km and Vmax using the sucrase enzyme assay. For glucose and 
sucrose grown cells, the chronic bonolive treatment reduced the Vmax by 34% 
(p<0.001) and 20% (p<0.001), respectively. The Km decreased with chronic 
bonolive treatment only in sucrose grown cells from 12.3 to 9.0 (p<0.001) 
(Figure 4D&E). The Km increased from 10.7 mM to 12.3 mM when cultured in 
sucrose compared to glucose (p=0.01) and there was no change in Vmax 
(Table  5-4). 
 
Figure  5-12.  Sucrase Lineweaver-Burk plot for the determination of Km and 
Vmax for cells cultured in 25 mM glucose (A) or 25 mM sucrose (B) with and 
without chronic bonolive treatment. Caco-2/TC7 cells were for 21 days and 
for cells treated with bonolive, 1.5 mg/mL was added to the medium for the 
final three days. The cells were lysed and a sucrase assay was performed 
with substrate concentrations from 5-60 mM, fixed time and fixed enzyme 
amount. Results from three independent experiments were normalised and 
plotted mean ± SEM where [S] is the sucrose substrate concentration and v 
is mmol/min of glucose produced (n/N = 3/9 
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Table  5-4. Kinetic parameters Km and Vmax determined from Caco-2/TC7 cells 
cultured in 25 mM glucose or 25 mM sucrose for 21 days with chronic bonolive 
treatment. 
 
Cell 
Medium 
Treated Linear Fit R2  Km (mM) P-
value 
Vmax 
(µmol/min) 
P-value 
Glucose 
 
- y= 201.0x + 17.9 0.99 10.7 ± 1.9 0.1 0.06 ± 0.01 p<0.001 
+ y=280.1x + 26.4 0.99 10.7 ± 3.0 0.04 ± 0.00 
Sucrose - y=225.5x + 19.5 0.99 12.3 ± 3.5 0.05 0.05 ± 0.01 p<0.001 
+ Y=280.1x + 26.4 0.99 9.0 ± 2.5 0.04 ± 0.01 
 
 Results summary 5.3.5
The results for the effects on sucrase from chronic exposure to 25 mM sucrose 
rather than 25 mM glucose (Chapter 4) are summarised in Table  5-5, along 
with the effects from chronic bonolive treatment (3 days, 1.5 mg/mL).  
Table  5-5. Summary of the effects of chronic bonolive treatment on sucrase in 
Caco-2/TC7 cells. Cells were cultured in 25 mM glucose or 25 mM sucrose for 
21 days and treated for the final 3 days of differentiation with 1.5 mg/mL 
bonolive. NS = not significant, NA = not applicable. 
 
 Glucose  
Sucrose 
Glucose  
Glucose + 
Bonolive 
Sucrose  
Sucrose + 
Bonolive 
Km ↑ 15%  
(p=0.01) 
NS ↓ 27%  
(p<0.001) 
Vmax NS ↓ 22%  
(p<0.001) 
↓ 20%  
(p<0.001) 
Specific Activity No change ↓31% 
(p<0.001) 
↓26% 
(p<0.001) 
mRNA NS ↓ 78%  
(p<0.001) 
↓74%  
(p<0.001) 
Total Sucrase 
Protein 
↑ 78% 
(p<0.001) 
NS ↓22% 
(p=0.004) 
Surface Sucrase 
Protein 
NS ↓ 41% 
(p=0.01) 
NS 
Sucrase Protein 
Size 
↑ 0.8% 
(p<0.001) 
NS ↑ 0.9% 
(p<0.001) 
Source of Size 
Change 
N- and O-
glycosylation 
N/A N-glycosylation 
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5.4 Discussion 
Following meal ingestion, carbohydrate hydrolysis and sugar transport across 
the intestinal wall is one of the critical points affecting subsequent glucose 
levels in the blood and supply to the tissues, presenting a unique target for 
interventions to limit excessive levels of blood glucose. This process requires 
coordinated action of glucosidases and sugar transporters to deliver 
monosaccharides to the target organs.  SI is the only enzyme capable of 
hydrolysing the α-1,4 glycosidic bond of sucrose, one of the most commonly 
used sweeteners (Van Beers, 1995). It was established in Chapter 3 that 
bonolive exerts acute inhibitory action on both sucrase and maltase activities, 
similar to the anti-diabetic drug acarbose. Chronic intake of acarbose reduced 
the risk of type 2 diabetes (Nijpels et al., 2008) so it is hypothesised that other 
α-glucosidase inhibitors such as bonolive may also exert chronic effects 
whereby long term consumption could lead to altered activity or expression of 
the SI enzyme. Caco-2 cells were exposed to a chronic 3-day treatment and 
the mRNA expression levels, cell surface and total lysate SI protein amounts, 
SI enzyme specific activity and kinetic parameters were determined to evaluate 
the potential chronic effects. A concentration of 1.5 mg/mL bonolive was used, 
equivalent to 1100 µM oleuropein, which would be achievable in the gut after 
consumption of bonolive supplement. For example the consumption of two 500 
mg capsules with 200 mL of water would yield a concentration of 5 mg/mL. 
Assuming a 3-fold dilution from digestion, the concentration reaching the gut 
would be greater than 1.5 mg/mL. The oleuropein-rich extract was applied 
directly into the cell culture medium on the apical side because it has previously 
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been established that oleuropein is stable in the stomach and to digestion in 
the proximal gut (Vissers et al., 2002; Markopoulos et al., 2009). 
Chronic bonolive treatment dramatically decreased mRNA expression under 
growth in both glucose and sucrose which did not correspond to total SI protein 
levels. The SI mRNA half-life has been reported as 30 hours (Chantret et al., 
1993) but  that can sometimes be a poor predictor of protein levels which  
depend on transcription rate and additional control mechanisms including 
nuclear export and mRNA localisation, transcript stability, translational 
regulation and protein degradation (Pradet-Balade et al., 2001); there is low 
correlation between mRNA and  protein if the protein half-life is longer than 
mRNA (Raj et al., 2006). The protein half-life for SI has not been reported but it 
is possible that it is longer than for mRNA because even 7-day treatment did 
not lead to a reduction of SI mRNA expression in glucose grown cells.  
There was no reduction in SI mRNA with green tea treatment, which is also an 
acute sucrase-isomaltase inhibitor, even though the treatment time was longer 
than that of bonolive. This implies that not all acute inhibitors will lead to chronic 
effects. The reduction in SI mRNA expression by bonolive occurred whether 
the cells were cultured on solid or transwell® supports and was observed to 
decrease linearly with concentration. A reduction in CDX2, one of the 
transcription factors required for SI expression along with HNF-1α and GATA-4 
(Boudreau et al., 2002) , has been shown to lead to a reduction in SI mRNA 
(Liu et al., 2011). Here, no change in CDX2 mRNA was observed implying that 
the bonolive effect on SI mRNA is achieved through an alternative mechanism. 
GLUT2 mRNA expression also decreased with chronic bonolive treatment, 
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although the decrease was not as great as for SI. SGLT1 mRNA expression 
was only reduced when cultured in glucose, however cells cultured in sucrose 
already had lowered expression of SGLT1. GLUT5 mRNA expression 
increased with bonolive treatment for cells cultured in sucrose. As mentioned in 
Section 5.3.2.1, there was high variation in GLUT5 mRNA expression and this 
was potentially due to sample degradation. Despite the variation, there was still 
a significant increase in GLUT5 mRNA with bonolive treatment for cells 
cultured in sucrose. For cells cultured in glucose, GLUT5 mRNA appeared to 
increase but due to the variation was not statistically significant. The reduction 
of SI mRNA is not just a total reduction of all genes; GLUT5 increased and the 
TBP housekeeping gene did not change with bonolive treatment.  
Chronic bonolive treatment reduced the amount of SI protein in the total cell 
lysate only when the level was already elevated by exposure to sucrose. The 
amount of apical surface SI decreased with bonolive only in cells cultured in 
glucose, implying a decrease in trafficking. Thus it appears that bonolive 
pleiotropic effects on protein depend on the previous sugar exposure and may 
be interplay between altered protein expression and trafficking.  A change in N-
glycosylation and Km with bonolive treatment only occurred in cells cultured in 
sucrose, however specific activity and Vmax decreased in both growth 
conditions. Specific activity was expected to decrease for cells cultured in 
sucrose due to the fact that there was less SI in the total lysate, and therefore 
less available active sites. However, specific activity also decreased for cells 
cultured in glucose, which had no significant change in the SI protein in the 
total lysate. Furthermore, cells cultured in sucrose had an increase in total 
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protein compared to those cultured in glucose, and that was not related to a 
change in activity. Therefore, it appears that the specific activity here is 
dependent on the glycosylation which can impact active site availability through 
steric hindrance and can therefore reduce or increase enzyme affinity for its 
substrate. This is supported by the fact that changes in glycosylation occurred 
alongside changes in Km. 
In the glucose grown cells, a potential decrease in trafficking was observed 
alongside an increase in N-glycosylation. Although the sucrose grown cells also 
had an increase in N-glycosylation, there was no change in trafficking in this 
case. However, cells cultured in sucrose already have altered glycosylation 
compared to cells cultured in glucose, and as discussed in chapter 4, this 
change is hypothesised to be both N and O-glycosylation. Post-translational 
modifications of SI are essential for correct folding and subsequent movement 
from ER to Golgi (Danielsen, 1992) and for trafficking to the cell surface by 
association with lipid rafts (Jacob and Naim, 2001). The glycosylation of other 
brush border proteins is related to their activity, for example the activity of 
DPP4 is related to its glycosylation state (Aertgeerts et al., 2004) and treatment 
of IEC-18 cells with L-NAME resulted in decreased N-glycosylation on SGLT-1 
corresponding to a decrease in Km (Arthur et al., 2014).  Altered glycosylation 
on SI has been reported in the diabetic Biobreed Wistar rats (Najjar et al., 
2001). Also, the impact of altered glycosylation of brush border proteins can 
extend beyond their own activity; for example N-glycans at the brush border 
can bind to pancreatic α-amylase  therefore affecting starch digestion 
(Asanuma-Date et al., 2012). The ability to detect these small changes in SI 
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protein size demonstrates a benefit of using automated capillary western 
blotting and although the size change observed is small relative to the overall 
protein size, it is large in terms of the change in glycosylation; glycosylation 
increased by 2.3 kDa which is approximately  7% increase of glycosylation.  
A limitation to the protein results is the lack of loading control in the cell surface 
fraction. Attempts were made to choose a suitable control for this purpose 
however it required many conditions; firstly, it must be greater than 100 kDa in 
size but not near SI size of 240 kDa.  It must be highly abundant because 
sucrase is abundant in the samples and requires a low protein concentration to 
fall within the quantification range without saturating the detection. It should 
also not change with the treatment and needs to be an anti-mouse secondary 
to be compatible with the sucrase isomaltase antibody. MRP2 and DPP4 were 
evaluated and found to be unsuitable due to poor abundance and an antibody 
unsuitable for the WES system. Despite having no loading control, the results 
from the analysis of SI at the cell surface had low variation as compared to the 
analysis of the total lysate and this is likely due to the purification procedure. To 
account for the lack of loading control, samples were analysed in duplicate and 
then the average of the two results was used.  
The mechanism for the chronic effect of the anti-hypoglycaemic compounds 
acarbose, the pharmacological inhibitor, and berberine, found in plants and 
used in traditional Chinese medicine, on sucrase has been investigated (Liu et 
al., 2010). Berberine was not an acute inhibitor of sucrase, however a 5-day 
chronic treatment led to a dose-dependent reduction in sucrase activity when 
tested from 10 to 50 µM. Berberine reduced SI mRNA levels whereas acarbose 
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did not. The effects were also confirmed in vivo using rats, where berberine 
attenuated the dissacharidase activity in the diabetic and normal models. 
Berberine is poorly absorbed and therefore remains at high concentrations in 
the gut. Similarly, it has been reported that oleuropein is poorly absorbed in the 
Caco-2 model (Corona et al., 2006). The reduction of sucrase activity after 
chronic treatment is therefore independent to the acute inhibitory effect, as was 
seen with green tea, and the actions appear to be exerted primarily in the gut 
lumen. The effect by berberine was linked to a protein kinase A (PKA) –
dependent pathway, therefore it was able to affect signalling pathway through 
unknown receptor at the cell surface. It is therefore possible that bonolive may 
exert effects through a similar mechanism, however further investigations into 
the pathways involved are required to elucidate by which signalling pathways 
these effects occur.  
The in vitro evidence here suggests that chronic treatment with an olive leaf 
extract can reduce sucrose hydrolysis by sucrase. Reduction of sucrase activity 
in vivo can lead to reduced glycaemic response to sucrose. In rats, digestion of 
sucrose by sucrase was rate-limiting towards the glycaemic response; in an 
oral sucrose tolerance test with a formulation containing L-arabinose, the 
incremental area under the curve for blood glucose was significantly reduced 
while no change was observed in glucose or starch tests (Preuss et al., 2007b; 
Preuss et al., 2007a). In humans, pure L-arabinose led to a delay in glucose 
absorption in response to sucrose and there were significant positive changes 
in GLP, GIP and insulin (Krog-Mikkelsen et al., 2011). Any reduction in SI 
levels would be beneficial beyond sucrose since the enzyme complex is the 
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primary source of maltase and isomaltase activity (Van Beers et al., 1995), 
therefore there could be wider impact on total starch digestion. Experiments 
here indicate that chronic olive leaf extract affects the activity of SI with several 
mechanisms at play, primarily post-translational modification. Chronic treatment 
with olive leaf extract has the potential to decrease saccharide hydrolysis 
warranting future investigation of the functional impact. Transport experiments 
in cells would be able to confirm in the chronic effects on sucrase could play a 
role in decreasing the glycaemic impact to sucrose.  
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6 Acute and chronic effects of bonolive on sucrose and 
glucose transport in Caco-2/TC7 cells 
6.1 Abstract 
The olive leaf extract bonolive was shown to be an acute inhibitor of sucrase 
and maltase (Chapter 3). Chronic treatment reduced sucrase activity and the 
amount of SI at the cell surface for cells cultured in glucose (Chapter 5). The in 
vitro methods were performed on whole cell lysate, with the exception of cell 
surface protein, which was determined from cells cultured on transwell® filters. 
The aim here was to determine if the same the acute and chronic effects of 
bonolive will occur with cells in situ on transwell® filters to give further 
information on the functional impact of reduced sucrase. Method parameters 
for a transport assay were set-up and HPAE-PAD detection was utilised to 
quantify glucose and fructose on the apical and basolateral sides. Both chronic 
and acute effects were evaluated. For acute effect, cells were cultured for 21-
days and then exposed to bonolive and sucrose during the transport incubation. 
To measure chronic effects, cells were treated with bonolive for the final 3 days 
of differentiation, bonolive was removed and transport experiments with 
sucrose or glucose were performed. The acute inhibition of sucrase by bonolive 
was greater for cells in situ than for inhibition on the whole cell lysate. Chronic 
bonolive treatment reduced glucose transport only under sodium-free 
conditions, indicating an effect on GLUT2. Chronic bonolive treatment reduced 
the hydrolysis of sucrase, as observed by less apical glucose and fructose. 
Basolateral fructose decreased, however no change in basolateral glucose 
occurred and this is hypothesised to be due to the glycolytic nature of the cells. 
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The results indicate that both chronic and acute bonolive treatments have the 
potential to reduce the glycaemic response to sucrose and warrant future 
investigations in humans.  
6.2 Introduction 
Previous studies suggest that the olive polyphenol oleuropein can influence 
glucose homeostasis. Chronic intake of an oleuropein-rich olive leaf extract 
attenuated hyperglycaemia in a rat model (Murotomi et al., 2015). In humans, a 
double-blind crossover study with 6-week consumption of an olive leaf extract  
led to a 15% improvement on insulin sensitivity, a 6% reduction in blood 
glucose and 14% reduction of insulin (de Bock et al., 2013). In Chapter 5, 
chronic treatment of Caco-2/TC7 cells with an olive leaf extract decreased the 
specific activity of sucrase in the whole cell lysate and cells cultured with 
normal growth conditions had decreased levels of SI at the cell surface. The 
olive leaf extract was also an acute sucrase and maltase inhibitor, as 
determined with an in vitro assay using Caco-2/TC7 whole cell lysates (Chapter 
3). Reduction of sucrase hydrolysis would be expected to reduce the glycaemic 
response and additional effect on glucose and fructose transport would 
strengthen the effect. This will be evaluated with transport experiments using 
Caco-2/TC7 cells in-situ in order to evaluate the functional impact of both 
chronic and acute treatments. The transport method takes into account 
hydrolysis of sucrase and subsequent transport of glucose and fructose 
products. Henceforth, the term “sucrose transport assay” will be used for the 
sake of brevity when sucrose is used as the substrate although sucrose itself is 
not transported.  
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Reduction of sucrase activity in vivo can lead to reduced glycaemic response to 
sucrose. In rats, digestion of sucrose by sucrase was rate-limiting towards the 
glycaemic response; in an oral sucrose tolerance test with a formulation 
containing L-arabinose, the incremental area under the curve for blood glucose 
was significantly reduced while no change was observed in glucose or starch 
tests (Preuss et al., 2007b; Preuss et al., 2007a). In humans, pure L-arabinose 
led to a delay in glucose absorption after sucrose intake and there were 
significant improvements in GLP, GIP and insulin (Krog-Mikkelsen et al., 2011). 
These results imply inhibition of sucrase can be rate-limiting in the glycaemic 
response and combined with effects on glucose transport, the olive leaf extract 
has the potential to yield a significant impact on glycaemic response.  
 
Figure  6-1. Sucrose is hydrolysed at the brush border of the small intestine into 
glucose (G) and fructose (F) which are subsequently transported. At the 
apical side, glucose is transported by SGLT1 and GLUT2 and fructose is 
transported by GLUT2 and GLUT5, a fructose specific transporter. GLUT2 is 
responsible for transport of both glucose and fructose at the basolateral side.  
A schematic of the transporters involved is presented in Figure  6-1. Glucose 
transport at the apical membrane primarily occurs by active transport through 
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SGLT1, which is reported to reach saturation at 30 mM glucose. SGLT1 
depends on sodium and the transport is driven by the gradient towards the 
lumen of Na+ which is maintained by the basolateral Na+K+/ATPase (Kellett et 
al., 2008). At concentrations greater than 30 mM, transport of glucose is 
reported to occur by diffusive transport by GLUT2, which is recruited and 
inserted into the apical membrane (Kellett et al., 2008). SGLT1 has a greater 
affinity (Km = 0.5 mM) (Röder et al., 2014) for glucose than GLUT2 (Km = 17 
mM) (Manolescu et al., 2007). To determine the relative contribution of each of 
the glucose transporters in the Caco-2/TC7 cell model, experiments can be 
performed in the absence of sodium in the transport buffer. This supresses 
SGLT1 activity and therefore can be used to evaluate effects on GLUT2. Apical 
transport of fructose occurs primarily through the fructose specific transporter 
GLUT5 (Km = 11-15 mM) (Douard and Ferraris, 2008) with some contribution of 
GLUT2 (Km = 66 mM) (Cura and Carruthers, 2012). Basolateral transport of 
glucose and fructose occurs through GLUT2 (Kellett et al., 2008). 
Caco-2 or Caco-2/TC7 cells have been commonly used for transport 
experiments with acute polyphenol treatment. For example, grape phenolics 
acutely inhibited both glucose and fructose transport (Moser et al., 2016),  
polyphenols from peanuts inhibited glucose transport by up to 50% (Tamura et 
al., 2015) and strawberry and apple polyphenols were able to reduce glucose 
uptake and transport (Manzano and Williamson, 2010). There are limited 
transport studies evaluating chronic effects; one study found that an 
anthocyanin-rich berry extract reduced glucose transport by GLUT2 after a 
chronic 16 hour treatment in Caco-2/TC7 cells (Alzaid et al., 2013). There have 
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been no published in vitro studies found that evaluated transport in cells after 
chronic treatments using sucrose as the substrate. One in vivo study in rats 
investigated the chronic effects of berberine on sucrase and observed a 
decrease in postprandial glucose following a sucrose load (Liu et al., 2010). 
One study evaluated the acute effects of an extract from mulberry leaves on 
sucrose and maltose hydrolysis and transport and observed mild inhibition 
(Hansawasdi and Kawabata, 2006). The glucose oxidase assay was used to 
quantify glucose, however, as discussed in Chapter 3, polyphenols can 
interfere with the detection method. Other transport methods often utilise 
radiolabelled substrates and scintillation counting to quantify the counts present 
on the apical and basolateral sides after transport. The disadvantage is that 
only the total radioactivity counts are presented and the individual sugars 
present cannot be distinguished. Here, the HPAE-PAD system (Section 2.4.3) 
is used to quantify sugars present in the apical and basolateral transport 
solutions. This is particularly important for investigating sucrose transport so 
that both glucose and fructose could be detected. With the ability to detect 
individual sugars, the contribution of hydrolysis or transport mechanisms is 
investigated. 
6.3 Method set-up for sucrose hydrolysis and glucose transport  
 Background  6.3.1
The method for transport studies in Caco-2 cells has been well established in 
this laboratory (Aydin, 2015). However, sucrose transport assay had not been 
performed in Caco-2/TC7 cell model or with HPAE-PAD detection so the aim 
here was to set up the method parameters.  For chronic experiments, briefly, 
154 
 
 
 
cells were seeded on transwell® filters and treated with bonolive for the final 3 
days of differentiation. The cells were washed to remove polyphenols and 
medium, pre-incubated in transport buffer and TEER values measured to 
ensure monolayer integrity. The transport solution with sucrose was added to 
the apical side, incubated for the specified time and apical and basolateral 
solutions were removed and glucose and fructose were quantified by HPAE-
PAD (Figure  6-2). The acute experiments were performed as described but 
without the chronic treatment and bonolive was added with sucrose during the 
transport incubation.  
 
Figure  6-2. Method flow chart for sugar transport in Caco2/TC7 cells. 
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 Materials and equipment 6.3.2
Calcium chloride, glucose, HEPES buffer, sodium bicarbonate solution, sodium 
chloride and sucrose were from Sigma Aldrich, Dorset, UK. Sterile 0.2 µm 
filters were from Whatman, Maidstone, UK. All cell culture materials are listed 
in Section 2.1. HPAE-PAD materials and equipment are listed in Section 2.4.3. 
 Cell culture and treatments 6.3.3
Caco-2/TC7 cells from passages 31 to 40 were seeded on 12-well transwell® 
plates according to section Section 2.1.3. Chronic treatments were performed 
according to Section 2.1.4. 
 Preparation of reagents  6.3.4
The transport buffer contained 20 mM HEPES buffer, 5.4 mM potassium 
chloride, 137 mM sodium chloride, 2.4 mM calcium chloride and 26.8 mM 
sodium bicarbonate. The pH was adjusted to 7.4 and then the solution was 
sterile filtered. Sodium-free transport buffer was prepared similarly but without 
sodium chloride and sodium bicarbonate, and with potassium chloride 
increased to 142 mM. Glucose and sucrose solutions were prepared at 50 mM 
in transport buffer and then diluted to the working concentration as reported for 
each experiment, referred to as transport solution. For acute experiments, 
bonolive was weighed and dissolved into transport solution containing sucrose 
at the specified concentrations.  
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 Procedure 6.3.5
Cells were washed three times with warmed transport buffer (37°) and pre-
incubated in transport buffer at 37°C with 10% CO2 for 30 min. The trans-
epithelial electric resistance (TEER) was measured using Millipore Millicell® 
Voltohmmeter three times per well, with TEER values greater than 200 Ω 
deemed acceptable monolayer formation for Caco-2/TC7 cells grown on 12-
well transwell®. For transport incubation, 1 mL of transport buffer was added to 
the basolateral side and 0.5 mL of transport solution containing glucose or 
sucrose was added to the apical side. Samples were incubated for the 
specified time in the incubator at 37°C with 10% CO2. Following incubation, the 
apical and basolateral solutions were transferred to micro-centrifuge tubes and 
stored at -80°C until further analysis. 
 Transport sample analysis by HPAE-PAD 6.3.6
Samples were analysed by HPAE-PAD according to the method in Section 
2.4.3. Samples were diluted to fall within the calibration range and the final 
sample vial contained up to 20% transport buffer, representing a 5-fold sample 
dilution. A matrix matched blank and 5 µM standard were prepared in 20% 
transport buffer to compare with standards in water. There were no interfering 
peaks observed in the blank and the peak areas for glucose, fructose and 
sucrose were within 2% of the standard in water. Therefore, transport buffer in 
the samples does not impact the quantitation of glucose, sucrose or fructose so 
standard curves were prepared in water.  
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6.3.6.1 Interference from bonolive on HPAE-PAD 
The samples from the acute experiments contain bonolive and were diluted 5-
fold for analysis, and therefore the final samples contained bonolive at 20% of 
the specified testing concentration. A matrix-matched blank and 5 µM standard 
were prepared to evaluate potential interference from bonolive (Figure  6-3). 
There are interfering peaks present in the bonolive blank (Figure  6-3B) so to 
correct for the interference, standard curves were prepared with the same 
amount of bonolive present as the samples. Standards were prepared at 0, 1, 
2.5, 5 and 10 µM with 20% of either 0.5 mg/mL bonolive, 1.5 mg/mL bonolive 
or 3.0 mg/mL bonolive.  Representative calibration curves for glucose and 
fructose with bonolive are shown in Figure  6-4. These standard curves were 
used to quantify glucose and fructose in samples from acute experiments. 
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Figure  6-3. Representative chromatograms from HPAE-PAD analysis of 
glucose (G), fructose (F) and sucrose (S) for the evaluation of matrix effects. 
Water blank (A), blank containing 20% 1.5 mg/mL bonolive (B), 5 µM 
standards in water (C) and 5 µM standards containing 20% 1.5 mg/mL 
bonolive (D).  
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Figure  6-4. Glucose (A) and Fructose (B) standard curves prepared in 20% 
bonolive at 0.5 mg/mL, 1.5 mg/mL or 3 mg/mL. 
 
 Set-up of sucrose hydrolysis and transport 6.3.7
6.3.7.1 Time-course 
Different transport incubation times (30, 60 and 90 min) were evaluated with 5 
mM sucrose as the substrate to select an incubation time for subsequent 
experiments. High biological variation was observed between the three 
experiments (Table 6-1).  
Table  6-1.  Comparison between apical glucose and apical fructose after 60 
min incubation with 5 mM sucrose. Three independent experiments were 
performed on subsequent passages of Caco-2/TC7 cells and results are 
presented as mean ± SD. 
Experiment 
(n) 
Apical Glucose 
(µM) 
Apical Fructose 
(µM) 
% Difference 
1 16.9 ± 1.50 28.4 ± 1.77 50.8% 
2 71.8 ± 4.81 84.6 ± 6.66 16.4% 
3 99.9 ± 15.8 123 ± 20.1 20.5% 
  Mean 29.2% 
  %CV 64.3% 
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Different absolute amount of apical fructose and apical glucose were measured 
in the 3 independent experiments (Table 6-1) and the percentage difference 
between apical glucose and apical glucose also varied (%CV = 64.3%). This 
difference highlights the high biological variation, possibly from the long time in 
culture. Each experiment was done with independent reagents and transport 
solutions which could also contribute. Despite this, the same pattern was 
observed where there is more apical fructose than apical glucose. Hydrolysis of 
sucrose should lead to equivalent amounts of glucose and fructose, so this 
pattern suggests that glucose is transported at a faster rate than fructose.  
Due to the detected biological variation between the three experiments, data 
were normalised by experiment to the 60 min time-point so that changes 
relative to the 60 min time-point could be evaluated. The normalised data from 
three experiments were combined and are presented in Figure 6-5. Statistical 
significance between time-points was determined for each of apical glucose, 
basolateral glucose, apical fructose and basolateral fructose using ANOVA 
followed by the Tukey post-hoc test.  
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Figure  6-5. Evaluation of transport time for sucrose transport experiments. 
Transport experiments were performed with 5 mM sucrose with 30, 60 or 90 
min incubation and the glucose and fructose at the apical and basolateral 
sides were quantified by HPAE-PAD. The sugar concentrations in µM were 
normalised for each experiment to the mean of the 60 min time-point and 
presented as mean ± SEM (n/N=3/18). *** p<0.001, ** p<0.01, * p<0.05, nd= 
not detected. 
 
Both apical glucose and fructose levels increased between all transport times 
(Figure  6-5). For basolateral glucose, there was no change from 30 to 60 min 
(p=0.5) and a significant increase between 60 to 90 min (p=0.004).  Basolateral 
fructose was not detected at 30 min and there was a slight decrease between 
60 and 90 min (p=0.04). This suggests that the transport of fructose to the 
basolateral side is saturated or has reached equilibrium.  For further tests, 60 
min was chosen as the transport time. 
The concentration of sucrose on the apical side was only quantified for the first 
experiment and results are not presented. The sample required a second 
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dilution to quantify sucrose because the concentration of 5 mM required a 100-
fold dilution to fall within the calibration range, which doubled the analysis time.  
6.3.7.2 Effect of different sucrose substrate concentration 
Different substrate concentrations were evaluated using 60 min incubation. 
Apical glucose, basolateral glucose and apical fructose all increased in 
response to increased sucrose (Figure  6-6). When plotted against substrate 
concentration, the amount of apical glucose and fructose produced was not 
linear at 25 mM. This implies that sucrase could be saturated when using 25 
mM as the substrate concentration. Basolateral fructose was below the 
detection limit using 1 or 5 mM sucrose, and was 3.9 µM with 25 mM sucrose. 
During the time course experiments, basolateral fructose was detected at an 
average of 6.7 ± 1.7 µM at 60 min, however here was not detected. This further 
highlights the biological variation that occurs with different passages of cells. 
Basolateral glucose did not increase in response to increased apical glucose; 
the transport of glucose could be rate-limiting at either the apical or basolateral 
side.  Furthermore, the difference observed could be due to metabolism within 
the cell because cultured cells tend to be more glycolytic; Caco-2/TC7 cells 
require 25 mM glucose in the culture medium for normal growth. Apical glucose 
and fructose values were significantly different with 1 mM sucrose (p<0.001) 
but not with 5 mM or 25 mM sucrose (p=0.08 and 0.9, respectively) (Figure 6-6). 
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Figure  6-6. Sucrose transport with 1, 5 or 25 mM sucrose and 60 min 
incubation. Apical glucose, basolateral glucose and apical fructose were 
quantified by HPAE-PAD and the concentrations are reported as mean ± 
SEM (n/N=3/18). *** p>0.001. 
 
 Method summary  6.3.8
The final transport incubation times and substrate concentrations that were 
used for subsequent experiments are summarised in Table  6-2. Both chronic 
and acute effects of bonolive were evaluated with sucrose as the substrate. 
The acute effect of bonolive on glucose transport has already been evaluated 
in this laboratory (Kerimi, 2017), therefore only the chronic effects are 
determined here. The optimal substrate concentration and incubation time for 
glucose transport were previously determined in this laboratory and are used 
as standard lab protocols (Aydin, 2015). 
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Table  6-2. Transport Method Details 
Substrate Treatment Substrate 
Concentration 
(mM) 
Incubation Time 
(min) 
Glucose Chronic 1 25 
Sucrose Acute 1, 5 and 25 60 
Sucrose Chronic 5 60 
 
6.4 Results 
 Glucose transport  6.4.1
6.4.1.1 Chronic bonolive: regular and sodium-free conditions 
The effect of chronic bonolive treatment (3 days, 1.5 mg/mL) on glucose 
transport was determined under regular transport conditions using 1 mM 
glucose and 25 min incubation. The results from each of 3 independent 
experiments (n/N=3/18) are presented in Figure 6-7 A&B. Statistical 
significance was determined with Student’s t-test. No significant change in 
either apical or basolateral glucose was observed. One experiment was done 
at higher glucose concentration of 5 mM (n/N=1/6) and again no change was 
observed (data not shown). 
The glucose transport experiments were repeated under sodium-free 
conditions to suppress participation of SGLT-1 which requires a Na+ gradient 
for its function. The results from each of 3 independent experiments (n/N=3/18) 
are presented in Figure 6-7 C&D. Under these conditions, GLUT2 is expected 
to be the dominant transporter. Bonolive inhibited glucose transport under 
sodium-free conditions with a 4.5% increase in glucose on the apical side 
(p<0.05) and a 24% reduction in glucose on the basolateral side (p<0.01). 
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Figure  6-7. Glucose transport in regular (A&B) and sodium-free (C&D) 
conditions after chronic bonolive treatment. Caco-2/TC7 cells were cultured 
for 3 weeks and treated with bonolive for the final three days of 
differentiation. Transport experiments were done with 1 mM glucose for 25 
min and the apical and basolateral glucose concentrations were determined 
by HPAE-PAD. Normalised results are presented as mean ± SEM, 
n/N=3/18, * p<0.05, ** p<0.01 
 
6.4.1.2 Contribution of SGLT1 and GLUT2 
The contribution to glucose transport by SGLT1 and GLUT2 was determined by 
comparing the percentage of glucose transported under regular and sodium-
free conditions (n/N=1/6). Under regular conditions, 4.8 ± 2.3% of the total 
glucose added reached the basolateral side whereas for sodium-free conditions, 
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significantly less glucose (2.6 ± 0.4%, p=0.04) was transported. Therefore, 54% 
of total glucose transport was attributed to SGLT1. 
 Sucrose hydrolysis and transport 6.4.2
6.4.2.1 Chronic bonolive treatment 
The effect of chronic bonolive treatment (3 days, 1. 5 mg/mL) on sucrose 
hydrolysis and transport was evaluated at 60 min using 5 mM sucrose. During 
the transport experiment, no bonolive would be present as it has been washed 
off the cells, and therefore any effects observed are due to changes from the 
chronic treatment.  The results from three independent experiments (n/N= 3/18). 
are presented in Figure 6-8. On the apical side, bonolive treatment resulted in a 
38% decrease in glucose (p<0.001) and a 21% decrease in fructose (p<0.001) 
(Figure  6-8). No change in basolateral glucose was observed, however the 
basolateral side is also impacted by cellular metabolism; as glucose passes to 
the basolateral side some is used by the cell. Since basolateral fructose levels 
are near the detection limit, basolateral fructose was only detected in the third 
experiment (n/N=1/6) reflecting some biological variation.  
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Figure  6-8. The effect of chronic bonolive treatment on sucrose hydrolysis and 
transport. Caco-2/TC7 cells were cultured for 21 days and treated with 1.5 
mg/mL for the final 3 days of differentiation.  Transport experiment was 
performed with 5 mM sucrose and 60 min incubation. Glucose and fructose 
from the apical and basolateral sides were quantitated by HPAE-PAD. 
Results are presented as mean ± SEM with n/N = 3/18 for all except for 
basolateral fructose where n/N= 1/6, presented as mean ± SD. *** p<0.001, 
** p<0.01. 
 
6.4.2.2 Effect of chronic forskolin treatment   
Forskolin was used as a positive control because chronic treatment with 
forskolin leads to reduced sucrase mRNA, biosynthesis and activity (Rousset et 
al., 1989).  The biosynthesis of SI, determined with pulse-chase experiments, 
was only 15% of the control for a treatment of 25 µM forskolin for 48 hours in 
Caco-2 cells at day 14. The decrease in biosynthesis corresponded to 
decreases in activity and mRNA levels and it has been reported that the 
forskolin leads to reversible decreased transcription of mRNA (Chantret et al., 
1993). Here, the cells were treated with forskolin for the final 3-days of 
differentiation to be consistent with the treatments with bonolive. Under these 
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conditions, less hydrolysis of sucrose occurred as seen by the 17.8% (p=0.05) 
and 10.1% (p=0.04) reduction in apical glucose and fructose, respectively 
(Figure  6-9). There was no change in basolateral glucose and basolateral 
fructose was below the detection limit. The reduction by this positive control 
was not as great as observed in the literature, however a lower concentration 
was used and the treatment began at day 18 rather than day 14, during which 
time the mRNA levels for SI are still increasing.  
 
Figure  6-9. The chronic effects of forskolin on sucrose hydrolysis and transport. 
Caco-2 cells were treated with 10 µM forskolin for the final 3 days of 
differentiation. Transport experiment was performed with 5 mM sucrose and 
60 min incubation. Glucose and fructose from the apical side and glucose 
from the basolateral sides were quantified by HPAE-PAD. Results are 
presented as mean ± SD. * p<0.05, ns = not significant, n/N=1/6.  
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6.4.2.3 Acute bonolive treatment  
The acute effect of bonolive on sucrose hydrolysis and subsequent glucose 
and fructose transport was determined by including 0.5, 1.5 and 3.0 mg/mL 
bonolive in the transport solution with 5 mM sucrose with 60 min incubation. A 
reduction in apical glucose, apical fructose and basolateral glucose occurred as 
the concentration of bonolive increased (Figure 6-10). The results are 
presented as a percent reduction from the control samples which had no 
bonolive treatment. Statistical significance was determined by ANOVA followed 
by Tukey’s post-hoc test. No basolateral fructose was detected in the control or 
treated samples.  
Bonolive at 0.5 mg/mL decreased apical glucose to 52.9% of the control 
(p<0.001) and further decreased to 23.9% of the control at 1.5 mg/mL 
(p<0.001). There was no change in apical glucose between 1.5 and 3 mg/mL 
(p=0.5). There was no change in apical fructose with 0.5 mg/mL bonolive but it 
decreased to 54.8% and 30.7% of the control with 1.5 mg/mL and 3.0 mg/mL 
bonolive, respectively  (p<0.001). Basolateral glucose decreased to 34.7% of 
the control with 0.5 mg/mL (p<0.001) and 9.9% of the control with 1.5 mg/mL 
(p=0.03) and no further decrease was observed at 3 mg/mL bonolive 
(Figure  6-10). 
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Figure  6-10. Acute effects of bonolive on sucrose hydrolysis and subsequent 
glucose and fructose transport with 60 min incubation. The 5 mM sucrose 
transport solution contained bonolive at 0.5, 1.5 or 3.0 mg/mL. Results for 
apical glucose and fructose and basolateral glucose are presented as a 
percentage of the apical glucose control, mean ± SEM. Significance 
between time-points was determined by ANOVA followed by Tukey’s post 
hoc test. *** p<0.001, * p<0.05, n/N=3/18. 
  
171 
 
 
 
Glucose transport and sucrose hydrolysis were determined for each bonolive 
concentration using following equations: 
% Glucose Transport =100 x (µM Basolateral Glucose)/ (µM Apical 
Glucose + µM Basolateral Glucose) 
% Sucrose Hydrolysis = 100 x (µM Apical Glucose + µM Basolateral 
Glucose)/ (µM Sucrose Substrate at time zero) 
% Sucrase Inhibition = 100- (µM Total Glucose/µM Total Glucose in 
Control)*100 
% Glucose Transport Inhibition = 100- (µM Basolateral Glucose/µM 
Basolateral Glucose in Control) x 100 
These calculations make the assumption that the results of glucose and 
fructose are independent of each other and that the cell metabolism is not 
affected by the treatment. The results are presented in Table 6-4. The IC50 for 
sucrase was approximately 0.5 mg/mL and 87.9% inhibition was achieved at 
the highest concentration. Slightly stronger inhibition was observed for glucose 
transport, with IC50 below 0.5 mg/mL. Up to 94% inhibition of glucose transport 
occurred with 3 mg/mL bonolive.  
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Table  6-3. Acute effects of bonolive on sucrose hydrolysis and subsequent 
glucose and fructose transport. Bonolive from 0.5 to 3.0 mg/mL was present in 
the transport solution with 5 mM sucrose and incubated for 60 min. Results 
from apical glucose and fructose and basolateral glucose are presented as 
mean ± SD. 
 
Bonolive 
Concentration 
(mg/mL) 
0 (Control) 0.5 1.5 3.0 
Percent of 
Glucose 
Transported 
29.8 ± 4.3 21.7 ± 3.4 14.9 ± 2.3 12.1 ± 2.4 
Percent of 
Sucrose 
Hydrolysed 
0.2 ± 0.005 0.1 ± 0.003 0.05 ± 0.001 0.03 ± 0.002 
Percent 
Inhibition of 
Sucrase 
NA 52.5 ± 4.1 80.3 ± 3.8 87.9 ± 3.9 
Percent 
Inhibition of 
Glucose 
Transport 
NA 65.3 ± 3.7 90.1 ± 3.2 94.1 ± 3.1 
 
 Effect of bonolive on TEER values 6.4.3
The TEER values were determined for each experiment and an increase of 
42.7 ± 2.7% occurred in wells with chronic bonolive treatment (3 days at 1.5 
mg/mL) compared to the control (Figure  6-11). 
 
 
Figure  6-11. Trans-epithelial electrical resistance (TEER) from Caco-2/TC7 
cells treated chronically with bonolive for the final 72 h of differentiation. 
Results are presented as mean ± SEM, n/N = 11/66, *** p<0.001. 
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6.5 Discussion  
The transport methodology that is traditionally used involves the use of a 14C 
radiolabelled substrate followed by liquid scintillation counting of the apical and 
basolateral sides. If sucrose were used as the substrate, both the glucose and 
fructose products are radiolabelled and therefore the counts observed in the 
final samples cannot distinguish between glucose and fructose. Here, HPAE-
PAD quantification of carbohydrates was used to improve the method so that 
more detailed information regarding specific changes in glucose and fructose 
was obtained. For acute transport experiments, it was essential to consider the 
interference from bonolive on the quantification. Bonolive was found to interfere 
with the quantification of carbohydrates and therefore appropriate standard 
curves containing bonolive were prepared to correct for this. Overall, the use of 
HPAE-PAD as an alternative to the previously used radiochemistry method 
improved the analysis time and cost. It also provided more information which 
allowed better interpretation of the results as compared to traditional methods. 
Oleuropein has been reported to acutely inhibit α-glucosidase enzymes such 
as sucrase (Hadrich et al., 2014) and in Chapter 3, the oleuropein-rich bonolive 
was observed to inhibit human sucrase and maltase in the assay using a Caco-
2/TC7 cell-free extract. Evidence from human studies suggest that oleuropein 
may inhibit glucose transport (de Bock et al., 2013) and this was confirmed in 
our lab where bonolive acutely inhibited glucose transport in Caco-2/TC7 cells 
in a concentration dependent manner. Using 5 mM glucose and a 25 min 
incubation time, 44% inhibition of glucose transport occurred with 1 mg/mL of 
bonolive under regular transport conditions (Kerimi, 2017). Here, the acute 
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effects of bonolive were evaluated using intact cells where both hydrolysis and 
product transport are involved.  
In experiments with acute bonolive treatment where sucrose was the substrate, 
the reduction in basolateral glucose compared to the untreated cells was 
greater than  the reduction in apical glucose. This is because the basolateral 
glucose includes the combined effects of the inhibition of sucrose hydrolysis 
and inhibition of glucose transport. As already mentioned, previous 
experiments demonstrated that bonolive can acutely inhibit glucose transport 
and sucrose hydrolysis, so the in situ experiments here were successful in 
reflecting the combined effect. If there was no effect on glucose transport, the 
ratio between the apical and basolateral sides would be expected to have 
remained constant. The fact that the ratio of apical to basolateral glucose 
increased supports the hypothesis that both sucrase hydrolysis and glucose 
transport were inhibited. In Chapter 3, there was 34.4% sucrase inhibition with 
1.5 mg/mL bonolive using the cell-free assay developed. The inhibition of 
sucrase was stronger here using intact cells (87.9%, Section 6.2.4.3).  
The effect of chronic 3-day treatment with 1.5 mg/mL bonolive was evaluated to 
further extend the results from Chapter 5 to cells in situ. Glucose transport was 
not affected in regular transport conditions confirming that the decrease in 
apical glucose observed with sucrose as the substrate was due to lower 
hydrolysis of sucrose and not because of altered transport. On the other hand, 
the fact that there was more apical fructose than glucose suggests a small 
inhibition on fructose transport. The chronic treatment did lead to a decrease in 
GLUT5 mRNA (Chapter 5). Chronic bonolive treatment only led to a change in 
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glucose transport under sodium free conditions, in which SGLT1 is not active 
(Kellett et al., 2008), therefore the treatment predominantly affects GLUT2 and 
not SGLT1. Under regular conditions, 54% of transport was attributed to 
SGLT1, in agreement with the literature (Kellett et al., 2008). SGLT1 and 
GLUT2 gene expression were reduced with bonolive treatment, with GLUT2 to 
a greater extent (Chapter 5). Based on the gene expression data, bonolive 
treatment would be expected to reduce glucose transport by both GLUT2 and 
SGLT1, however it is possible that for SGLT1, the effects observed for the 
mRNA were not translated on the protein level. A similar phenomenon was 
observed in a study by Alzaid et. al;  glucose transport inhibition was only 
observed in sodium-free conditions for a 16 h treatment with anthocyanin-rich 
berry extract on Caco-2/TC7 cells. GLUT2 and SGLT1 mRNA levels were both 
significantly decreased but only GLUT2 protein level was decreased (Alzaid et 
al., 2013). When considering the impact that these results could have in vivo, 
the effect on GLUT2 observed here under sodium-free conditions is important 
because at high glucose concentrations, GLUT2 is the main glucose 
transporter (Kellett et al., 2008).  Chronic bonolive treatment reduced sucrase 
hydrolysis, supported by results in Chapter 5 where less surface protein, 
decreased specific activity and mRNA occurred.  
The trans-epithelial resistance increased with chronic bonolive treatment. This 
could be similar to previously reported effect of quercetin increasing the trans-
epithelial resistance which was correlated to an increase in claudin-4, a tight 
junction protein (Amasheh et al., 2008). Tight junction proteins link cells 
together and help dictate paracellular permeability, and is not expected to 
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impact transport of sugars which occurs through the cells. However, one of the 
major roles of the small intestine is to provide a protective barrier against 
harmful substances. Inflammation can lead to dysregulation of tight junction 
proteins in patients with ulcerative colitis (Schmitz et al., 1999).  There is 
clinical interest in improving tight junction permeability since a “leaky gut” 
occurs  in cases of inflammatory bowel diseases such as Chrohn’s and celiac 
disease (Hollander, 1999). 
There are some limitations to the transport experiment methodology. Firstly, the 
amount of fructose on the basolateral side was not detected in the experiments 
so the effect of fructose transport can only be speculated by the amount on the 
apical side. The amount of sucrose that is hydrolysed in the 60 minute time 
point was low so longer times could be evaluated to try and increase the 
concentration of basolateral fructose. Since the experiments involve the effect 
of hydrolysis and transport, the interpretation of the results is challenging but 
the independent results from glucose transport and sucrose hydrolysis support 
the observed results.   Finally, the calculations for the acute effects of bonolive 
made the assumption is made that the cellular metabolism and glucose and 
fructose is not affected. In order to verify this, cell metabolism studies could be 
performed with bonolive treatment.  
In summary, the transport model used here in Caco-2/TC7 cells was able to 
detect changes in sucrose hydrolysis by sucrase for both acute and chronic 
bonolive treatments. Chronic treatment inhibited glucose transport via GLUT2, 
however this effect was masked by SGLT1 transport under normal conditions, 
when sucrose was used as a substrate. Chronic treatment with olive leaf 
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extract has the potential to decrease disaccharide hydrolysis and transport 
warranting future investigation in humans for glycaemic control after sugar 
consumption for the reduction of type 2 diabetes risk.   
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7 Summary, discussion and future prospective 
7.1 Summary of results 
 Acute inhibition assay 7.1.1
One strategy for reducing postprandial glycaemia is though inhibition of starch 
and sugar digesting enzymes. Type 2 diabetes treatment with the drug 
acarbose is based on this approach (Breuer, 2003). Due to side effects of 
pharmacological treatments, natural compounds such as polyphenols are often 
screened as potential inhibitors of α-glucosidases (Hanhineva et al., 2010). 
Most inhibition assays use a readily available rat intestinal powder preparation 
as a source of α-glucosidase enzymes and it was hypothesised that human or 
rat enzyme sources might yield different inhibition results due to their different 
genetic sequence. An assay using human Caco-2/TC7 cells was optimised in 
Chapter 3 and used to compare the inhibition by selected polyphenols and 
acarbose towards sucrase and maltase with results from an assay using the rat 
enzyme source. Caco-2/TC7 cells have high levels of SI and the sequence was 
confirmed for the first time to be identical to human SI in Chapter 4, making this 
a suitable source of enzyme. 
Using this in vitro assay, inhibitors were more effective towards human 
compared to rat sucrase. Therefore, it is possible that in vivo studies the effect 
in humans could be greater than that observed in rat studies. The opposite 
situation occurred for maltase where inhibitors were stronger towards the rat 
enzyme source. This is important because the rat intestinal preparation is 
commonly used as the enzyme source and then the in vivo effect is determined 
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in rats. If the study is then progressed into human interventions, a lack of effect 
could occur.  The enzyme assay based on the rat enzyme is useful for 
comparing the strength between different inhibitors, for example in the design 
of pharmacological treatments. Since the rat enzyme source is readily 
available, it could be used for screening purposes however the strength of 
inhibition observed would not be the same as towards a human enzyme 
source. If screening is performed using an assay with rat enzyme, the inhibitors 
evaluated will also inhibit the human enzyme but the enzyme assay with the 
human enzyme source should be used to quantify and confirm the result. The 
evidence here highlights the importance of confirming enzyme inhibition with 
the more physiologically relevant human source.  
Experiments in Chapter 3 also demonstrated that inconsistent results can be 
obtained if the amount of enzyme and assay conditions are not optimised. 
Further, results were presented that demonstrate the importance of considering 
interference by the inhibitors on the detection methods. Taken together, this 
information established an improved method for inhibition of α-glucosidases. 
Previously published literature results should be critically considered for these 
factors. In the literature there was limited strong evidence that polyphenols can 
specifically inhibit sucrase. Here, inhibition was observed with EGCG, green 
tea, an olive-leaf extract and quercetin and the inhibition values obtained would 
be achievable in the gut lumen. For example, one 200 mL portion of green tea 
extract prepared as a drink would contain approximately 5 mg/mL of green tea 
polyphenols. The IC50 value obtained for sucrase inhibition was 1 mg/mL, a 
concentration required in the gut lumen. Taking into account an approximate 3-
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fold dilution due to intestinal dilution (Williamson, 2013), a 200 mL cup of green 
tea would lead to a concentration in the gut lumen which could inhibit sucrase 
by at least 50%.  
Other studies have demonstrated that acute sucrase inhibition observed in vitro 
does lead to an effect in vivo, so this is a suitable strategy (Krog-Mikkelsen et 
al., 2011). Interestingly, a synergistic effect with acarbose has also been 
described for several polyphenols and polyphenol-rich extracts. For example, 
using an in vitro inhibition assay, an anthocyanin-rich blackcurrant and 
chlorogenic acid-rich rowanberry extracts were able to recover the inhibition 
that was lost when the acarbose dose was lowered (Boath et al., 2012). The 
anthocyanin cyanidin-3-rutinoside has also been reported to work 
synergistically towards α-glucosidase inhibition (Adisakwattana et al., 2011). 
Polyphenols that are identified as strong α-glucosidase inhibitors could 
potentially be used as a replacement for or in conjunction with pharmaceutical 
drugs for maintaining glycaemic control. 
 Effect of sucrose on sucrase in Caco-2 model 7.1.2
Some reports in the literature suggest that sucrase expression is modulated by 
its substrate sucrose. As discussed in Chapter 1, many of these reports 
compare the expression of SI to a starved state. There is no evidence 
comparing the effect of glucose exposure with sucrose exposure. This is of 
interest due to the fact that sucrose is the most commonly consumed sugar in 
the UK (SACN, 2015). The effect of sucrose on sucrase was evaluated 
because it is the sole enzyme capable of its hydrolysis. Since SI has sucrase 
and maltase activities, a decrease in sucrase activity would have beneficial 
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effects on both starch and sugar hydrolysis and could affect the postprandial 
glycaemic response. The results from Chapter 4 indicated that chronic sucrose 
exposure in the Caco-2/TC7 cell model did not lead to a change in SI mRNA 
expression, surface protein or specific activity. There was a slight decrease in 
the affinity for sucrose and it is hypothesised that this is due to the change in N- 
and O-glycosylation. A limitation to this work is that regulation in cell culture 
models can be different than what occurs in vivo (Ferraris, 2001). The small 
intestine has enteroendocrine cells in addition to enterocytes and these have 
been suggested to be involved in sugar sensing in the gut (Le Gall et al., 2007; 
Miguel-Aliaga, 2012). The regulation of brush border enzymes and transporters 
in vivo most likely involves coordinated action of the different cell types 
therefore the regulation of SI in vivo could be different to what was observed in 
the cell model here. However, the use of this model was able to identify the fact 
that sugar exposure can affect glycosylation. Future work to identify the effect 
of sucrose, glucose and fructose on the steps of glycosylation would be of 
interest. As an aside, it would also be interesting to evaluate the effects from 
synthetic sweeteners since they are commonly used by the food industry as a 
"healthier" sugar replacement however limited work has been done to evaluate 
any chronic effects from long-term consumption. Overall, the evaluation of 
sucrose exposure as a nutritional sugar stress indicated that sucrose can affect 
the post-translational modification of the enzyme. Glycosylation plays a role in 
protein localisation, activity and degradation so therefore there several 
widespread implications. These results add to the body of evidence that cells 
can respond to sugars.  
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 Acute and chronic effects of bonolive 7.1.3
There are many reports that investigate the acute inhibition of a range of 
polyphenols towards α-glucosidase enzymes, with the aim of reducing sugar 
and starch digestion for the attenuation of the postprandial glycaemic response. 
Up to 5 mg of polyphenols are consumer per day (Scalbert and Williamson, 
2000) so any beneficial effects from long-term exposure are of interest. An 
olive-leaf extract was used here as the model compound due to the fact that 
olive polyphenols have been reported to aid in glucose homeostasis (de Bock 
et al., 2013) and bonolive was found to be an acute sucrase and maltase 
inhibitor (Chapter 3). In the Caco-2/TC7 cell model, a chronic 3-day treatment 
with 1.5 mg/mL of bonolive led to a reduction in sucrase activity. The activity, 
mRNA, total SI protein, enzyme kinetics were first evaluated in whole cell 
lysates (Chapter 5) and then further investigated in more physiological state in 
situ with transport studies, where a greater effect occurred. In transport studies, 
both chronic and acute treatments with bonolive reduced the hydrolysis of 
sucrose by sucrase. The chronic bonolive treatment also reduced glucose 
transport by GLUT2 when SGLT1 was supressed. The determination of 
glucose on the basolateral side depends on intra-cellular metabolism and efflux 
from the cell and the model assumes that these are not affected. Cells in 
culture are more glycolytic and utilise majority of the glucose they take up so it 
is possible that effects at the basolateral side cannot be detected. 
Nevertheless, changes were observed on the apical side that suggest sucrase 
hydrolysis was reduced after chronic treatment. 
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Reduction of sucrase activity in vivo can lead to reduced glycaemic response to 
sucrose. In rats, digestion of sucrose by sucrase was rate-limiting towards the 
glycaemic response; in an oral sucrose tolerance test with a formulation 
containing L-arabinose, the incremental area under the curve for blood glucose 
was significantly reduced while no change was observed in glucose or starch 
tests (Preuss et al., 2007b; Preuss et al., 2007a). In humans, pure L-arabinose 
led to a delay in glucose absorption in response to sucrose and there were 
significant positive changes in GLP, GIP and insulin (Krog-Mikkelsen et al., 
2011). These results suggest that sucrase can be rate-limiting in the uptake of 
sugars in vivo. In contrast, an isotopic tracer study in humans demonstrated 
that the uptake rate of glucose after consumption of either sucrose or a mixture 
of glucose and fructose was the same, for which it was suggested that sucrose 
digestion is rapid and not rate-limiting in vivo (Sun and Empie, 2012). However, 
the fact that the same glucose uptake rate was observed does not provide 
alone enough evidence to claim which steps are limiting. Any reduction in SI 
levels would be beneficial beyond sucrose since the enzyme complex is the 
primary source of maltase and isomaltase activity (Van Beers et al., 1995), 
therefore there could be wider impact on total starch digestion. Reduction in the 
level of SI at the brush border of the small intestine would be of particular 
importance to diabetic patients who have elevated levels (Dyer et al., 2002). 
These findings enhance the understanding of chronic effects by which 
polyphenols can lead to health benefits. The results are the first to identify 
chronic changes in SI with chronic treatment with an olive leaf extract.  
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7.2 Future prospective 
 Human intervention study 7.2.1
One of the main questions raised from these results is whether the effects 
observed using the in vitro cell model would also occur in vivo. Intra- and inter- 
individual variation of the expression of transporters and SI in vivo makes 
comparison to the cell model challenging (Zeevi et al., 2015). Furthermore, 
level of glucose transporters in vivo is not constant due to the proposed 
recruitment of GLUT2 to the apical cell surface at high glucose concentrations 
(Kellett et al., 2008). In the transport studies in Chapter 6, there was no change 
detected on the basolateral side, which is representing the blood glucose 
response. This was one main limitation and is in part due to the fact that the 
cultured cells are highly glycolytic and most of the glucose taken up in the cell 
would have been metabolised and used within the cell. The next logical step to 
test the hypothesis that bonolive is able to reduce sucrase activity and 
therefore influence the glycaemic response to sucrose is to evaluate using 
human intervention trials.  
Human studies to evaluate the acute effects of bonolive have already been 
undertaken in the Williamson laboratory. In the first study, after an overnight 
fast, participants consumed 100 g of white bread with or without 125 mg of 
bonolive and on the second visit, the opposite treatment (cross-over design). 
Blood glucose was measured up to 3 hours and there was no change between 
the bonolive and placebo (Li, 2016). The use of white bread involves the effect 
on starch digestion and glucose transport. The second study was performed in 
the same manner but with 25 g of sucrose instead of white bread and a dose of 
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290 mg bonolive. In this case, there was statistically significant reduction in 
blood glucose response (13%) (Shelley, 2017). The differences between these 
two studies highlight the fact that sucrase inhibition combined with inhibition of 
glucose transport is a good strategy to reduce the postprandial glycaemic 
response; bonolive was more effective against sucrose than starch digestion. 
As we consume polyphenols regularly over the course of our lifetime, chronic 
effects that they could potentially exert are of interest. The results in Chapter 5 
and Chapter 6 primarily focused on the chronic effect of bonolive. It is therefore 
recommended that a pilot study to evaluate the chronic consumption of 
bonolive capsules on the glycaemic response to sucrose should be undertaken. 
The proposed study is a randomised, double-blind, placebo controlled, cross-
over intervention trial. The study would have two intervention periods of one 
week, during which the participant would consume either the placebo or 
treatment daily, with a one month minimum washout between interventions to 
allow any effects from treatment to be eliminated. The cross-over design in 
which participants undertake both interventions and therefore serve as their 
own control would help account for inter-individual variation. 
Healthy participants with BMI 18-25 (healthy weight according to NHS) and 
fasting blood glucose within the normal range of 4.0 to 5.9 mmol/L (according 
to National Institute for Clinical Excellence Guidelines) would be recruited and 
then screened based on the inclusion criteria of the study. Providing they met 
the inclusion criteria, participants would be coded and then randomly assigned 
the order of interventions. During the intervention phase, participants would 
consume the placebo/treatment for a total of seven days. The dose of the 
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treatment would be two 500 mg per day with 200 mL of water. With digestive 
dilution, a concentration near 1.5 mg/mL, the concentration that was evaluated 
with the in vitro model, would be achieved in the gut lumen.  At the end of each 
intervention, participants would undertake an oral sucrose tolerance test. The 
baseline blood glucose would be measured and then the participant would 
consume 50 g of sucrose dissolved in 250 mL of water (within 5 min) and the 
blood glucose would be determined every 15 minutes up to 3 hours. Some 
factors would be controlled in order to help with consistency of the blood 
glucose measurements (Brouns et al., 2005). It is recommended that 
participants consume the same meal before the 10-12 h overnight fast and 
testing, therefore a standardised meal could be provided to ensure compliance. 
Participants should be asked to consume 250 mL of water upon waking on the 
testing morning, to ensure that they are hydrated when the testing begins. A 
sleep diary could also be recorded because evidence suggests that sleep 
duration is associated with fasting blood glucose (Twedt et al., 2015). The 
effect on the incremental area under the curve (IAUC) from the blood glucose 
response would be determined and data analysed using previously described 
methodology (Brouns et al., 2005).  
There is high inter-individual variation in the postprandial glycaemic response 
and individuals have different levels of sugar transporters (Zeevi et al., 2015). 
Furthermore, cell studies here saw different effects of bonolive depending on 
the whether cells were exposed chronically to glucose or sucrose therefore 
carbohydrate consumption habits could be taken into consideration. An ideal 
situation would be to provide a standardised diet to control carbohydrate 
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composition; however this type of study is not practical due to expense. Food 
frequency questionnaires would help in understanding the general eating 
patterns of participants. 
 Glycosylation analysis 7.2.2
Long-term culture of Caco-2/TC7 cells in sucrose led to altered N- and O-
glycosylation (Chapter 4) and the chronic bonolive treatment led to altered N-
glycosylation for cells cultured in sucrose (Chapter 5). It has been previously 
discussed that both N- and O-glycosylation play a role in the processing and 
trafficking of SI and the investigation of the phenotypes of sucrase isomaltase 
deficiency disorder (CSID) has aided in understanding the role of glycosylation 
in these processes (Lee et al., 2010; Naim et al., 2012; Naim et al., 1999). The 
carbohydrates attached to proteins at the cell surface also play an important 
role in cell-cell interactions. Specific alterations in glycosylation has been used 
as a biomarker for disease, such as cancer (Ohtsubo and Marth, 2006). Altered 
glycosylation has been observed in the diabetic rat model so it is possible that it 
plays a role in diabetes (Najjar et al., 2001). Dietary sugar and its relation to 
glycosylation and human health have not been established so the results here 
add to the gap in knowledge.  
Glycotransferases are the enzymes responsible for the formation of the glycans 
in the ER and Golgi during translation. Regulation of glycosylation is a complex 
interplay of processes involving the gene transcription of the 
glycosyltransferase enzymes, synthesis of sugar donors and transport to the 
ER and Golgi, protein turnover and other factors (Ohtsubo and Marth, 2006). 
Lectins are glycan binding proteins that are highly specific for glycan structures 
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and can be useful for studying altered glycosylation. Glycans can play a role in 
health and disease based on their interaction with lectins and effect on cellular 
mechanisms including cell adhesion, cell recognition, molecular trafficking and 
clearance, receptor activation and endocytosis, all of which have been 
reviewed (Ohtsubo and Marth, 2006).  
Detailed glycosylation analysis would aid in understanding the changes 
observed. Here, an increase in glycosylation was observed and this could be 
due to additional sites or changes to the oligosaccharide chains. Two analyses 
would be required to distinguish if one or both of these changes occurred. To 
determine sites of N-glycosylation, the sample is first de-glycosylation with 
PNGase F. The removal of N-glycans converts asparagine into aspartic acid 
and this alters the mass of the peptide by +1 Da. MALDI-MS analysis would 
allow for the identification and exact mass determination of the peptides 
(Wilson et al., 2009). Identification of the O-glycans is complicated by the fact 
that a mixture of enzymes is required to remove all types of O-glycans. The 
most favoured method of removal is an ammonia-based non-reductive β-
elimination followed by MS detection (Mariño et al., 2010). The detailed 
structure of the removed N- and O-glycans is complex and several methods 
exist. One method is based on hydrophilic interaction chromatography (HILIC) 
to allow good separation of glycans including separation of structural isomers. 
The glycans are first labelled with 2-aminobenzamide to allow fluorescent 
detection. A series of exoglycosidase digestions coupled with the analysis 
allows for the determination of detailed N-glycan structures through comparison 
to a database (Campbell et al., 2008; Mariño et al., 2010). MALDI-TOF-MS of 
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permethylated glycan mixtures offers another alternative. The determination of 
O-glycans is more challenging because they are more structurally diverse and 
have smaller mass. The methods for the analysis of glycans and their sites of 
occupancy has been improving with advances in technology but still proves 
very challenging and requires highly specialist instrumentation and use of 
several techniques. Once the post-translational changes have been identified, 
the functional impact and mechanisms could be investigated.   
7.3 Conclusion 
The health burden and increasing incidence of diabetes is of great concern. 
Any lifestyle factors which can aid in glucose homeostasis are important and 
diet is an easily modifiable factor. Evidence here suggests that olive 
polyphenols can decrease the digestion of sucrose and could therefore aid in 
reduction of the glycaemic response to foods containing sucrose. Since SI also 
has maltase and isomaltase activities, the reduction of activity or levels at the 
cell surface could have a beneficial impact on starch digestion. Inter-individual 
variation occurs in the glycaemic response therefore the therapeutic use may 
not benefit everyone and the effect could potentially depend upon the amount 
of dietary sugars consumed. Evidence from the in vitro cell studies here 
demonstrated that bonolive treatment was only able to reduce the amount of SI 
at the cell surface when cells were cultured under their regular conditions in 
glucose. When exposed long-term to sucrose, there was no change in SI at the 
cell surface, where it exerts its function. From this it could be speculated that in 
vivo, those with high sucrose exposure may not see the benefit from bonolive 
treatment. The in vitro studies using the Caco-2/TC7 cell model indicated that 
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both acute and chronic bonolive treatment can inhibit sucrase activity. These 
results warrant investigation in humans to determine if the effects observed in 
the cell model will translate into a positive effect in vivo therefore future studies 
in humans, such as the pilot study described above, are recommended. The 
Mediterranean diet is well established as a pattern for healthy eating, and the 
olive-leaf polyphenols could play a role, in part through the mechanisms 
discovered here. Polyphenols have many modes of actions and health benefits 
are due to a combined effect. Every small individual change such as observed 
here could contribute to overall improved health status.  
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Appendix 1 
Results from cDNA sequencing of SI from Caco-2/TC7 cells and DV Biologics 
human intestinal RNA sample. The bold capitalised letter represents a 
difference as compared to the NCBI reference sequence NM_001041.3. 
atggcaagaaagaaatttagtggattggaaatctctctgattgtcctttttgtcatagttactataatagctattgcct
taattgttgttttagcaactaagacacctgctgttgatgaaattagtgattctacttcaactccagctactactcgtgt
gactacaaatccttctgattcaggaaaatgtccaaatgtgttaaatgatcctgtcaatgtgagaataaactgcatt
ccagaacaattcccaacagagggaatttgtgcacagagaggctgctgctggaggccgtggaatgactctctt
attccttggtgcttcttcgttgataatcatggttataacgttcaagacatgacaacaacaagtattggagttgaagc
caaattaaacaggataccttcacctacactatttggaaatgacatcaacagtgttctcttcacaactcaaaatca
gacacccaatcgtttccggttcaagattactgatccaaataatagaagatatgaagttcctcatcagtatgtaaa
agagtttactggacccacagtttctgatacgttgtatgatgtgaaggttgcccaaaacccatttagcatccaagtt
attaggaaaagcaacggtaaaactttgtttgacaccagcattggtcccttagtgtactctgaccagtacttacag
atctcaacccgtcttccaagtgattatatttatggtattggagaacaagttcataagagatttcgtcatgatttatcct
ggaaaacatggccaatttttactcgagaccaacttcctggtgataataataataatttatacggccatcaaacat
tctttatgtgtattgaagatacatctggaaagtcattcggtgtttttttaatgaatagcaatgcaatggagatttttatc
cagcctactccaatagtaacatatagagttaccggtggcattctggatttttacatccttctaggagatacaccag
aacaagtagttcaacagtatcaacagcttgttggactaccagcaatgccagcatattggaatcttggattccaa
ctaagtcgctggaattataagtcactagatgtagtgaaagaagtggtaaggagaaaccgggaagctggcat
accatttgatacacaggtcactgatattgactacatggaagacaagaaagactttacttatgatcaagttgcgttt
aacggactccctcaatttgtgcaagatttgcatgaccatggacagaaatatgtcatcatcttggaccctgcaattt
ccataggtcgacgtgccaatggaacaacatatgcaacctatgagaggggaaacacacaacatgtgtggat
aaatgagtcagatggaagtacaccaattattggagaggtatggccaggattaacagtataccctgatttcacta
acccaaactgcattgattggtgggcaaatgaatgcagtattttccatcaagaagtgcaatatgatggactttgga
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ttgacatgaatgaagtttccagctttattcaaggttcaacaaaaggatgtaatgtaaacaaattgaattatccacc
gtttactcctgatattcttgacaaactcatgtattccaaaacaatttgcatggatgctgtgcagaactggggtaaa
cagtatgatgttcatagcctctatggatacagcatggctatagccacagagcaagctgtacaaaaagtttttcct
aataagagaagcttcattcttacccgctcaacatttgctggatctggaagacatgctgcgcattggttaggaga
caatactgcttcatgggaacaaatggaatggtctataactggaatgctggagttcagtttgtttggaatacctttg
gttggagcagacatctgtggatttgtggctgaaaccacagaagaactttgcagaagatggatgcaacttggg
gcattttatccattttccagaaaccataattctgacggatatgaacatcaggatcctgcattttttgggcagaattc
acttttggttaaatcatcaaggcagtatttaactattcgctacaccttattacccttcctctacactctgttttataaag
cccatgtgtttggagaaacagtagcaagaccagttcttcatgagttttatgaggatacgaacagctggattgag
gacactgagtttttgtggggccctgcattacttattactcctgttctaaaacagggagcagatactgtgagtgcct
acatccctgatgctatttggtatgattatgaatctggtgcaaaaaggccatggaggaaacaacgggttgatatg
tatcttccagcagacaaaataggattacatcttagaggaggttatatcatccccattcaagaaccagatgtaac
aacaacagcaagccgtaagaatcctctaggacttatagtcgcattaggtgaaaacaacacagccaaagga
gactttttctgggatgatggagaaactaaagatacaatacaaaatggcaactacatattatatacattttcagttt
ctaataacacattagatattgtgtgcacacattcatcatatcaggaaggaactaccttagcatttcagactgtaa
aaatccttgggttgacagacagtgttacagaagttagagtggcggaaaataatcaaccaatgaacgctcattc
caatttcacttatgatgcttctaaccaggttctcctaattgcagatctcaaacttaatcttggaagaaactttagtgtt
caatggaatcaaattttctcagaaaatgaaagatttaattgttatccagatgcagatttggcaactgaacaaaa
gtgcacacaacgtggctgtgtatggagaacgggttcttctctatccaaagcacctgagtgttactttcccagaca
agataactcttattcagtcaactcagctcgctattcatccatgggtataacagctgacctccaactaaatactgc
aaatgccagaataaagttaccttctgaccccatctcaactcttcgtgtggaggtgaaatatcacaaaaatgata
tgttgcagtttaagatttatgatccccaaaagaagagatatgaagtaccagtaccgttaaacattccaaccacc
ccaataagtacttatgaagacagactttatgatgtggaaatcaaggaaaatccttttggcatccagattcgacg
gagaagcagtggaagagtcatttgggattcttggctgcctggatttgcttttaatgaccagttcattcaaatatcga
ctcgcctgccatcagaatatatatatggttttggggaagtggaacatacagcatttaagcgagatctgaactgg
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aatacttggggaatgttcacaagagaccaaccccctggttacaaacttaattcctatggatttcatccctattaca
tggctctggaagaggagggcaatgctcatggtgttttcttactcaacagcaatgcaatggatgttacattccagc
caactcctgctctaacttaccgtacagttggagggatcttggatttttatatgtttttgggcccaactccagaagttg
caacaaagcaataccatgaagtaattggccatccagtcatgccagcttattgggctttgggattccaattatgtc
gttatggatatgcaaatacttcagaggttcgggaattatatgacgctatggtggctgctaacatcccctatgatgtt
cagtacacagacattgactacatggaaaggcagctagactttacaattggtgaagcattccaggaccttcctc
agtttgttgacaaaataagaggagaaggaatgagatacattattatcctggatccagcaatttcaggaaatga
aacaaagacttaccctgcatttgaaagaggacagcagaatgatgtctttgtcaaatggccaaacaccaatga
catttgttgggcaaaggtttggccagatttgcccaacataacaatagataaaactctaacggaagatgaagct
gttaatgcttccagagctcatgtagctttcccagatttcttcaggacttccacagcagagtggtgggccagagaa
attgtggacttttacaatgaaaagatgaagtttgatggtttgtggattgatatgaatgagccatcaagttttgtaaat
ggaacaactactaatcaatgcagaaatgacgaactaaattatccaccttatttcccagaactcacaaaaaga
actgatggattacatttcagaacaatttgcatggaagctgagcagattcttagtgatggaacatcagttttgcatt
acgatgttcacaatctctatggatggtcacagatgaaacctactcatgatgcattgcagaagacaactggaaa
aagagggattgtaatttctcgttccacgtatcctactagtggacgatggggaggacactggcttggagacaact
atgcacgatgggacaacatggacaaatcaatcattggtatgatggaatttagtctgtttggaatAtcatatactg
gagcagacatctgtggttttttcaacaactcagaatatcatctctgtacccgctggatgcaacttggagcattttat
ccatactcaaggaatcacaacattgcaaatactagaagacaagatcccgcttcctggaatgaaacttttgctg
aaatgtcaaggaatattctaaatattagatacaccttattgccctatttttacacacaaatgcatgaaattcatgct
aatggtggcactgttatccgaccccttttgcatgagttctttgatgaaaaaccaacctgggatatattcaagcagt
tcttatggggtccagcatttatggttaccccagtactggaaccttatgttcaaactgtaaatgcctacgtccccaat
gctcggtggtttgactaccatacaggcaaagatattggcgtcagaggacaatttcaaacatttaatgcttcttatg
acacaataaacctacatgtccgtggtggtcacatcctaccatgtcaagagccagctcaaaacacattttacag
tcgacaaaaacacatgaagctcattgttgctgcagatgataatcagatggcacagggttctctgttttgggatga
tggagagagtatagacacctatgaaagagacctatatttatctgtacaatttaatttaaaccagaccaccttaac
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aagcactatattgaagagaggttacataaataaaagtgaaacgaggcttggatcccttcatgtatgggggaa
aggaactactcctgtcaatgcagttactctaacgtataacggaaataaaaattcgcttccttttaatgaagacac
taccaacatgatattacgtattgatctgaccacacacaatgttactctagaagaaccaatagaaatcaactggt
catga 
 
